

    <!DOCTYPE html>
<html class="">

        
<head>
    <title>Emerging concepts and recent advances in basal cell... | F1000Research</title>
    <meta charset="utf-8">
    <!--<meta http-equiv="Content-Type" content="text/html; charset=utf-8"/>-->
    <!--<meta lang="$locale">-->
    <meta http-equiv="X-UA-Compatible" content="IE=edge">
    <meta name="google-site-verification" content="9-QVycOO2_ob3Z9QzRmXv2CF08A9oyYXqWyTiVdKPlU" />
    <!-- This is commented out to fix display problems on mobile devices.
    We may use it again once we implement a responsive design that supports native device resolutions.
    <meta name="viewport" content="width=device-width"> -->

    <meta name="viewport" content="width=device-width, initial-scale=1, maximum-scale=1">



    <link rel="alternate" title="Recent articles published in F1000Research" href="/rss" type="application/rss+xml">
            <link rel="alternate" type="application/pdf" title="PDF" href="https://f1000research.com/articles/6-2085/pdf"/>
        <link rel="canonical" href="https://f1000research.com/articles/6-2085" />
    
            <meta name="description" content="Read the original article in full on F1000Research: Emerging concepts and recent advances in basal cell carcinoma" />
    
            <meta name="og:title" content="F1000Research Article: Emerging concepts and recent advances in basal cell carcinoma.">
            <meta name="og:description" content="Read the latest article version by Mariam Totonchy, David Leffell, at F1000Research.">
            <meta name="og:image" content="/img/sharing/og_research.png">
            <meta name="version-id" content="12209">
            <meta name="article-id" content="11314">
            <meta name="dc.title" content="Emerging concepts and recent advances in basal cell carcinoma">
            <meta name="dc.description" content="Basal cell carcinoma (BCC) is the most common malignancy worldwide, arising from non-keratinizing cells within the basal layer of the epidermis. The incidence of BCC continues to rise annually, increasing the burden of management of these carcinomas and the morbidity associated with their treatment. While surgical interventions such as Mohs micrographic surgery and surgical excision are the standard of care and yield the highest cure rates, the number of non-surgical interventions approved for the treatment of BCC continues to expand. We review various surgical and non-surgical approaches to the treatment of BCC, focusing on targeted molecular therapies that are approved for locally advanced or recurrent disease.">
            <meta name="dc.subject" content="basal cell carcinoma,non-melanoma,squamous cell,vismodegib">
            <meta name="dc.creator" content="Totonchy, Mariam">
            <meta name="dc.creator" content="Leffell, David">
            <meta name="dc.date" content="2017/12/04">
            <meta name="dc.identifier" content="doi:10.12688/f1000research.11314.1">
            <meta name="dc.source" content="F1000Research 2017 6:2085">
            <meta name="dc.format" content="text/html">
            <meta name="dc.language" content="en">
            <meta name="dc.publisher" content="F1000 Research Limited">
            <meta name="dc.rights" content="https://creativecommons.org/licenses/by/3.0/igo/">
            <meta name="dc.type" content="text">
            <meta name="prism.keyword" content="basal cell carcinoma">
            <meta name="prism.keyword" content="non-melanoma">
            <meta name="prism.keyword" content="squamous cell">
            <meta name="prism.keyword" content="vismodegib">
            <meta name="prism.publication.Name" content="F1000Research">
            <meta name="prism.publicationDate" content="2017/12/04">
            <meta name="prism.volume" content="6">
            <meta name="prism.number" content="2085">
            <meta name="prism.versionIdentifier" content="1">
            <meta name="prism.doi" content="10.12688/f1000research.11314.1">
            <meta name="prism.url" content="https://f1000research.com/articles/6-2085">
            <meta name="citation_title" content="Emerging concepts and recent advances in basal cell carcinoma">
            <meta name="citation_abstract" content="Basal cell carcinoma (BCC) is the most common malignancy worldwide, arising from non-keratinizing cells within the basal layer of the epidermis. The incidence of BCC continues to rise annually, increasing the burden of management of these carcinomas and the morbidity associated with their treatment. While surgical interventions such as Mohs micrographic surgery and surgical excision are the standard of care and yield the highest cure rates, the number of non-surgical interventions approved for the treatment of BCC continues to expand. We review various surgical and non-surgical approaches to the treatment of BCC, focusing on targeted molecular therapies that are approved for locally advanced or recurrent disease.">
            <meta name="citation_description" content="Basal cell carcinoma (BCC) is the most common malignancy worldwide, arising from non-keratinizing cells within the basal layer of the epidermis. The incidence of BCC continues to rise annually, increasing the burden of management of these carcinomas and the morbidity associated with their treatment. While surgical interventions such as Mohs micrographic surgery and surgical excision are the standard of care and yield the highest cure rates, the number of non-surgical interventions approved for the treatment of BCC continues to expand. We review various surgical and non-surgical approaches to the treatment of BCC, focusing on targeted molecular therapies that are approved for locally advanced or recurrent disease.">
            <meta name="citation_keywords" content="basal cell carcinoma,non-melanoma,squamous cell,vismodegib">
            <meta name="citation_journal_title" content="F1000Research">
            <meta name="citation_author" content="Mariam Totonchy">
            <meta name="citation_author_institution" content="Department of Dermatology, Yale University School of Medicine, 333 Cedar Street, P.O. Box 208059, New Haven, CT 06520-8059, Connecticut, USA">
            <meta name="citation_author" content="David Leffell">
            <meta name="citation_author_institution" content="Department of Dermatology, Section of Cutaneous Oncology and Dermatologic Surgery , Yale University School of Medicine, 40 Temple Street 5A, New Haven, Connecticut, USA">
            <meta name="citation_publication_date" content="2017/12/04">
            <meta name="citation_volume" content="6">
            <meta name="citation_publication_number" content="2085">
            <meta name="citation_version_number" content="1">
            <meta name="citation_doi" content="10.12688/f1000research.11314.1">
            <meta name="citation_firstpage" content="2085">
            <meta name="citation_pdf_url" content="https://f1000research.com/articles/6-2085/v1/pdf">
    

    
    <link href="/img/favicon-research.ico" rel="shortcut icon" type="image/ico">
    <link href="/img/favicon-research.ico" rel="icon" type="image/ico">

        <link rel="stylesheet" href="/1597255280893/css/mdl/material-design-lite.css" type="text/css" media="all" />
    <link href="https://fonts.googleapis.com/icon?family=Material+Icons" rel="stylesheet">
    <link href="https://fonts.googleapis.com/css?family=Roboto:100,100i,300,300i,400,400i,500,500i,700,700i,900,900i" rel="stylesheet">
    <link rel="stylesheet" href="https://cdnjs.cloudflare.com/ajax/libs/MaterialDesign-Webfont/2.2.43/css/materialdesignicons.min.css" />

        
            
    <link rel="stylesheet" href="/1597255280893/css/F1000Research.css" type="text/css" media="all" />
    <link rel="stylesheet" href="/css/F1000ResearchFontIcons/F1000ResearchFontIcons.css" type="text/css" media="all" />
    <link rel="stylesheet" href="/css/F1000ResearchFontIcons/animation.css" type="text/css" media="all" />

        <!--[if IE 7]><link rel="stylesheet" href="/css/F1000ResearchFontIcons/F1000ResearchFontIcons-ie7.css" media="all" /><![endif]-->

                    <script>dataLayer = [];</script>
        <!-- Google Tag Manager -->
        <script>(function(w,d,s,l,i){w[l]=w[l]||[];w[l].push({'gtm.start':
        new Date().getTime(),event:'gtm.js'});var f=d.getElementsByTagName(s)[0],
        j=d.createElement(s),dl=l!='dataLayer'?'&l='+l:'';j.async=true;j.src=
        'https://www.googletagmanager.com/gtm.js?id='+i+dl;f.parentNode.insertBefore(j,f);
        })(window,document,'script','dataLayer','GTM-54Z2SBK');</script>
        <!-- End Google Tag Manager -->
    
    <script src="https://ajax.googleapis.com/ajax/libs/jquery/1.8.1/jquery.min.js"></script>
    <script>window.jQuery || document.write('<script src="/js/vendor/jquery-1.8.1.min.js"><\/script>')</script>
    <script src="/1597255280893/js/vendor/modernizr-2.6.1-respond-1.1.0.min.js"></script>
    <script src="/1597255280893/js/shared_scripts/sticky.js"></script>
    <script src="/1597255280893/js/shared_scripts/helpers.js"></script>
    <script src="/1597255280893/js/shared_scripts/menu.js"></script>
    <script src="/1597255280893/js/shared_scripts/navbar.js"></script>
    <script src="/1597255280893/js/shared_scripts/platforms.js"></script>
    <script src="/1597255280893/js/shared_scripts/object-polyfills.js"></script>
            <script src="/1597255280893/js/vendor/lodash.min.js"></script>
        <script>CKEDITOR_BASEPATH='https://f1000research.com/js/ckeditor/'</script>
    <script src="https://f1000researchdata.s3-eu-west-1.amazonaws.com/js/plugins.js"></script>
    <script src="/1597255280893/js/shared_scripts/helpers.js"></script>
    <script src="/1597255280893/js/app/research.js"></script>
    <script>window.reactTheme = 'research';</script>
    <script src="/1597255280893/js/public/bundle.js"></script>

    <script src="/1597255280893/js/app/research.ui.js"></script>
    <script src="/1597255280893/js/app/login.js"></script>
    <script src="/1597255280893/js/app/main.js"></script>
    <script src="/1597255280893/js/app/js-date-format.min.js"></script>
    <script src="/1597255280893/js/app/search.js"></script>
    <script src="/1597255280893/js/app/cookies_warning.js"></script>
    <script src="/1597255280893/js/mdl/mdl.min.js"></script>

    <script src="https://cdnjs.cloudflare.com/ajax/libs/mathjax/2.7.1/MathJax.js?config=TeX-AMS-MML_HTMLorMML"></script>
                <script src="https://f1000researchdata.s3-eu-west-1.amazonaws.com/js/ckeditor.js"></script>
            <script src="/js/ckeditor/adapters/jquery.js"></script>
                <script src="/js/article/article_scrolling_module.js"></script>
            <script src="/js/article/article_stats.js"></script>
            <script src="/js/article/article.js"></script>
            <script src="/js/shared_scripts/referee_timeline_pagination.js"></script>
            <script src="/js/app/text_editor_controller.js"></script>
            <script src="//s7.addthis.com/js/250/addthis_widget.js#pubid=ra-503e5e99593dc42c"></script>
            <script src="/js/article/article_metrics.js"></script>
        
                                                                            <script>
            if (window.location.hash == '#_=_'){
                window.location = window.location.href.split('#')[0]
            }
        </script>

                    
        
    <!-- pixelId: 1641728616063202 :: assetPixelId: 6034867600215 :: funderPixelId:  -->

            <!-- Facebook pixel code (merged with EP GTM code) -->
        <script>
            !function(f,b,e,v,n,t,s){if(f.fbq)return;n=f.fbq=function()

            {n.callMethod? n.callMethod.apply(n,arguments):n.queue.push(arguments)}
            ;if(!f._fbq)f._fbq=n;
            n.push=n;n.loaded=!0;n.version='2.0';n.queue=[];t=b.createElement(e);t.async=!0;
            t.src=v;s=b.getElementsByTagName(e)[0];s.parentNode.insertBefore(t,s)}(window,
            document,'script','https://connect.facebook.net/en_US/fbevents.js');

            fbq('init', '1641728616063202');

            
            fbq('track', "PixelInitialized", {});
        </script>

        <noscript><img height="1" width="1" style="display:none"
            src="https://www.facebook.com/tr?id=1641728616063202&noscript=1&amp;ev=PixelInitialized"
        /></noscript>
        <!-- End Facebook Pixel Code -->
    
                <script>
            (function(h,o,t,j,a,r){
                h.hj=h.hj||function(){(h.hj.q=h.hj.q||[]).push(arguments)};
                h._hjSettings={hjid:917825,hjsv:6};
                a=o.getElementsByTagName('head')[0];
                r=o.createElement('script');r.async=1;
                r.src=t+h._hjSettings.hjid+j+h._hjSettings.hjsv;
                a.appendChild(r);
            })(window,document,'https://static.hotjar.com/c/hotjar-','.js?sv=');
        </script>
    
</head>
<body  class="o-page-container no-js p-article o-layout-reset   ">

    
                            <!-- Google Tag Manager (noscript) -->
        <noscript><iframe src="https://www.googletagmanager.com/ns.html?id=GTM-54Z2SBK"
        height="0" width="0" style="display:none;visibility:hidden"></iframe></noscript>
        <!-- End Google Tag Manager (noscript) -->
    
        
    <div class="o-page">

        <div id="notify-container"></div>
        <div id="pageWarning"></div>
        <div id="pageMessage"></div>
        <div id="pageFooterMessage"></div>

                                <div id="f1r-ga-data" data-name="f1r-ga-data" class="f1r-ga-data"
                data-user-registered="false"
                data-user-module=""
                data-current-path=""
                data-location=""
                data-website="F1000Research"
                data-websiteDisplayName="F1000Research">
            </div>
        
                
        
        <div class="header-wrapper   js-navbar-space ">
                            


    










        
                            
    
            



<nav class="c-navbar js-navbar js-mini-nav js-sticky c-navbar--js-sticky c-navbar--userSite c-navbar__platform-bgcolor  c-navbar--bg-f1000research ">

    <div class="c-navbar__content">

                                <div class="c-navbar__extras">
            <div class="o-wrapper">
                <div class="o-actions o-actions--middle c-navbar__extras-row">
                    <div class="o-actions__primary">
                        
                                            </div>
                                    </div>
            </div>
        </div>

        <div class="o-wrapper t-inverted js-sticky-start">

            <div class="c-navbar__branding-row">
                <div class="c-navbar__row">


                                        
                    <div class="c-navbar__primary u-mr--2">

                                                                                                                                                                                                    <a href="/" class="c-navbar__branding u-ib u-middle"   data-test-id="nav_branding"  >
                                <img class="u-ib u-middle" src="/img/research/F1000Research_white_solid.svg" alt="F1000Research">
                            </a>
                                            </div>

                    <div class="c-navbar__secondary c-navbar__row">


                                                
                                                    <form action="/search" class="-navbar__secondary u-mr--2 c-search-form js-search-form u-hide u-show@navbar">
                                <label for="searchInput" class="c-search-form__label _mdl-layout">
                                    <input name="q" type="search" class="c-search-form__input" id="searchInput" placeholder="Search">
                                    <button type="submit" class="c-search-form__submit mdl-button mdl-js-button mdl-button--icon"><i class="material-icons">search</i></button>
                                </label>
                            </form>
                        
                                                
                                                    <div class="c-navbar__primary u-hide u-show@navbar">
                                <div class="_mdl-layout c-navbar__cta">
                                    <a class="mdl-button mdl-js-button mdl-button--raised mdl-button--no-shadow mdl-button--multi-line mdl-js-ripple-effect mdl-button--inverted c-navbar__submit" href="/for-authors/publish-your-research"   data-test-id="nav_submit_research"  ><i class="material-icons">file_upload</i>Submit your research</a>
                                </div>
                            </div>
                        

                                                
                        <span class="u-hide@navbar _mdl-layout u-nowrap">

                                                            <button type="button" class="mdl-button mdl-js-button mdl-js-ripple-effect mdl-button--icon c-navbar__toggle c-navbar__toggle--menu js-navbar-toggle" data-focus="#navbar_mob_search_input" data-toggle="navbarMenu" data-target="navbarMenu" aria-controls="navbarMenu" aria-expanded="false" aria-label="Toggle navigation"   data-test-id="nav_menu_search_mob"  ><i class="material-icons">search</i></button>
                            
                                                            <button class="mdl-button mdl-js-button mdl-js-ripple-effect mdl-button--icon mdl-button--multi-line c-navbar__toggle c-navbar__toggle--menu js-navbar-toggle" type="button" data-toggle="navbarMenu" data-target="navbarMenu" aria-controls="navbarMenu" aria-expanded="false" aria-label="Toggle navigation"   data-test-id="nav_menu_toggle_mob"  >
                                    <i class="material-icons c-navbar__toggle-open">menu</i>
                                    <i class="material-icons c-navbar__toggle-close">close</i>
                                </button>
                                                    </span>
                    </div>

                </div>
            </div>

                        
                            <div class="c-navbar__menu-row js-navbar-block is-collapsed" id="navbarMenu">

                                                                                                                                                
                                                                    
                                                                    
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        
                                            

                                                                
                                                                                                                                                                                                                                
                                            
                    <div class="c-navbar__menu-row-content">

                                                                            <div class="u-hide@navbar c-navbar__menu-bar-spacing">
                                <form action="/search" class="c-search-form js-search-form">
                                    <label for="navbar_mob_search_input" class="c-search-form__label _mdl-layout">
                                        <input id="navbar_mob_search_input" name="q" type="search" class="c-search-form__input" placeholder="Search">
                                        <button type="submit" class="c-search-form__submit mdl-button mdl-js-button mdl-button--icon"><i class="material-icons">search</i></button>
                                    </label>
                                </form>
                            </div>
                        
                        <div class="o-actions o-actions--middle">

                            <div class="o-actions__primary">

                                                                
    <ul class="c-menubar c-navbar__menu-bar js-main-menu"   id="main-menu"   role="menubar" aria-label="Main Navigation"  data-menu-group="navbar" >

        
            
                                                                
                                
                                
                                    <li role="none"
                        data-index="0"
                        class="c-menubar__item js-menu-item  c-navbar__menu-bar-item
                                                              ">

                        <a href="/browse/articles" class="c-navbar__menu-bar-link js-menu-link " role="menuitem"
                                                                                    tabindex="0"
                              data-test-id="nav_browse"                              >Browse</a>

                                            </li>
                
            
        
            
                                                                
                
                                
                                    <li role="none"
                        data-index="1"
                        class="c-menubar__item js-menu-item  c-navbar__menu-bar-item
                                                              ">

                        <a href="/gateways" class="c-navbar__menu-bar-link js-menu-link " role="menuitem"
                                                                                    tabindex="-1"
                              data-test-id="nav_gatewaysViewAndBrowse"                              >Gateways & Collections</a>

                                            </li>
                
            
        
            
                                                                
                
                                
                                    <li role="none"
                        data-index="2"
                        class="c-menubar__item js-menu-item  c-navbar__menu-bar-item
                                                               c-menubar__item--selected c-navbar__menu-bar-item--parent ">

                        <a href="#" class="c-navbar__menu-bar-link js-menu-link " role="menuitem"
                                                         aria-haspopup="true" aria-expanded="false"                             tabindex="-1"
                              data-test-id="nav_for-authors"                              >How to Publish</a>

                                                    
    <ul class="c-menu js-menu
                is-collapsed                c-menubar__menu c-navbar__menu"
                  role="menu"
        aria-label="How to Publish">

        
            
                                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_submit-manuscript"                      href="/for-authors/publish-your-research"
                    role="menuitem"
                    tabindex="0">Submit your Research</a>

                </li>

                    
            
                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_my-submissions"                      href="/for-authors/my-submissions"
                    role="menuitem"
                    tabindex="-1">My Submissions</a>

                </li>

                    
            
                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_article-guidelines"                      href="/for-authors/article-guidelines"
                    role="menuitem"
                    tabindex="-1">Article Guidelines</a>

                </li>

                    
            
                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_article-guidelines-new-versions"                      href="/for-authors/article-guidelines-new-versions"
                    role="menuitem"
                    tabindex="-1">Article Guidelines (New Versions)</a>

                </li>

                    
            
                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_data-guidelines"                      href="/for-authors/data-guidelines"
                    role="menuitem"
                    tabindex="-1">Data Guidelines</a>

                </li>

                    
            
                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_asset-guidelines"                      href="/for-authors/posters-and-slides-guidelines"
                    role="menuitem"
                    tabindex="-1">Posters and Slides Guidelines</a>

                </li>

                    
            
                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_document-guidelines"                      href="/for-authors/document-guidelines"
                    role="menuitem"
                    tabindex="-1">Document Guidelines</a>

                </li>

                    
            
                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_article-processing-charges"                      href="/for-authors/article-processing-charges"
                    role="menuitem"
                    tabindex="-1">Article Processing Charges</a>

                </li>

                    
            
                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_finding-referees"                      href="/for-authors/tips-for-finding-referees"
                    role="menuitem"
                    tabindex="-1">Finding Article Reviewers</a>

                </li>

                        </ul>
                                            </li>
                
            
        
            
                                                                
                
                                
                                    <li role="none"
                        data-index="3"
                        class="c-menubar__item js-menu-item  c-navbar__menu-bar-item
                                                               c-menubar__item--selected c-navbar__menu-bar-item--parent ">

                        <a href="#" class="c-navbar__menu-bar-link js-menu-link " role="menuitem"
                                                         aria-haspopup="true" aria-expanded="false"                             tabindex="-1"
                              data-test-id="nav_about-contact"                              >About</a>

                                                    
    <ul class="c-menu js-menu
                is-collapsed                c-menubar__menu c-navbar__menu"
                  role="menu"
        aria-label="About">

        
            
                                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_about-page"                      href="/about"
                    role="menuitem"
                    tabindex="0">How it Works</a>

                </li>

                    
            
                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_referee-guidelines"                      href="/for-referees/guidelines"
                    role="menuitem"
                    tabindex="-1">For Reviewers</a>

                </li>

                    
            
                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_advisoryPanel"                      href="/advisors"
                    role="menuitem"
                    tabindex="-1">Our Advisors</a>

                </li>

                    
            
                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_policy-page"                      href="/about/policies"
                    role="menuitem"
                    tabindex="-1">Policies</a>

                </li>

                    
            
                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_glossary-page"                      href="/glossary"
                    role="menuitem"
                    tabindex="-1">Glossary</a>

                </li>

                    
            
                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_faqs-page"                      href="/faqs"
                    role="menuitem"
                    tabindex="-1">FAQs</a>

                </li>

                    
            
                
                                
                <li class="c-menu__item js-menu-item
                                              u-hide u-show@navbar"
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      u-hide u-show@navbar"
                                          data-test-id="nav_for-developers"                      href="/developers"
                    role="menuitem"
                    tabindex="-1">For Developers</a>

                </li>

                    
            
                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_newsroom-page"                      href="/newsroom"
                    role="menuitem"
                    tabindex="-1">Newsroom</a>

                </li>

                    
            
                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_contact-page"                      href="/contact"
                    role="menuitem"
                    tabindex="-1">Contact</a>

                </li>

                        </ul>
                                            </li>
                
            
        
            
                                                                
                
                                
                                    <li role="none"
                        data-index="4"
                        class="c-menubar__item js-menu-item  c-navbar__menu-bar-item
                                                              ">

                        <a href="https://blog.f1000.com/blogs/f1000research/" class="c-navbar__menu-bar-link js-menu-link " role="menuitem"
                             target="_blank"                                                         tabindex="-1"
                              data-test-id="nav_blog"                              >Blog</a>

                                            </li>
                
            
        
    </ul>



                            </div>

                            <div class="o-actions__secondary">

                                                                
    <ul class="c-menubar c-navbar__menu-bar js-main-menu"   id="secondary-items"   role="menubar" aria-label="My Account"  data-menu-group="navbar" >

        
            
                                                                
                                
                                
                                    <li role="none"
                        data-index="0"
                        class="c-menubar__item js-menu-item  c-navbar__menu-bar-item
                                                               c-menubar__item--selected c-navbar__menu-bar-item--parent ">

                        <a href="#" class="c-navbar__menu-bar-link js-menu-link " role="menuitem"
                                                         aria-haspopup="true" aria-expanded="false"                             tabindex="0"
                              data-test-id="nav_my-research"                              >My Research</a>

                                                    
    <ul class="c-menu js-menu
                is-collapsed                c-menubar__menu c-navbar__menu"
                  role="menu"
        aria-label="My Research">

        
            
                                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_my-submissions"                      href="/login?originalPath=/my/submissions"
                    role="menuitem"
                    tabindex="0">Submissions</a>

                </li>

                    
            
                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_my-email-alerts"                      href="/login?originalPath=/my/email-alerts"
                    role="menuitem"
                    tabindex="-1">Content and Tracking Alerts</a>

                </li>

                    
            
                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_my-user-details"                      href="/login?originalPath=/my/user-details"
                    role="menuitem"
                    tabindex="-1">My Details</a>

                </li>

                        </ul>
                                            </li>
                
            
        
            
                                                                
                
                                
                                    <li role="none"
                        data-index="1"
                        class="c-menubar__item js-menu-item  c-navbar__menu-bar-item
                                                              ">

                        <a href="/login?originalPath=/articles/6-2085.html" class="c-navbar__menu-bar-link js-menu-link " role="menuitem"
                                                                                    tabindex="-1"
                              data-test-id="nav_sign-in"                              >Sign In</a>

                                            </li>
                
            
        
    </ul>



                            </div>

                                                                                        <div class="_mdl-layout c-navbar__cta u-hide@navbar c-navbar__menu-bar-spacing">
                                    <a class="mdl-button mdl-js-button mdl-button--raised mdl-button--multi-line mdl-button--no-shadow mdl-js-ripple-effect mdl-button--inverted c-navbar__submit" href="/for-authors/publish-your-research"   data-test-id="nav_submit_research_mob"  ><i class="material-icons">file_upload</i>Submit your research</a>
                                </div>
                                                    </div>

                    </div>

                </div>
            
        </div>

    </div>

</nav>
                    </div>

        <div class="content-wrapper o-page__main row ">
            <div id="highlight-area" class="content ">
                





<div id=article-metadata class=hidden> <input type=hidden name=versionId value=12209 /> <input type=hidden id=articleId name=articleId value=11314 /> <input type=hidden id=xmlUrl value="/articles/6-2085/v1/xml"/> <input type=hidden id=xmlFileName value="-6-2085-v1.xml"> <input type=hidden id=article_uuid value=074aeb04-cfd6-4281-b35d-42794bfeaa8b /> <input type=hidden id=referer value=""/> <input type=hidden id=meta-article-title value="Emerging concepts and recent advances in basal cell carcinoma"/> <input type=hidden id=workspace-export-url value="https://sciwheel.com/work/api/import/external?doi=10.12688/f1000research.11314.1"/> <input type=hidden id=versionDoi value="10.12688/f1000research.11314.1"/> <input type=hidden id=usePmcStats value=true /> </div> <main class="o-wrapper p-article__wrapper js-wrapper"> <script type="application/ld+json">
{
  "@context": "https://schema.org",
  "@type": "ScholarlyArticle",
  "mainEntityOfPage": {
    "@type": "WebPage",
    "@id": "https://f1000research.com/articles/6-2085"
  },
  "headline": "Emerging concepts and recent advances in basal cell carcinoma",
  "datePublished": "2017-12-04T11:30:19",
  "dateModified": "2017-12-04T11:30:19",
  "author": [
    {
      "@type": "Person",
      "name": "Mariam Totonchy"
    },    {
      "@type": "Person",
      "name": "David Leffell"
    }  ],
  "publisher": {
    "@type": "Organization",
    "name": "F1000Research",
    "logo": {
      "@type": "ImageObject",
      "url": "https://f1000research.com/img/AMP/F1000Research_image.png",
      "height": 480,
      "width": 60
    }
  },
  "image": {
    "@type": "ImageObject",
    "url": "https://f1000research.com/img/AMP/F1000Research_image.png",
    "height": 1200,
    "width": 150
  },
  "description": "Basal cell carcinoma (BCC) is the most common malignancy worldwide, arising from non-keratinizing cells within the basal layer of the epidermis. The incidence of BCC continues to rise annually, increasing the burden of management of these carcinomas and the morbidity associated with their treatment. While surgical interventions such as Mohs micrographic surgery and surgical excision are the standard of care and yield the highest cure rates, the number of non-surgical interventions approved for the treatment of BCC continues to expand. We review various surgical and non-surgical approaches to the treatment of BCC, focusing on targeted molecular therapies that are approved for locally advanced or recurrent disease."
}
</script> <div class="o-layout o-layout--right-gutter"> <div id=article_secondary-column class="p-article__main o-layout__item u-font-size--legal u-2/3@article not-expanded "> <div class=float-left> <script type="application/ld+json">
  {
    "@context": "http://schema.org",
    "@type": "BreadcrumbList",
    "itemListElement": [
              {
          "@type": "ListItem",
          "position": "1",
          "item": {
            "@id": "https://f1000research.com/",
            "name": "Home"
          }
        },              {
          "@type": "ListItem",
          "position": "2",
          "item": {
            "@id": "https://f1000research.com/browse/articles",
            "name": "Browse"
          }
        },              {
          "@type": "ListItem",
          "position": "3",
          "item": {
            "@id": "https://f1000research.com/articles/6-2085.html",
            "name": "Emerging concepts and recent advances in basal cell carcinoma"
          }
        }          ]
  }
  </script> <div class="breadcrumbs js-breadcrumbs"> <a href="/" class=f1r-standard-link>Home</a> <span class=item_separator></span> <a href="/browse/articles" class=f1r-standard-link>Browse</a> <span class=item_separator></span> Emerging concepts and recent advances in basal cell carcinoma </div> </div> <div class="article-badges-container u-mb--2"> <div class=crossmark-new> <script src="https://crossmark-cdn.crossref.org/widget/v2.0/widget.js"></script> <a data-target=crossmark><img height=30 width=150 src="https://crossmark-cdn.crossref.org/widget/v2.0/logos/CROSSMARK_Color_horizontal.svg"/></a> </div> <div id=crossmark-dialog style="display: none;" title=""> <iframe id=crossmark-dialog-frame frameborder=0></iframe> </div> <div class=clearfix></div> </div> <div class=article-interaction-container> <div id=main-article-count-box class=article-count-box> <div class="article-metrics-wrapper metrics-icon-wrapper" data-version-id=12209 data-id=11314 data-downloads="" data-views="" data-scholar="10.12688/f1000research.11314.1" data-recommended="" data-doi="10.12688/f1000research.11314.1" data-f1r-ga-helper="Article Page Metrics (Desktop)"> <span class="metrics-on-browse article-metrics-icon f1r-icon icon-89_metrics"></span> <div class="count-title article-metrics-text">ALL Metrics</div> <div class=js-article-metrics-container></div> </div> <div> <div class=count-delimiter></div> <div title="Total views from F1000Research and PubMed Central"> <div class="count-container view-count js-views-count">-</div> <div class=count-title><span class="count-title-icon count-title-views-icon"></span>Views</div> </div> <div class=download-counts hidden> <div class=count-delimiter></div> <div title="Total downloads from F1000Research and PubMed Central"> <div class="count-container js-downloads-count"></div> <div class=count-title><span class="count-title-icon f1r-icon icon-76_download_file"></span>Downloads</div> </div> </div> </div> </div> <div id=main-article-interaction-box class="article-interaction-box has-control-tab"> <div class="article-interaction-info article-page"> <div class=article-interaction-button> <span class="f1r-icon icon-102_download_pdf"></span> <a href="https://f1000research.com/articles/6-2085/v1/pdf?article_uuid=074aeb04-cfd6-4281-b35d-42794bfeaa8b" title="Download PDF" class="button-link download pdf-download-helper" target=_blank>Get PDF</a> </div> </div> <div class="article-interaction-info article-page"> <div class=article-interaction-button> <span class="f1r-icon icon-103_download_xml"></span> <a id=download-xml href="#" class="button-link download" title="Download XML">Get XML</a> </div> </div> <div class="article-interaction-info article-page"> <div class="cite-article-popup-wrapper article-page-interaction-box"> <div class="article-interaction-button cite-article-button" title="Cite this article" data-windowref=cite-article-popup-11314-1> <span class="f1r-icon icon-82_quote"></span> <a href="#" class="button-link cite-article-popup-link" title="Cite Article">Cite</a> </div> <div id=cite-article-popup-11314-1 class="popup-window-wrapper is-hidden"> <div class=cite-popup-background></div> <div class="popup-window top-popup cite-this-article-box research-layout"> <div class="popup-window-title small cite-title">How to cite this article</div> <span id=cite-article-text-11314-1 data-test-id=copy-citation_text> <span class="article-title-and-info in-popup">Totonchy M and Leffell D. Emerging concepts and recent advances in basal cell carcinoma [version 1; peer review: 2 approved]</span>. <i>F1000Research</i> 2017, <b>6</b>(F1000 Faculty Rev):2085 (<a class=new-orange href="https://doi.org/10.12688/f1000research.11314.1" target=_blank>https://doi.org/10.12688/f1000research.11314.1</a>) </span> <div class="popup-window-title small margin-top-20 margin-bottom-20 note"> <strong>NOTE:</strong> it is important to ensure the information in square brackets after the title is included in all citations of this article. </div> <div class=float-right> <button class="secondary no-fill orange-text-and-border margin-right-20 close-cite-popup uppercase">Close</button> <button id=copy-citation-details class="secondary orange copy-cite-article-version uppercase js-clipboard" title="Copy the current citation details to the clipboard." data-clipboard-target="#cite-article-text-11314-1" data-test-id=copy-citation_button>Copy Citation Details</button> </div> </div> </div> </div> </div> <div class="article-interaction-info article-page"> <div class=article-interaction-button> <span class="f1r-icon icon-76_download_file"></span> <a id=export-citation href="#" class="button-link download" title="Export Citation">Export</a> </div> <div class="modal-window-wrapper is-hidden"> <div id=export-citation-popup class="modal-window padding-20"> <div class=modal-window-close-button></div> <div class=modal-window-title>Export Citation</div> <div class=modal-window-row> <div> <input type=radio name=export-citation-option value=WORKSPACE /> <span class=radio-label>Sciwheel</span> </div> <div> <input type=radio name=export-citation-option value=ENDNOTE /> <span class=radio-label>EndNote</span> </div> <div> <input type=radio name=export-citation-option value=REF_MANAGER /> <span class=radio-label>Ref. Manager</span> </div> <div> <input type=radio name=export-citation-option value=BIBTEX /> <span class=radio-label>Bibtex</span> </div> <div> <input type=radio name=export-citation-option value=PROCITE /> <span class=radio-label>ProCite</span> </div> <div> <input type=radio name=export-citation-option value=SENTE /> <span class=radio-label>Sente</span> </div> </div> <div class=modal-window-footer> <button class=general-white-orange-button id=export-citation-submit>EXPORT</button> </div> <div class=default-error style="display: none;">Select a format first</div> </div> </div> </div> <div class="article-interaction-info article-page"> <div class=article-interaction-button> <span class="f1r-icon icon-90_track"></span> <a class="button-link track-article" data-article-id=11314 id=track-article-signin-11314 title="Receive updates on new activity such as publication of new versions, peer reviews or author responses." href="/login?originalPath=/trackArticle/11314?target=/articles/6-2085.html">Track</a> </div> </div> <div class="article-interaction-info article-page"> <div class="article-interaction-button email-article"> <span class="f1r-icon icon-6_email"></span> <a href="#" class=button-link title="Email this article">Email</a> </div> <div class="email-article-version-container small-tooltip _chrome-fix"> <div class=close-icon><span class="f1r-icon icon-3_close_big"></span></div> <script src='https://www.recaptcha.net/recaptcha/api.js'></script> <form class="recommend-version-form research-layout"> <p>All fields are required.</p> <input name=versionId type=hidden value=12209 /> <input name=articleId type=hidden value=11314 /> <input name=senderName class="form-input-field reg-form" value="" type=text placeholder="Your name"/> <input name=senderEmail class="form-input-field reg-form margin-top" value="" type=text placeholder="Your email address"/> <textarea name=recipientEmails class="form-textarea-field ninetynine-percent-wide margin-top no-resize" placeholder="Recipient email address(es) (comma delimited)"></textarea> <input class="form-input-field reg-form margin-top" name=subject type=text value="Interesting article on F1000Research" placeholder=Subject /> <textarea name=message class="form-textarea-field reg-form margin-top no-resize">I thought this article from F1000Research (https://f1000research.com) would be of interest to you.</textarea> <div class="g-recaptcha margin-top" data-sitekey=6LcHqxoUAAAAANP3_0TzpGG6qFvl4DhbUcuRzw7W></div> <input value="" name=captcha type=hidden /> <p>A full article citation will be automatically included.</p> <p><img class="ticker-email-article-details hidden" src="/img/ticker.gif" alt=loading /></p> <button class="secondary orange margin-bottom" data-test-id=version_share_email_send>SEND EMAIL</button> <div class="orange-message margin-bottom is-hidden" data-test-id=version_share_email_message></div> </form> </div> </div> <div class="article-interaction-info article-page"> <div class=article-interaction-button> <span class="f1r-icon icon-34_share"></span> <a href="#" class="button-link last addthis_button share-article" title="Share this article">Share</a> </div> </div> </div> <div id=article-interaction-control-tab class=article-interaction-control-tab> <div id=hide-article-interaction class=article-interaction-control title="Hide Toolbox">&#9644;</div> <div id=show-article-interaction class="article-interaction-control open" title="Show Toolbox">&#10010;</div> </div> </div> <div class="article-header-information article-page"> <div class="f1r-article-mobile article-heading-bar"></div> <div class="article-type article-display">Review </div> <div class="article-title-and-info article-view highlighted-article" id=anchor-title> <h1>Emerging concepts and recent advances in basal cell carcinoma</h1><span class=other-info> [version 1; peer review: 2 approved]</span> </div> <div class=article-subtitle></div> <div class=f1r-article-desk> <div class="authors _mdl-layout"><span class=""><a href="mailto:mariam.totonchy@yale.edu" title="Send email" class="cauthor research-layout"><span class='f1r-icon icon-6_email orange'></span><span>Mariam Totonchy</span></a><a href="https://orcid.org/0000-0001-7609-5235" target=_blank id=author-orcid-0><span class=orcid-logo-for-author-list></span></a><div class="mdl-tooltip mdl-tooltip--wider" for=author-orcid-0><span class=orcid-logo-for-author-list></span> https://orcid.org/0000-0001-7609-5235</div><sup>1</sup>,&nbsp;</span><span class="">David Leffell<sup>2</sup></span></div> </div> <div class=f1r-article-mobile> <div class="authors _mdl-layout"><span class=""><a href="mailto:mariam.totonchy@yale.edu" title="Send email" class="cauthor research-layout"><span class='f1r-icon icon-6_email orange'></span><span>Mariam Totonchy</span></a><a href="http://orcid.org/0000-0001-7609-5235" target=_blank id=mauthor-orcid-0><span class=orcid-logo-for-author-list></span></a><div class="mdl-tooltip mdl-tooltip--wider" for=mauthor-orcid-0><span class=orcid-logo-for-author-list></span> https://orcid.org/0000-0001-7609-5235</div><sup>1</sup>,&nbsp;</span><span class="">David Leffell<sup>2</sup></span></div> </div> <div class=f1r-article-mobile> <div class=article-pubinfo-mobile> PUBLISHED 04 Dec 2017 </div> </div> <span class=Z3988 title="ctx_ver=Z39.88-2004&amp;rft_val_fmt=info:ofi/fmt:kev:mtx:journal&amp;rft_id=info:doi/10.12688%2Ff1000research.11314.1"></span> <div class=f1r-article-desk> <div class="contracted-details first"> <a href="#" class="contracted-details-label author-affiliations"><span class=contracted></span>Author details</a> <a href="#" class=section-title>Author details</a> <span class="f1r-icon icon-14_more_small section-control"></span> <span class="f1r-icon icon-10_less_small section-control"></span> <div class="expanded-details affiliations is-hidden"> <sup>1</sup> Department of Dermatology, Yale University School of Medicine, 333 Cedar Street, P.O. Box 208059, New Haven, CT 06520-8059, Connecticut, USA<br/> <sup>2</sup> Department of Dermatology, Section of Cutaneous Oncology and Dermatologic Surgery , Yale University School of Medicine, 40 Temple Street 5A, New Haven, Connecticut, USA<br/> <p> </p> </div> </div> </div> <div class=f1r-article-mobile> <div class="article-page-section-box margin-bottom-40 research-layout"> <span class=box-title> <span class="f1r-icon icon-85_peer_review"></span> OPEN PEER REVIEW </span> <button class="tertiary grey float-right" data-scrollto=article-reports>DETAILS</button> <div class="status-row referee-reports-container"> REVIEWER STATUS <span class=status-icons> <span class="f1r-icon icon-86_approved status-green smaller" title=Approved data-refInfo=11837-28458></span> <span class="f1r-icon icon-86_approved status-green smaller" title=Approved data-refInfo=28478-28457></span> </span> </div> </div> </div> </div> <h2 class="article-headings article-page-abstract" id=anchor-abstract> <span class="f1r-article-mobile-inline abstract-heading-border"></span> Abstract </h2> <div class="article-abstract article-page-general-text-mobile research-layout"> <div class="abstract-text is-expanded"> Basal cell carcinoma (BCC) is the most common malignancy worldwide, arising from non-keratinizing cells within the basal layer of the epidermis. The incidence of BCC continues to rise annually, increasing the burden of management of these carcinomas and the morbidity associated with their treatment. While surgical interventions such as Mohs micrographic surgery and surgical excision are the standard of care and yield the highest cure rates, the number of non-surgical interventions approved for the treatment of BCC continues to expand. We review various surgical and non-surgical approaches to the treatment of BCC, focusing on targeted molecular therapies that are approved for locally advanced or recurrent disease. </div> <div class=abstract-for-mobile> <div class="margin-top-30 padding-bottom-30 research-layout is-centered"> <button class="primary orange-text white-bg bigger-text abstract-expand-button-mobile with-border show" style="display: none;"> READ ALL <span class="f1r-icon icon-14_more_small orange vmiddle big"></span> </button> <button class="primary orange-text white-bg bigger-text abstract-expand-button-mobile with-border hide"> READ LESS <span class="f1r-icon icon-10_less_small orange vmiddle big"></span> </button> </div> </div> </div> <div class=clearfix></div> <div class="article-context no-divider"> <div class="article-abstract article-page-general-text-mobile research-layout generated-article-body"> <h2 class=main-title>Keywords</h2> <p class="u-mb--0 u-pb--2"> basal cell carcinoma,non-melanoma,squamous cell,vismodegib </p> </div> </div> <div class=article-information> <span class="info-separation padding-bottom"> <div id=corresponding-author-icon class="email-icon float-left"> <span class="f1r-icon icon-6_email orange"></span> <div id=corresponding-author-window class="margin-top-20 popup-window-wrapper is-hidden"> <div class="popup-window corresponding-authors-popup"> <div class=corresponding-author-container> <div class="popup-window-title small">Corresponding Author(s)</div> <div class=authors> Mariam Totonchy (<a href="mailto:mariam.totonchy@yale.edu">mariam.totonchy@yale.edu</a>) </div> </div> <div class="margin-top margin-bottom float-left"> <button id=close-popup-window class=general-white-orange-button>Close</button> </div> </div> </div> </div> <span class="icon-text float-left" data-test-id=box-corresponding-author> <b>Corresponding author:</b> Mariam Totonchy </span> <div class=clearfix></div> </span> <span class="info-separation padding-bottom competing-interests-display"> <span class=competing-interests-title>Competing interests:</span> No competing interests were disclosed. </span> <div class="info-separation padding-bottom grant-information-display"> <span class=grant-information-title>Grant information:</span> The author(s) declared that no grants were involved in supporting this work. </div> <span class="f1r-article-desk info-separation padding-bottom"> <span class="copywrite-icon float-left"> <span class="f1r-icon icon-100_open_access"></span> </span> <span class="icon-text float-left" data-test-id=box-copyright-text> <b>Copyright:</b>&nbsp; © 2017 Totonchy M and Leffell D. This is an open access article distributed under the terms of the <a href="http://creativecommons.org/licenses/by/4.0/" target=_blank data-test-id=box-licence-link>Creative Commons Attribution License</a>, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. </span> <div class=clearfix></div> </span> <span class="info-separation padding-bottom" data-test-id=box-how-to-cite> <b>How to cite:</b> <span class="article-title-and-info in-article-box"> Totonchy M and Leffell D. Emerging concepts and recent advances in basal cell carcinoma [version 1; peer review: 2 approved]</span>. <i>F1000Research</i> 2017, <b>6</b>(F1000 Faculty Rev):2085 (<a href="https://doi.org/10.12688/f1000research.11314.1" target=_blank>https://doi.org/10.12688/f1000research.11314.1</a>) </span> <span class=info-separation data-test-id=box-first-published><b>First published:</b> 04 Dec 2017, <b>6</b>(F1000 Faculty Rev):2085 (<a href="https://doi.org/10.12688/f1000research.11314.1" target=_blank>https://doi.org/10.12688/f1000research.11314.1</a>)</span> <span class=info-separation data-test-id=box-latest-published><b>Latest published:</b> 04 Dec 2017, <b>6</b>(F1000 Faculty Rev):2085 (<a href="https://doi.org/10.12688/f1000research.11314.1" target=_blank>https://doi.org/10.12688/f1000research.11314.1</a>)</span> </div> <div class=clearfix></div> <div id=article-context class=article-context> <div id=article1-body class=generated-article-body><h2 class=main-title id=d52561e159>Introduction</h2><p class="" id=d52561e162>Non-melanoma skin cancers (NMSCs), which include basal cell carcinoma (BCC) and squamous cell carcinoma (SCC), are the most common cancers in Caucasians. One in five Americans will develop skin cancer in their lifetime<sup><a href="#ref-1">1</a></sup>. In 2012, 5.4 million NMSCs were diagnosed in the US alone<sup><a href="#ref-2">2</a></sup>. BCC comprises approximately 80% of these NMSCs, and incidence rates are increasing worldwide<sup><a href="#ref-2">2</a>,<a href="#ref-3">3</a></sup>. Incidence rates of BCC in the US have risen by approximately 2% per year<sup><a href="#ref-3">3</a></sup>, and there are significant increases among women and individuals younger than 40 years of age<sup><a href="#ref-3">3</a>–<a href="#ref-6">6</a></sup>. BCCs are treatable cancers and have low rates of metastasis and mortality<sup><a href="#ref-7">7</a>,<a href="#ref-8">8</a></sup>; however, their high incidence rates and treatment costs contribute significantly to the rising economic burden of health care<sup><a href="#ref-9">9</a></sup>. From 2007 to 2011, as compared with from 2002 to 2006, the aggregate cost of treating skin cancer in the US rose from $3.6 to $8.1 billion per year, and the average cost of treatment per patient has also increased significantly, from $1,000 in 2006 to $1,600 in 2011<sup><a href="#ref-9">9</a>–<a href="#ref-11">11</a></sup>. In addition to the rising cost of treatment, BCCs are associated with significant morbidity, making their management an important public health concern.</p></div><div id=article1-body class=generated-article-body><h2 class=main-title id=d52561e213>Risk factors</h2><p class="" id=d52561e216>The increase in incidence rates of BCC may indicate changes in environmental or lifestyle and behavioral risk factors. Solar ultraviolet (UV) irradiation is a known risk factor for BCC<sup><a href="#ref-12">12</a></sup>. Exposure to UV light, particularly UVB, induces mutations in tumor suppressor genes and plays a key role in the pathogenesis of BCC<sup><a href="#ref-13">13</a>–<a href="#ref-15">15</a></sup>. A history of blistering sunburn and younger age at first blistering sunburn have been associated with BCC, yet it is still unclear whether continuous or intermittent sun exposure poses a greater risk<sup><a href="#ref-16">16</a>–<a href="#ref-18">18</a></sup>. Exposure to UV radiation early in life or intermittent exposure throughout life may be more important than overall cumulative exposure<sup><a href="#ref-19">19</a></sup>. In the past decade, indoor tanning has emerged as a significant risk factor for skin cancer, including early-onset BCC<sup><a href="#ref-20">20</a>–<a href="#ref-24">24</a></sup>. The melanocortin 1 receptor gene, <i>MC1R</i>, is associated with fair skin, red hair, and increased risk for melanoma and NMSC<sup><a href="#ref-25">25</a>–<a href="#ref-30">30</a></sup>. Both MC1R genotype and indoor tanning have been used to predict risk of early-onset BCC in statistical models<sup><a href="#ref-28">28</a></sup>.</p><p class="" id=d52561e263>Increasing age, male sex, and white race have also been correlated with higher rates of BCC<sup><a href="#ref-31">31</a>,<a href="#ref-32">32</a></sup>. Higher risk with age may be due in part to a reduced ability to repair DNA damage from UV radiation, leading to the accumulation of carcinogenic photoproducts<sup><a href="#ref-33">33</a>,<a href="#ref-34">34</a></sup>. Other important risk factors include a family history of skin cancer, fair complexion, light eye/hair color, and a low ability to tan<sup><a href="#ref-35">35</a>,<a href="#ref-36">36</a></sup>. Interestingly, a recent study also found that adult body mass index was inversely associated with early-onset BCC<sup><a href="#ref-37">37</a></sup>.</p><p class="" id=d52561e291>In addition to risk factors for developing BCC, there are certain features of BCCs that place them in a high-risk category. High-risk BCC features include tumors of longstanding duration, diameter of greater than 2 cm, aggressive histo-pathologic subtype, perivascular or perineural infiltration, location in the mid-face or ears, history of radiation exposure, and prior treatment failure<sup><a href="#ref-38">38</a></sup>. Morpheaform, infiltrative, and micronodular histo-pathologic subtypes are considered aggressive.</p><p class="" id=d52561e298>Chronically immunosuppressed patients are at high risk not only for NMSC but also for more aggressive phenotypes of these cutaneous carcinomas due to impaired immune surveillance of the skin<sup><a href="#ref-39">39</a>–<a href="#ref-41">41</a></sup>. Solid organ transplant recipients comprise an important subgroup of immunosuppressed patients for whom skin cancer is the most common post-transplant malignancy<sup><a href="#ref-42">42</a>–<a href="#ref-46">46</a></sup>. While the relative increased risk of developing SCC is higher compared with BCC in this group, the risk of BCC is still significantly increased at a factor of 7 to 20 as compared with the normal population<sup><a href="#ref-43">43</a>,<a href="#ref-47">47</a></sup>. The number of solid organ transplants in the US is increasing annually, making treatment of NMSC in this high-risk group of heightened concern<sup><a href="#ref-48">48</a></sup>.</p></div><div id=article1-body class=generated-article-body><h2 class=main-title id=d52561e329>Genetic basis of disease</h2><p class="" id=d52561e332>UV radiation plays a critical role in the pathogenesis of BCC, accounting for the high rate of somatic mutations and “UV signatures” seen in this type of carcinoma<sup><a href="#ref-49">49</a>,<a href="#ref-50">50</a></sup>. In addition to these “UV signature” genetic alterations, mutations in the patched 1 (<i>PTCH1</i>) gene on chromosome 9q22 have been shown to play a key role in the pathogenesis of sporadic BCC<sup><a href="#ref-51">51</a>,<a href="#ref-52">52</a></sup>. Loss of heterozygosity of <i>PTCH1</i> is the most frequent genetic alteration in BCC, occurring in a reported 53% to 69% of BCCs<sup><a href="#ref-53">53</a>–<a href="#ref-57">57</a></sup>. <i>PTCH</i> allele alterations are seen in approximately 83% of BCCs<sup><a href="#ref-55">55</a></sup>. Critical to this discovery was the characterization of a subset of patients with nevoid BCC syndrome (Gorlin syndrome). This syndrome, first characterized by Gorlin<sup><a href="#ref-58">58</a></sup>, is an autosomal dominant disorder caused by mutations in the <i>PTCH1</i> gene, resulting in the inappropriate activation of hedgehog (HH) signaling and an increased risk of BCC and developmental defects<sup><a href="#ref-58">58</a>–<a href="#ref-61">61</a></sup>. <i>PTCH1</i> encodes a protein that functions as the receptor for sonic HH ligands which, when mutated, leads to uncontrolled cell growth and BCC tumorigenesis<sup><a href="#ref-60">60</a>,<a href="#ref-62">62</a></sup>. The HH signaling pathway has been the genetic basis for the development of targeted therapies for BCC, which will be discussed below.</p><p class="" id=d52561e395>Though less critical than <i>PTCH1</i> in the pathogenesis of BCC, p53 is another important tumor suppressor gene that has been implicated in BCC tumorigenesis<sup><a href="#ref-54">54</a></sup>. P53 plays a critical role in DNA repair and cell cycle regulation<sup><a href="#ref-63">63</a></sup> and has altered expression in a range of tumor types. Reported rates of p53 mutation are between 44% and 56% in BCC<sup><a href="#ref-54">54</a>,<a href="#ref-64">64</a>,<a href="#ref-65">65</a></sup>.</p></div><div id=article1-body class=generated-article-body><h2 class=main-title id=d52561e422>Management</h2><div class=section><a name=d52561e425 class=n-a></a><h3 class=section-title>Targeted molecular therapies</h3><p class="" id=d52561e430><b><i>Smoothened inhibitors.</i></b> Several molecular therapies for BCC have focused on the HH signaling pathway. Binding of HH ligands to <i>PTCH1</i> leads to a loss of inhibition of this pathway, leading to activation of smoothened (SMO), a seven-transmembrane protein downstream of <i>PTCH1</i>. SMO then interacts with several proteins and ultimately leads to the expression of the GLI family of transcription factors that promote proliferation, survival, and differentiation, key genes involved in BCC tumorigenesis<sup><a href="#ref-59">59</a>,<a href="#ref-66">66</a></sup>. Several of the small-molecule targeted therapies therefore have focused on SMO inhibition.</p><p class="" id=d52561e449><b><i>Vismodegib.</i></b> In 2012, vismodegib became the first SMO inhibitor to gain US Food and Drug Administration (FDA) approval. It was approved for use in metastatic BCC (a very rare occurrence), for locally advanced BCC recurrent after surgery, and for patients who are not candidates for surgical resection or radiation. The initial phase 1 trial studied 33 patients with locally advanced BCC treated with vismodegib at one of three doses (150, 270, or 540 mg daily) and found that 18 out of 33 patients responded<sup><a href="#ref-67">67</a></sup>. Two patients had a complete response, defined as a 100% regression of the visible/palpable lesions, and six had a partial response, defined as a more than 50% reduction in tumor diameter. The median duration of response was 12.8 months<sup><a href="#ref-67">67</a></sup>. Of the patients who did not respond, 15 had stable disease and four had progression of their BCCs while on treatment<sup><a href="#ref-67">67</a></sup>. Interestingly, two patients with progressive disease had elevated GLI1 mRNA levels in tissue samples, raising the question of possible resistance mechanisms in these patients.</p><p class="" id=d52561e467>The phase II trial of the efficacy and safety of vismodegib in advanced basal-cell carcinoma (ERIVANCE) by Sekulic <i>et al</i>. led to the approval of vismodegib<sup><a href="#ref-68">68</a></sup>. This trial enrolled 104 patients (33 patients with metastatic BCC and 71 patients with locally advanced BCC) who took 150 mg daily of vismodegib<sup><a href="#ref-68">68</a></sup>. In patients with metastatic BCC, the response rate was 30%, whereas in 63 patients with locally advanced BCC, the response rate was 43%. Response rate was defined as a decrease of 30% or more in the externally visible or radiographic dimension or as complete resolution of ulceration (if present at baseline). The median duration of response was 7.6 months<sup><a href="#ref-68">68</a></sup> and the median progression-free survival was 9.5 months according to independent review. All patients had at least one adverse event, and in 12% of patients, adverse events led to discontinuation of vismodegib. The most common adverse events reported with vismodegib include alopecia, dysgeusia, muscle spasms, weight loss, fatigue, decreased appetite, nausea, and diarrhea<sup><a href="#ref-67">67</a>–<a href="#ref-69">69</a></sup>.</p><p class="" id=d52561e492>Similar response rates were seen in a subsequent open-label, two-cohort, multicenter study of 119 patients with advanced BCC who were poor candidates for surgical resection or radiotherapy. They were also treated with vismodegib 150 mg daily. Response rates were 30.8% for those with metastatic disease and 46.4% for those with locally advanced BCC<sup><a href="#ref-70">70</a></sup>. Of the 115 patients included as efficacy-evaluable patients, about half (49.5%) experienced stable disease—27 out of 56 patients with locally advanced BCC and 20 out of 39 patients with metastatic BCC. The median treatment period was 5.5 months, and the most common adverse events reported were muscle spasms, dysgeusia, alopecia, and diarrhea<sup><a href="#ref-70">70</a></sup>.</p><p class="" id=d52561e504>The study of vismodegib in patients with advanced basal cell carcinoma (STEVIE) is the largest vismodegib trial to date; 499 patients (468 with locally advanced BCC and 31 with metastatic disease)<sup><a href="#ref-71">71</a></sup>. Objective responses were seen in 66.7% of patients with locally advanced BCC and 37.9% of those with metastatic disease. The median time to response for both groups was 2.7 months, and the median duration of the response was 22.7 months. The median duration of vismodegib treatment was 36.4 weeks, and 80% of patients discontinued therapy (36% due to adverse events, 14% due to progressive disease, and 10% from patient request to stop treatment).</p><p class="" id=d52561e511>Vismodegib has recently been evaluated as a neoadjuvant to surgery for high-risk BCC<sup><a href="#ref-72">72</a></sup>. An open-label single-arm study of 15 enrolled patients examined vismodegib 150 mg/day as neoadjuvant for a goal of 3 to 6 months of therapy prior to surgical resection<sup><a href="#ref-72">72</a></sup>. A total of 11 out of 15 patients completed the trial. Of the four who could not complete the trial, one was lost to follow-up and two withdrew due to vismodegib-related side effects and one due to an unrelated adverse event. Of the 13 BCCs that were selected for surgery, vismodegib reduced the surgical defect area by 27% from baseline. In the non-recurrent tumors (9 out of 13), vismodegib reduced the surgical defect area by 36%; however, for the recurrent BCCs (4 out of 13), there was no reduction in surgical defect area, introducing the possibility that these tumors had acquired mutations that rendered them resistant to the effects of vismodegib.</p><p class="" id=d52561e522>Owing to the genetic basis of nevoid basal cell nevus syndrome, patients with this disorder are of particular interest for treatment with SMO inhibitors. A randomized, double-blind, placebo-controlled trial by Tang <i>et al</i>. examined treatment with vismodegib in 41 patients with nevoid basal cell nevus syndrome<sup><a href="#ref-73">73</a></sup>. After 3 months of therapy, the number of new surgically eligible BCCs was significantly reduced in the vismodegib-treated group as compared with the placebo group (mean of 2 versus 29, respectively, of new surgically eligible BCCs per year)<sup><a href="#ref-73">73</a></sup>. Unfortunately, 54% of patients (14 out of 26) receiving vismodegib discontinued treatment because of adverse drug side effects. Overall, while the results of vismodegib treatment have been promising, there remain important questions regarding durability of the response, long-term tolerability of the adverse effects, and acquisition of resistant mutations over time.</p><p class="" id=d52561e536><b><i>Sonidegib.</i></b> Sonidegib is an SMO inhibitor that gained FDA approval in 2015 for treatment of patients with locally advanced BCC who are not candidates for curative surgery or radiation<sup><a href="#ref-74">74</a></sup>. Approval was based on data from the phase II randomized, double-blind Basal Cell Carcinoma Outcomes with LDE225 Treatment (BOLT) trial assessing the efficacy of sonidegib for metastatic or locally advanced BCC<sup><a href="#ref-75">75</a></sup>. A total of 230 patients were enrolled and placed on either 200 or 800 mg daily, and objective response rates were 36% (20 out of 55) and 34% (39 out of 116), respectively. There were both greater response rates and fewer adverse events in the 200mg dose sonidegib group as compared with the 800 mg group<sup><a href="#ref-75">75</a></sup>. In analyzing objective response rates for tumor types, 43% and 38% of patients with locally advanced BCC and 15% and 17% of patients with metastatic BCC responded in the 200 and 800 mg dosing schedules, respectively. The median time to tumor response was 4 months, and median progression-free survival was 22.1 months<sup><a href="#ref-75">75</a>–<a href="#ref-78">78</a></sup>. The adverse effect profile of sonidegib is similar to that of vismodegib.</p><p class="" id=d52561e561>Although there are no direct head-to-head comparisons of vismodegib with sonidegib, objective response rates were similar using BCC modified Response Criteria In Solid Tumors (BCC-mRECIST), at 48% in the ERIVANCE (vismodegib, 150 mg daily) study with a minimum follow-up of 21 months, and 56% in the BOLT (sonidegib, 200 mg daily) trial with a minimum follow-up of 18 months<sup><a href="#ref-68">68</a>,<a href="#ref-69">69</a>,<a href="#ref-78">78</a></sup>. It should be noted that this is an indirect comparison that should be interpreted with caution. Further randomized, double-blind controlled trials comparing both the safety and efficacy of both SMO inhibitors are needed.</p><p class="" id=d52561e574><b><i>Hedgehog pathway resistance.</i></b> Primary and secondary drug resistances to SMO inhibitors have been reported. Novel heterozygous missense SMO mutations were sequenced in recurrent and resistant BCC tissue to vismodegib<sup><a href="#ref-79">79</a>,<a href="#ref-80">80</a></sup>. In cases of secondary resistance, the SMO mutations that were isolated were not present in the primary tumors that had originally responded to treatment, and distinct recurrent nodules of BCC demonstrated unique SMO mutations, suggesting a heterogeneous and dynamic mechanism of resistance that can rapidly arise in recurrent tumor tissue<sup><a href="#ref-79">79</a></sup>. In cases of primary resistance in the tumor tissue of origin, given the cost of treatment with SMO inhibitors as compared with genetic sequencing, it may be more cost-effective for all patients to undergo screening prior to the initiation of targeted therapy. Interestingly, a study of nine patients with advanced BCC resistant to treatment with vismodegib also demonstrated resistance to sonidegib, suggesting that chemoresistance can occur between different SMO inhibitors<sup><a href="#ref-81">81</a></sup>.</p><p class="" id=d52561e596>It is appropriate to consider cost in deciding therapeutic options. According to Centers for Medicare and Medicaid Services (CMS) data from 1992 to 1995, the cost per episode of care for NMSC was estimated at $492 in the outpatient setting<sup><a href="#ref-82">82</a></sup>. In a more recent study comparing the economic cost of treating patients with advanced versus non-advanced BCC from 2010 to 2014, the mean cost of treating an advanced BCC was $11,143 compared with $1,171 for a non-advanced BCC<sup><a href="#ref-83">83</a></sup>. The majority of patients with advanced BCC (93.7%, n = 794) received radiation therapy, at a mean cost of $10,317. Of the 847 patients with advanced BCCs, only three received vismodegib. The cost of vismodegib is $250 per capsule or $7,500 per month<sup><a href="#ref-83">83</a></sup>. Treatment length varies by patient, and the treatment is not curative per se, but rather suppressive. However, an expected 10-month treatment course of vismodegib costs approximately $75,000<sup><a href="#ref-84">84</a></sup>. It is important to reserve this treatment approach for patients who are not candidates for surgery or radiation.</p></div><div class=section><a name=d52561e616 class=n-a></a><h3 class=section-title>Mohs, surgical excision, and electrodessication and curettage</h3><p class="" id=d52561e621>Standard surgical excision with 4-mm margins is the recommended treatment for BCCs with non-aggressive histology, size of less than 2 cm, and occurrence on low-risk sites where tissue sparing is not critical (trunk and extremities)<sup><a href="#ref-85">85</a></sup>. With 4-mm surgical margins, 95% of cases of BCC less than 2 cm were cleared with standard excision<sup><a href="#ref-86">86</a></sup>. BCC of the face demonstrates high rates of incomplete excision, and greater efficacy has been demonstrated using Mohs micrographic surgery (MMS) as compared with standard excision<sup><a href="#ref-87">87</a>–<a href="#ref-92">92</a></sup>. Five-year rates of recurrence following MMS for primary BCC are approximately 1.4% to 3.2% for primary and 2.4% to 6.7% for recurrent BCCs<sup><a href="#ref-89">89</a>–<a href="#ref-91">91</a></sup>. Low rates of recurrence in MMS are attributed to optimal margin control given full histologic examination at the time of surgery of all peripheral and deep margins. MMS is recommended in cases of aggressive histology, recurrent BCC, and critical areas of skin conservation (head, neck, genitalia, hand/feet, nipples, and so on) and for tumors of large size (more than 2 cm)<sup><a href="#ref-85">85</a></sup>.</p><p class="" id=d52561e650>Electrodessication and curettage (EDC) has been used for decades to treat BCC. Although this can be a cost-effective treatment, cure rates are highly operator-dependent. One study demonstrated five-year recurrence rates at 5.7% to 18.1% depending on the skill level of the physician<sup><a href="#ref-93">93</a></sup>. Higher recurrence rates were seen on the forehead, paranasal areas, and nose, and overall cosmesis tends to be poor in the head and neck regions. For these reasons, this treatment is now rarely recommended for BCC in these locations.</p></div><div class=section><a name=d52561e658 class=n-a></a><h3 class=section-title>Topical therapy</h3><p class="" id=d52561e663><b><i>Imiquimod.</i></b> Imiquimod 5% is a topical Toll-like receptor 7 agonist approved by the FDA for treatment of superficial BCCs less than 2 cm in diameter. A recent randomized controlled trial comparing imiquimod 5% cream (daily for 6 weeks in superficial BCC and daily for 12 weeks in nodular BCC) with surgical excision found five-year success rates of 82.5% for the imiquimod treatment group and 97.7% for the standard surgical excision group<sup><a href="#ref-94">94</a></sup>. A randomized, vehicle-controlled study of subjects with superficial BCC treated with imiquimod 5 to 7 times per week for 6 weeks as compared with vehicle showed composite clinical and histologic clearance rates of 75% for imiquimod 5 times per week and 73% for imiquimod 7 times per week<sup><a href="#ref-95">95</a></sup>. Imiquimod is generally well tolerated, but the most common treatment effects include erythema, crusting, erosions, and scabbing, which correlate positively with histologic clearance rates<sup><a href="#ref-96">96</a></sup>. A randomized single-blind, non-inferiority randomized controlled trial demonstrated topical treatment with imiquimod 5% (daily, 5 times per week for 6 weeks) to be superior to methylaminolevulinate-photodynamic therapy (MAL-PDT) with the proportion of patients with successful disease clearance at 3 and 12 months to be 72.8% for MAL-PDT as compared with 83.4% for imiquimod<sup><a href="#ref-97">97</a></sup>. Imiquimod is considered a useful treatment modality for predominantly superficial BCC in patients who are poor candidates for surgical or destructive modalities.</p><p class="" id=d52561e685><b><i>5-Fluorouracil.</i></b> 5-Fluorouracil (5-FU) is a topical pyrimidine analog which functions as an antimetabolite, interfering with DNA synthesis. 5-FU is FDA-approved for treatment of superficial BCC. A double-blind randomized trial of 13 patients showed a 90% cure rate in lesions treated with 5% 5-FU twice daily for two weeks<sup><a href="#ref-98">98</a></sup>, and another study of 5% 5-FU twice daily for up to 12 weeks showed a similar histologic cure rate of 90%. The efficacy of Efudex 5% was reported to be comparable to that of MAL-PDT and to have a clearance rate of 80.1% in a single-blind, randomized controlled trial<sup><a href="#ref-97">97</a></sup>. Erythema, erosions, and ulceration are the most common side effects with use of 5-FU.</p><p class="" id=d52561e699><b><i>Photodynamic therapy.</i></b> PDT uses photosensitizing agents—aminolevulinic acid (ALA) or MAL—to create a photochemical reaction by producing activated oxygen species that destroy cancer cells when exposed to oxygen and light<sup><a href="#ref-99">99</a></sup>. Photosensitizing agents act through intracellular protoporphyrin IX, which preferentially accumulates in tumor tissues. In a randomized prospective study of excision versus MAL-PDT for nodular BCC at five years, the complete response rates were 76% for MAL-PDT and 96% for excisional surgery, and recurrence rates were 14% with MAL-PDT and 4% for those who underwent excision<sup><a href="#ref-100">100</a></sup>. A recent randomized controlled trial comparing effectiveness of ALA-PDT with surgical excision found five-year recurrence rates of 30.7% for ALA-PDT and 2.3% for surgical excision<sup><a href="#ref-101">101</a></sup>. While recurrence rates are higher for PDT-treated BCCs, cosmesis was found to be superior to surgical excision<sup><a href="#ref-100">100</a>,<a href="#ref-102">102</a></sup>. For superficial BCC, complete response rates ranged between 73% and 92%, and some studies suggest improved efficacy with repeated PDT cycles<sup><a href="#ref-97">97</a>,<a href="#ref-103">103</a>–<a href="#ref-105">105</a></sup>. Although PDT represents an important treatment modality for those who are not good surgical candidates and have a large burden of superficial disease, surgical interventions should remain the standard of care for invasive disease given high recurrence rates with PDT.</p></div><div class=section><a name=d52561e735 class=n-a></a><h3 class=section-title>Radiation therapy</h3><p class="" id=d52561e740>Radiotherapy treatment for BCC can be divided into three main categories: conventional external radiotherapy, superficial x-ray therapy, and brachytherapy. A newer irradiation technique is volumetric modulated arc therapy. This modality allows for complex dose distributions to tumor tissue while minimizing involvement of healthy tissue<sup><a href="#ref-106">106</a></sup>. A detailed examination of these modalities is beyond the scope of this review, but radiation is a valuable treatment for non-surgical candidates and patients who decline invasive treatments. Major disadvantages of radiation include multiple visits, lack of confirmation of histologic clearance, development of aggressive phenotypes in some recurrent tumors, poor long-term cosmesis with conventional radiotherapy, and high cost as compared with surgical treatments<sup><a href="#ref-107">107</a></sup>. In a randomized trial comparing surgical excision with 2-mm margins versus radiation with brachytherapy, superficial x-ray therapy or conventional radiotherapy showed four-year recurrence rates of 0.7% in patients who underwent surgery versus 7.5% in those who underwent radiotherapy<sup><a href="#ref-108">108</a></sup>. Rates of BCC recurrence following superficial x-ray have been reported to be 2% at two years and 4.2% at five years<sup><a href="#ref-109">109</a></sup>. Brachytherapy used as treatment for NMSC has been reported to have good cosmesis and recurrence rates of less than 1% to 1.3% after median follow-up times between 4 and 16.1 months<sup><a href="#ref-110">110</a></sup>. It is likely that the follow-up interval is not sufficient to determine the true recurrence rates with this modality as compared with more established forms of treatment. External electron beam therapy has shown efficacy rates of 92% at five years in the treatment of NMSC<sup><a href="#ref-111">111</a></sup>.</p></div><div class=section><a name=d52561e770 class=n-a></a><h3 class=section-title>Chemoprevention</h3><p class="" id=d52561e775><b><i>Nicotinamide.</i></b> Nicotinamide, otherwise known as vitamin B<sub>3</sub>, has emerged as an oral therapy with potential for skin cancer prevention. In one study, nicotinamide was found to reduce UV-induced immunosuppression<sup><a href="#ref-112">112</a></sup>. A recent randomized double-blind controlled trial reported a reduction of 20% in new BCCs at 12 months in patients on treatment with 500 mg nicotinamide twice daily<sup><a href="#ref-113">113</a></sup>. There are no significant adverse events associated with nicotinamide. While studies have demonstrated a decreased risk of developing NMSC, further investigation is needed to determine the long-term benefits of this treatment<sup><a href="#ref-114">114</a></sup>.</p></div><div class=section><a name=d52561e797 class=n-a></a><h3 class=section-title>Chemotherapy and immune checkpoint inhibitors</h3><p class="" id=d52561e802>Targeted SMO inhibitors have largely replaced other forms of chemotherapy for advanced or metastatic BCC. Cituximab showed efficacy in certain cases of metastatic BCC or nevoid BCC syndrome<sup><a href="#ref-115">115</a>,<a href="#ref-116">116</a></sup>. Newer immunotherapies have emerged that target programmed death 1 (PD-1) immune checkpoint receptors and ligands. A recent case report of a patient with metastatic BCC who failed therapy with vismodegib showed a partial response to an anti–PD-1 monoclonal antibody<sup><a href="#ref-117">117</a></sup>. In another recent case report, a 58-year-old male with metastatic BCC who failed therapy with vismodegib, paclitaxel, and cisplatin was placed on the anti–PD-1 antibody, nivolumab, at 240 mg intravenously every 2 weeks. The patient demonstrated near complete resolution of metastatic disease within 4 months of treatment<sup><a href="#ref-118">118</a></sup>.</p></div></div><div id=article1-body class=generated-article-body><h2 class=main-title id=d52561e824>Conclusions</h2><p class="" id=d52561e827>MMS and surgical excision remain the standard of care for treating BCC. However, new targeted molecular therapies now provide effective treatment options for patients with locally advanced or metastatic BCC. Topical therapies may be effective in treating superficial disease in many cases, although careful surveillance is needed to confirm tumor clearance. Further randomized prospective studies are needed to examine the long-term effectiveness of these alternative modalities and their ability to decrease overall morbidity.</p></div><div id=article1-back class=generated-article-footer><div class=back-section><a name=d52561e1 class=n-a></a><h2 class=main-title id=d52911>Competing interests</h2><p class=metadata-entry><a name=d52561e96 class=n-a></a><p id=d52561e97> No competing interests were disclosed.</p></p></div><div class=back-section><a name=d52561e1 class=n-a></a><h2 class=main-title id=d52913>Grant information</h2><p>The author(s) declared that no grants were involved in supporting this work.</p></div><div class=back-section><a name=d52561e834 class=n-a></a><span class="research-layout prime-recommended-wrapper reference-heading"><span class="f1r-icon icon-79_faculty_recommended_badge red vmiddle default-cursor"></span><span class="prime-red big">F1000 recommended</span></span><h2 class=main-title id=d53282>References</h2><div class="section ref-list"><a name=d52561e834 class=n-a></a><ul><li><a name=ref-1 class=n-a></a><span class=label>1. </span>&nbsp;<span class=citation><a name=d52561e841 class=n-a></a>Stern RS: Prevalence of a history of skin cancer in 2007: results of an incidence-based model. <i>Arch Dermatol.</i> 2010; <b>146</b>(3): 279–82. <a target=xrefwindow id=d52561e849 href="http://www.ncbi.nlm.nih.gov/pubmed/20231498">PubMed Abstract </a> | <a target=xrefwindow id=d52561e852 href="http://dx.doi.org/10.1001/archdermatol.2010.4">Publisher Full Text </a></span></li><li><a name=ref-2 class=n-a></a><span class=label>2. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/2975957"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d52561e861 class=n-a></a>Rogers HW, Weinstock MA, Harris AR, <i> et al.</i>: Incidence estimate of nonmelanoma skin cancer in the United States, 2006. <i>Arch Dermatol.</i> 2010; <b>146</b>(3): 283–7. <a target=xrefwindow id=d52561e872 href="http://www.ncbi.nlm.nih.gov/pubmed/20231499">PubMed Abstract </a> | <a target=xrefwindow id=d52561e875 href="http://dx.doi.org/10.1001/archdermatol.2010.19">Publisher Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/2975957">F1000 Recommendation</a></span></li><li><a name=ref-3 class=n-a></a><span class=label>3. </span>&nbsp;<span class=citation><a name=d52561e888 class=n-a></a>Lomas A, Leonardi-Bee J, Bath-Hextall F: A systematic review of worldwide incidence of nonmelanoma skin cancer. <i>Br J Dermatol.</i> 2012; <b>166</b>(5): 1069–80. <a target=xrefwindow id=d52561e896 href="http://www.ncbi.nlm.nih.gov/pubmed/22251204">PubMed Abstract </a> | <a target=xrefwindow id=d52561e899 href="http://dx.doi.org/10.1111/j.1365-2133.2012.10830.x">Publisher Full Text </a></span></li><li><a name=ref-4 class=n-a></a><span class=label>4. </span>&nbsp;<span class=citation><a name=d52561e908 class=n-a></a>Bath-Hextall F, Leonardi-Bee J, Smith C, <i> et al.</i>: Trends in incidence of skin basal cell carcinoma. Additional evidence from a UK primary care database study. <i>Int J Cancer.</i> 2007; <b>121</b>(9): 2105–8. <a target=xrefwindow id=d52561e919 href="http://www.ncbi.nlm.nih.gov/pubmed/17640064">PubMed Abstract </a> | <a target=xrefwindow id=d52561e922 href="http://dx.doi.org/10.1002/ijc.22952">Publisher Full Text </a></span></li><li><a name=ref-5 class=n-a></a><span class=label>5. </span>&nbsp;<span class=citation><a name=d52561e931 class=n-a></a>Birch-Johansen F, Jensen A, Mortensen L, <i> et al.</i>: Trends in the incidence of nonmelanoma skin cancer in Denmark 1978–2007: Rapid incidence increase among young Danish women. <i>Int J Cancer.</i> 2010; <b>127</b>(9): 2190–8. <a target=xrefwindow id=d52561e942 href="http://www.ncbi.nlm.nih.gov/pubmed/20473901">PubMed Abstract </a> | <a target=xrefwindow id=d52561e945 href="http://dx.doi.org/10.1002/ijc.25411">Publisher Full Text </a></span></li><li><a name=ref-6 class=n-a></a><span class=label>6. </span>&nbsp;<span class=citation><a name=d52561e955 class=n-a></a>Christenson LJ, Borrowman TA, Vachon CM, <i> et al.</i>: Incidence of basal cell and squamous cell carcinomas in a population younger than 40 years. <i>JAMA.</i> 2005; <b>294</b>(6): 681–90. <a target=xrefwindow id=d52561e966 href="http://www.ncbi.nlm.nih.gov/pubmed/16091570">PubMed Abstract </a> | <a target=xrefwindow id=d52561e969 href="http://dx.doi.org/10.1001/jama.294.6.681">Publisher Full Text </a></span></li><li><a name=ref-7 class=n-a></a><span class=label>7. </span>&nbsp;<span class=citation><a name=d52561e978 class=n-a></a>Miller DL, Weinstock MA: Nonmelanoma skin cancer in the United States: incidence. <i>J Am Acad Dermatol.</i> 1994; <b>30</b>(5 Pt 1): 774–8. <a target=xrefwindow id=d52561e986 href="http://www.ncbi.nlm.nih.gov/pubmed/8176018">PubMed Abstract </a> | <a target=xrefwindow id=d52561e989 href="http://dx.doi.org/10.1016/S0190-9622(08)81509-5">Publisher Full Text </a></span></li><li><a name=ref-8 class=n-a></a><span class=label>8. </span>&nbsp;<span class=citation><a name=d52561e998 class=n-a></a>Weinstock MA: Epidemiologic investigation of nonmelanoma skin cancer mortality: the Rhode Island Follow-Back Study. <i>J Invest Dermatol.</i> 1994; <b>102</b>(6): 6S–9. <a target=xrefwindow id=d52561e1006 href="http://www.ncbi.nlm.nih.gov/pubmed/8006441">PubMed Abstract </a></span></li><li><a name=ref-9 class=n-a></a><span class=label>9. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/727327828"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d52561e1015 class=n-a></a>Verkouteren JAC, Ramdas KHR, Wakkee M, <i> et al.</i>: Epidemiology of basal cell carcinoma: scholarly review. <i>Br J Dermatol.</i> 2017; <b>177</b>(2): 359–72. <a target=xrefwindow id=d52561e1026 href="http://www.ncbi.nlm.nih.gov/pubmed/28220485">PubMed Abstract </a> | <a target=xrefwindow id=d52561e1029 href="http://dx.doi.org/10.1111/bjd.15321">Publisher Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/727327828">F1000 Recommendation</a></span></li><li><a name=ref-10 class=n-a></a><span class=label>10. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/726871887"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d52561e1042 class=n-a></a>Chen JT, Kempton SJ, Rao VK: The Economics of Skin Cancer: An Analysis of Medicare Payment Data. <i>Plast Reconstr Surg Glob Open.</i> 2016; <b>4</b>(9): e868. <a target=xrefwindow id=d52561e1050 href="http://www.ncbi.nlm.nih.gov/pubmed/27757333">PubMed Abstract </a> | <a target=xrefwindow id=d52561e1053 href="http://dx.doi.org/10.1097/GOX.0000000000000826">Publisher Full Text </a> | <a target=xrefwindow id=d52561e1056 href="http://www.ncbi.nlm.nih.gov/pmc/articles/5054999">Free Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/726871887">F1000 Recommendation</a></span></li><li><a name=ref-11 class=n-a></a><span class=label>11. </span>&nbsp;<span class=citation><a name=d52561e1069 class=n-a></a>Guy GP Jr, Holman DM, Watson M: The Important Role of Schools in the Prevention of Skin Cancer. <i>JAMA Dermatol.</i> 2016; <b>152</b>(10): 1083–4. <a target=xrefwindow id=d52561e1077 href="http://www.ncbi.nlm.nih.gov/pubmed/27580085">PubMed Abstract </a> | <a target=xrefwindow id=d52561e1080 href="http://dx.doi.org/10.1001/jamadermatol.2016.3453">Publisher Full Text </a></span></li><li><a name=ref-12 class=n-a></a><span class=label>12. </span>&nbsp;<span class=citation><a name=d52561e1090 class=n-a></a>Bauer A, Diepgen TL, Schmitt J: Is occupational solar ultraviolet irradiation a relevant risk factor for basal cell carcinoma? A systematic review and meta-analysis of the epidemiological literature. <i>Br J Dermatol.</i> 2011; <b>165</b>(3): 612–25. <a target=xrefwindow id=d52561e1098 href="http://www.ncbi.nlm.nih.gov/pubmed/21605109">PubMed Abstract </a> | <a target=xrefwindow id=d52561e1101 href="http://dx.doi.org/10.1111/j.1365-2133.2011.10425.x">Publisher Full Text </a></span></li><li><a name=ref-13 class=n-a></a><span class=label>13. </span>&nbsp;<span class=citation><a name=d52561e1110 class=n-a></a>Gailani MR, Leffell DJ, Ziegler A, <i> et al.</i>: Relationship between sunlight exposure and a key genetic alteration in basal cell carcinoma. <i>J Natl Cancer Inst.</i> 1996; <b>88</b>(6): 349–54. <a target=xrefwindow id=d52561e1121 href="http://www.ncbi.nlm.nih.gov/pubmed/8609643">PubMed Abstract </a> | <a target=xrefwindow id=d52561e1124 href="http://dx.doi.org/10.1093/jnci/88.6.349">Publisher Full Text </a></span></li><li><a name=ref-14 class=n-a></a><span class=label>14. </span>&nbsp;<span class=citation><a name=d52561e1133 class=n-a></a>Situm M, Buljan M, Bulat V, <i> et al.</i>: The role of UV radiation in the development of basal cell carcinoma. <i>Coll Antropol.</i> 2008; <b>32 Suppl 2</b>: 167–70. <a target=xrefwindow id=d52561e1144 href="http://www.ncbi.nlm.nih.gov/pubmed/19138022">PubMed Abstract </a></span></li><li><a name=ref-15 class=n-a></a><span class=label>15. </span>&nbsp;<span class=citation><a name=d52561e1153 class=n-a></a>Narayanan DL, Saladi RN, Fox JL: Ultraviolet radiation and skin cancer. <i>Int J Dermatol.</i> 2010; <b>49</b>(9): 978–86. <a target=xrefwindow id=d52561e1161 href="http://www.ncbi.nlm.nih.gov/pubmed/20883261">PubMed Abstract </a> | <a target=xrefwindow id=d52561e1164 href="http://dx.doi.org/10.1111/j.1365-4632.2010.04474.x">Publisher Full Text </a></span></li><li><a name=ref-16 class=n-a></a><span class=label>16. </span>&nbsp;<span class=citation><a name=d52561e1173 class=n-a></a>Gallagher RP, Hill GB, Bajdik CD, <i> et al.</i>: Sunlight exposure, pigmentary factors, and risk of nonmelanocytic skin cancer. I. Basal cell carcinoma. <i>Arch Dermatol.</i> 1995; <b>131</b>(2): 157–63. <a target=xrefwindow id=d52561e1184 href="http://www.ncbi.nlm.nih.gov/pubmed/7857111">PubMed Abstract </a> | <a target=xrefwindow id=d52561e1187 href="http://dx.doi.org/10.1001/archderm.1995.01690140041006">Publisher Full Text </a></span></li><li><a name=ref-17 class=n-a></a><span class=label>17. </span>&nbsp;<span class=citation><a name=d52561e1196 class=n-a></a>Iannacone MR, Wang W, Stockwell HG, <i> et al.</i>: Patterns and timing of sunlight exposure and risk of basal cell and squamous cell carcinomas of the skin--a case-control study. <i>BMC Cancer.</i> 2012; <b>12</b>: 417. <a target=xrefwindow id=d52561e1207 href="http://www.ncbi.nlm.nih.gov/pubmed/22994655">PubMed Abstract </a> | <a target=xrefwindow id=d52561e1210 href="http://dx.doi.org/10.1186/1471-2407-12-417">Publisher Full Text </a> | <a target=xrefwindow id=d52561e1214 href="http://www.ncbi.nlm.nih.gov/pmc/articles/3517361">Free Full Text </a></span></li><li><a name=ref-18 class=n-a></a><span class=label>18. </span>&nbsp;<span class=citation><a name=d52561e1224 class=n-a></a>Rosso S, Zanetti R, Martinez C, <i> et al.</i>: The multicentre south European study 'Helios'. II: Different sun exposure patterns in the aetiology of basal cell and squamous cell carcinomas of the skin. <i>Br J Cancer.</i> 1996; <b>73</b>(11): 1447–54. <a target=xrefwindow id=d52561e1235 href="http://www.ncbi.nlm.nih.gov/pubmed/8645596">PubMed Abstract </a> | <a target=xrefwindow id=d52561e1238 href="http://dx.doi.org/10.1038/bjc.1996.275">Publisher Full Text </a> | <a target=xrefwindow id=d52561e1242 href="http://www.ncbi.nlm.nih.gov/pmc/articles/2074492">Free Full Text </a></span></li><li><a name=ref-19 class=n-a></a><span class=label>19. </span>&nbsp;<span class=citation><a name=d52561e1251 class=n-a></a>Kricker A, Armstrong BK, English DR, <i> et al.</i>: Does intermittent sun exposure cause basal cell carcinoma? a case-control study in Western Australia. <i>Int J Cancer.</i> 1995; <b>60</b>(4): 489–94. <a target=xrefwindow id=d52561e1262 href="http://www.ncbi.nlm.nih.gov/pubmed/7829262">PubMed Abstract </a> | <a target=xrefwindow id=d52561e1265 href="http://dx.doi.org/10.1002/ijc.2910600411">Publisher Full Text </a></span></li><li><a name=ref-20 class=n-a></a><span class=label>20. </span>&nbsp;<span class=citation><a name=d52561e1274 class=n-a></a>Colantonio S, Bracken MB, Beecker J: The association of indoor tanning and melanoma in adults: systematic review and meta-analysis. <i>J Am Acad Dermatol.</i> 2014; <b>70</b>(5): 847–57.e1-18. <a target=xrefwindow id=d52561e1282 href="http://www.ncbi.nlm.nih.gov/pubmed/24629998">PubMed Abstract </a> | <a target=xrefwindow id=d52561e1285 href="http://dx.doi.org/10.1016/j.jaad.2013.11.050">Publisher Full Text </a></span></li><li><a name=ref-21 class=n-a></a><span class=label>21. </span>&nbsp;<span class=citation><a name=d52561e1294 class=n-a></a>Cust AE, Armstrong BK, Goumas C, <i> et al.</i>: Sunbed use during adolescence and early adulthood is associated with increased risk of early-onset melanoma. <i>Int J Cancer.</i> 2011; <b>128</b>(10): 2425–35. <a target=xrefwindow id=d52561e1305 href="http://www.ncbi.nlm.nih.gov/pubmed/20669232">PubMed Abstract </a> | <a target=xrefwindow id=d52561e1308 href="http://dx.doi.org/10.1002/ijc.25576">Publisher Full Text </a> | <a target=xrefwindow id=d52561e1312 href="http://www.ncbi.nlm.nih.gov/pmc/articles/2993823">Free Full Text </a></span></li><li><a name=ref-22 class=n-a></a><span class=label>22. </span>&nbsp;<span class=citation><a name=d52561e1321 class=n-a></a>Ferrucci LM, Cartmel B, Molinaro AM, <i> et al.</i>: Indoor tanning and risk of early-onset basal cell carcinoma. <i>J Am Acad Dermatol.</i> 2012; <b>67</b>(4): 552–62. <a target=xrefwindow id=d52561e1332 href="http://www.ncbi.nlm.nih.gov/pubmed/22153793">PubMed Abstract </a> | <a target=xrefwindow id=d52561e1335 href="http://dx.doi.org/10.1016/j.jaad.2011.11.940">Publisher Full Text </a> | <a target=xrefwindow id=d52561e1339 href="http://www.ncbi.nlm.nih.gov/pmc/articles/3307842">Free Full Text </a></span></li><li><a name=ref-23 class=n-a></a><span class=label>23. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/3548956"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d52561e1348 class=n-a></a>Lazovich D, Vogel RI, Berwick M, <i> et al.</i>: Indoor tanning and risk of melanoma: a case-control study in a highly exposed population. <i>Cancer Epidemiol Biomarkers Prev.</i> 2010; <b>19</b>(6): 1557–68. <a target=xrefwindow id=d52561e1359 href="http://www.ncbi.nlm.nih.gov/pubmed/20507845">PubMed Abstract </a> | <a target=xrefwindow id=d52561e1362 href="http://dx.doi.org/10.1158/1055-9965.EPI-09-1249">Publisher Full Text </a> | <a target=xrefwindow id=d52561e1366 href="http://www.ncbi.nlm.nih.gov/pmc/articles/2883000">Free Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/3548956">F1000 Recommendation</a></span></li><li><a name=ref-24 class=n-a></a><span class=label>24. </span>&nbsp;<span class=citation><a name=d52561e1380 class=n-a></a>Wehner MR, Shive ML, Chren M, <i> et al.</i>: Indoor tanning and non-melanoma skin cancer: systematic review and meta-analysis. <i>BMJ.</i> 2012; <b>345</b>: e5909. <a target=xrefwindow id=d52561e1391 href="http://www.ncbi.nlm.nih.gov/pubmed/23033409">PubMed Abstract </a> | <a target=xrefwindow id=d52561e1394 href="http://dx.doi.org/10.1136/bmj.e5909">Publisher Full Text </a> | <a target=xrefwindow id=d52561e1398 href="http://www.ncbi.nlm.nih.gov/pmc/articles/3462818">Free Full Text </a></span></li><li><a name=ref-25 class=n-a></a><span class=label>25. </span>&nbsp;<span class=citation><a name=d52561e1407 class=n-a></a>Box NF, Duffy DL, Irving RE, <i> et al.</i>: Melanocortin-1 receptor genotype is a risk factor for basal and squamous cell carcinoma. <i>J Invest Dermatol.</i> 2001; <b>116</b>(2): 224–9. <a target=xrefwindow id=d52561e1418 href="http://www.ncbi.nlm.nih.gov/pubmed/11179997">PubMed Abstract </a> | <a target=xrefwindow id=d52561e1421 href="http://dx.doi.org/10.1046/j.1523-1747.2001.01224.x">Publisher Full Text </a></span></li><li><a name=ref-26 class=n-a></a><span class=label>26. </span>&nbsp;<span class=citation><a name=d52561e1430 class=n-a></a>Cust AE, Goumas C, Vuong K, <i> et al.</i>: <i>MC1R</i> genotype as a predictor of early-onset melanoma, compared with self-reported and physician-measured traditional risk factors: an Australian case-control-family study. <i>BMC Cancer.</i> 2013; <b>13</b>: 406. <a target=xrefwindow id=d52561e1444 href="http://www.ncbi.nlm.nih.gov/pubmed/24134749">PubMed Abstract </a> | <a target=xrefwindow id=d52561e1448 href="http://dx.doi.org/10.1186/1471-2407-13-406">Publisher Full Text </a> | <a target=xrefwindow id=d52561e1451 href="http://www.ncbi.nlm.nih.gov/pmc/articles/3766240">Free Full Text </a></span></li><li><a name=ref-27 class=n-a></a><span class=label>27. </span>&nbsp;<span class=citation><a name=d52561e1460 class=n-a></a>Dwyer T, Stankovich JM, Blizzard L, <i> et al.</i>: Does the addition of information on genotype improve prediction of the risk of melanoma and nonmelanoma skin cancer beyond that obtained from skin phenotype? <i>Am J Epidemiol.</i> 2004; <b>159</b>(9): 826–33. <a target=xrefwindow id=d52561e1471 href="http://www.ncbi.nlm.nih.gov/pubmed/15105175">PubMed Abstract </a> | <a target=xrefwindow id=d52561e1474 href="http://dx.doi.org/10.1093/aje/kwh120">Publisher Full Text </a></span></li><li><a name=ref-28 class=n-a></a><span class=label>28. </span>&nbsp;<span class=citation><a name=d52561e1483 class=n-a></a>Molinaro AM, Ferrucci LM, Cartmel B, <i> et al.</i>: Indoor tanning and the <i>MC1R</i> genotype: risk prediction for basal cell carcinoma risk in young people. <i>Am J Epidemiol.</i> 2015; <b>181</b>(11): 908–16. <a target=xrefwindow id=d52561e1497 href="http://www.ncbi.nlm.nih.gov/pubmed/25858289">PubMed Abstract </a> | <a target=xrefwindow id=d52561e1501 href="http://dx.doi.org/10.1093/aje/kwu356">Publisher Full Text </a> | <a target=xrefwindow id=d52561e1504 href="http://www.ncbi.nlm.nih.gov/pmc/articles/4445390">Free Full Text </a></span></li><li><a name=ref-29 class=n-a></a><span class=label>29. </span>&nbsp;<span class=citation><a name=d52561e1513 class=n-a></a>Scherer D, Bermejo JL, Rudnai P, <i> et al.</i>: <i>MC1R</i> variants associated susceptibility to basal cell carcinoma of skin: interaction with host factors and <i>XRCC3</i> polymorphism. <i>Int J Cancer.</i> 2008; <b>122</b>(8): 1787–93. <a target=xrefwindow id=d52561e1531 href="http://www.ncbi.nlm.nih.gov/pubmed/18067130">PubMed Abstract </a> | <a target=xrefwindow id=d52561e1534 href="http://dx.doi.org/10.1002/ijc.23257">Publisher Full Text </a></span></li><li><a name=ref-30 class=n-a></a><span class=label>30. </span>&nbsp;<span class=citation><a name=d52561e1544 class=n-a></a>Smith AG, Box NF, Marks LH, <i> et al.</i>: The human melanocortin-1 receptor locus: analysis of transcription unit, locus polymorphism and haplotype evolution. <i>Gene.</i> 2001; <b>281</b>(1–2): 81–94. <a target=xrefwindow id=d52561e1555 href="http://www.ncbi.nlm.nih.gov/pubmed/11750130">PubMed Abstract </a> | <a target=xrefwindow id=d52561e1558 href="http://dx.doi.org/10.1016/S0378-1119(01)00791-0">Publisher Full Text </a></span></li><li><a name=ref-31 class=n-a></a><span class=label>31. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/725532477"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d52561e1567 class=n-a></a>Asgari MM, Moffet HH, Ray GT, <i> et al.</i>: Trends in Basal Cell Carcinoma Incidence and Identification of High-Risk Subgroups, 1998–2012. <i>JAMA Dermatol.</i> 2015; <b>151</b>(9): 976–81. <a target=xrefwindow id=d52561e1578 href="http://www.ncbi.nlm.nih.gov/pubmed/26039887">PubMed Abstract </a> | <a target=xrefwindow id=d52561e1581 href="http://dx.doi.org/10.1001/jamadermatol.2015.1188">Publisher Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/725532477">F1000 Recommendation</a></span></li><li><a name=ref-32 class=n-a></a><span class=label>32. </span>&nbsp;<span class=citation><a name=d52561e1594 class=n-a></a>Flohil SC, Seubring I, van Rossum MM, <i> et al.</i>: Trends in Basal cell carcinoma incidence rates: a 37-year Dutch observational study. <i>J Invest Dermatol.</i> 2013; <b>133</b>(4): 913–8. <a target=xrefwindow id=d52561e1605 href="http://www.ncbi.nlm.nih.gov/pubmed/23190883">PubMed Abstract </a> | <a target=xrefwindow id=d52561e1608 href="http://dx.doi.org/10.1038/jid.2012.431">Publisher Full Text </a></span></li><li><a name=ref-33 class=n-a></a><span class=label>33. </span>&nbsp;<span class=citation><a name=d52561e1617 class=n-a></a>Moriwaki S, Ray S, Tarone RE, <i> et al.</i>: The effect of donor age on the processing of UV-damaged DNA by cultured human cells: reduced DNA repair capacity and increased DNA mutability. <i>Mutat Res.</i> 1996; <b>364</b>(2): 117–23. <a target=xrefwindow id=d52561e1628 href="http://www.ncbi.nlm.nih.gov/pubmed/8879277">PubMed Abstract </a> | <a target=xrefwindow id=d52561e1631 href="http://dx.doi.org/10.1016/0921-8777(96)00029-8">Publisher Full Text </a></span></li><li><a name=ref-34 class=n-a></a><span class=label>34. </span>&nbsp;<span class=citation><a name=d52561e1640 class=n-a></a>Wei Q, Matanoski GM, Farmer ER, <i> et al.</i>: DNA repair and aging in basal cell carcinoma: a molecular epidemiology study. <i>Proc Natl Acad Sci U S A.</i> 1993; <b>90</b>(4): 1614–8. <a target=xrefwindow id=d52561e1651 href="http://www.ncbi.nlm.nih.gov/pubmed/8434025">PubMed Abstract </a> | <a target=xrefwindow id=d52561e1654 href="http://dx.doi.org/10.1073/pnas.90.4.1614">Publisher Full Text </a> | <a target=xrefwindow id=d52561e1658 href="http://www.ncbi.nlm.nih.gov/pmc/articles/45925">Free Full Text </a></span></li><li><a name=ref-35 class=n-a></a><span class=label>35. </span>&nbsp;<span class=citation><a name=d52561e1667 class=n-a></a>Naldi L, DiLandro A, D'Avanzo B, <i> et al.</i>: Host-related and environmental risk factors for cutaneous basal cell carcinoma: evidence from an Italian case-control study. <i>J Am Acad Dermatol.</i> 2000; <b>42</b>(3): 446–52. <a target=xrefwindow id=d52561e1678 href="http://www.ncbi.nlm.nih.gov/pubmed/10688715">PubMed Abstract </a> | <a target=xrefwindow id=d52561e1681 href="http://dx.doi.org/10.1016/S0190-9622(00)90217-2">Publisher Full Text </a></span></li><li><a name=ref-36 class=n-a></a><span class=label>36. </span>&nbsp;<span class=citation><a name=d52561e1691 class=n-a></a>van Dam RM, Huang Z, Rimm EB, <i> et al.</i>: Risk factors for basal cell carcinoma of the skin in men: results from the health professionals follow-up study. <i>Am J Epidemiol.</i> 1999; <b>150</b>(5): 459–68. <a target=xrefwindow id=d52561e1702 href="http://www.ncbi.nlm.nih.gov/pubmed/10472945">PubMed Abstract </a> | <a target=xrefwindow id=d52561e1705 href="http://dx.doi.org/10.1093/oxfordjournals.aje.a010034">Publisher Full Text </a></span></li><li><a name=ref-37 class=n-a></a><span class=label>37. </span>&nbsp;<span class=citation><a name=d52561e1714 class=n-a></a>Zhang Y, Cartmel B, Choy CC, <i> et al.</i>: Body mass index, height and early-onset basal cell carcinoma in a case-control study. <i>Cancer Epidemiol.</i> 2017; <b>46</b>: 66–72. <a target=xrefwindow id=d52561e1725 href="http://www.ncbi.nlm.nih.gov/pubmed/28039770">PubMed Abstract </a> | <a target=xrefwindow id=d52561e1728 href="http://dx.doi.org/10.1016/j.canep.2016.12.007">Publisher Full Text </a> | <a target=xrefwindow id=d52561e1732 href="http://www.ncbi.nlm.nih.gov/pmc/articles/5272867">Free Full Text </a></span></li><li><a name=ref-38 class=n-a></a><span class=label>38. </span>&nbsp;<span class=citation><a name=d52561e1741 class=n-a></a>Wollina U, Tchernev G: Advanced basal cell carcinoma. <i>Wien Med Wochenschr.</i> 2013; <b>163</b>(15–16): 347–53. <a target=xrefwindow id=d52561e1749 href="http://www.ncbi.nlm.nih.gov/pubmed/23589318">PubMed Abstract </a> | <a target=xrefwindow id=d52561e1752 href="http://dx.doi.org/10.1007/s10354-013-0193-5">Publisher Full Text </a></span></li><li><a name=ref-39 class=n-a></a><span class=label>39. </span>&nbsp;<span class=citation><a name=d52561e1761 class=n-a></a>Wisgerhof HC, Edelbroek JR, de Fijter JW, <i> et al.</i>: Subsequent squamous- and basal-cell carcinomas in kidney-transplant recipients after the first skin cancer: cumulative incidence and risk factors. <i>Transplantation.</i> 2010; <b>89</b>(10): 1231–8. <a target=xrefwindow id=d52561e1772 href="http://www.ncbi.nlm.nih.gov/pubmed/20410852">PubMed Abstract </a> | <a target=xrefwindow id=d52561e1775 href="http://dx.doi.org/10.1097/TP.0b013e3181d84cdc">Publisher Full Text </a></span></li><li><a name=ref-40 class=n-a></a><span class=label>40. </span>&nbsp;<span class=citation><a name=d52561e1784 class=n-a></a>Forchetti G, Suppa M, Del Marmol V: Overview on non-melanoma skin cancers in solid organ transplant recipients. <i>G Ital Dermatol Venereol.</i> 2014; <b>149</b>(4): 383–7. <a target=xrefwindow id=d52561e1792 href="http://www.ncbi.nlm.nih.gov/pubmed/25068224">PubMed Abstract </a></span></li><li><a name=ref-41 class=n-a></a><span class=label>41. </span>&nbsp;<span class=citation><a name=d52561e1801 class=n-a></a>Tessari G, Girolomoni G: Nonmelanoma skin cancer in solid organ transplant recipients: update on epidemiology, risk factors, and management. <i>Dermatol Surg.</i> 2012; <b>38</b>(10): 1622–30. <a target=xrefwindow id=d52561e1809 href="http://www.ncbi.nlm.nih.gov/pubmed/22805312">PubMed Abstract </a> | <a target=xrefwindow id=d52561e1812 href="http://dx.doi.org/10.1111/j.1524-4725.2012.02520.x">Publisher Full Text </a></span></li><li><a name=ref-42 class=n-a></a><span class=label>42. </span>&nbsp;<span class=citation><a name=d52561e1822 class=n-a></a>Euvrard S, Kanitakis J, Claudy A: Skin cancers after organ transplantation. <i>N Engl J Med.</i> 2003; <b>348</b>(17): 1681–91. <a target=xrefwindow id=d52561e1830 href="http://www.ncbi.nlm.nih.gov/pubmed/12711744">PubMed Abstract </a> | <a target=xrefwindow id=d52561e1833 href="http://dx.doi.org/10.1056/NEJMra022137">Publisher Full Text </a></span></li><li><a name=ref-43 class=n-a></a><span class=label>43. </span>&nbsp;<span class=citation><a name=d52561e1842 class=n-a></a>Moloney FJ, Comber H, O'Lorcain P, <i> et al.</i>: A population-based study of skin cancer incidence and prevalence in renal transplant recipients. <i>Br J Dermatol.</i> 2006; <b>154</b>(3): 498–504. <a target=xrefwindow id=d52561e1853 href="http://www.ncbi.nlm.nih.gov/pubmed/16445782">PubMed Abstract </a> | <a target=xrefwindow id=d52561e1856 href="http://dx.doi.org/10.1111/j.1365-2133.2005.07021.x">Publisher Full Text </a></span></li><li><a name=ref-44 class=n-a></a><span class=label>44. </span>&nbsp;<span class=citation><a name=d52561e1865 class=n-a></a>Berg D, Otley CC: Skin cancer in organ transplant recipients: Epidemiology, pathogenesis, and management. <i>J Am Acad Dermatol.</i> 2002; <b>47</b>(1): 1–17; quiz 18–20. <a target=xrefwindow id=d52561e1873 href="http://www.ncbi.nlm.nih.gov/pubmed/12077575">PubMed Abstract </a> | <a target=xrefwindow id=d52561e1876 href="http://dx.doi.org/10.1067/mjd.2002.125579">Publisher Full Text </a></span></li><li><a name=ref-45 class=n-a></a><span class=label>45. </span>&nbsp;<span class=citation><a name=d52561e1885 class=n-a></a>Kalinova L, Majek O, Stehlik D, <i> et al.</i>: Skin cancer incidence in renal transplant recipients - a single center study. <i>Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub.</i> 2010; <b>154</b>(3): 257–60. <a target=xrefwindow id=d52561e1896 href="http://www.ncbi.nlm.nih.gov/pubmed/21048813">PubMed Abstract </a></span></li><li><a name=ref-46 class=n-a></a><span class=label>46. </span>&nbsp;<span class=citation><a name=d52561e1905 class=n-a></a>Zwald FO, Brown M: Skin cancer in solid organ transplant recipients: advances in therapy and management: part I. Epidemiology of skin cancer in solid organ transplant recipients. <i>J Am Acad Dermatol.</i> 2011; <b>65</b>(2): 253–61; quiz 262. <a target=xrefwindow id=d52561e1913 href="http://www.ncbi.nlm.nih.gov/pubmed/21763561">PubMed Abstract </a> | <a target=xrefwindow id=d52561e1916 href="http://dx.doi.org/10.1016/j.jaad.2010.11.062">Publisher Full Text </a></span></li><li><a name=ref-47 class=n-a></a><span class=label>47. </span>&nbsp;<span class=citation><a name=d52561e1925 class=n-a></a>Hartevelt MM, Bavinck JN, Kootte AM, <i> et al.</i>: Incidence of skin cancer after renal transplantation in The Netherlands. <i>Transplantation.</i> 1990; <b>49</b>(3): 506–9. <a target=xrefwindow id=d52561e1936 href="http://www.ncbi.nlm.nih.gov/pubmed/2316011">PubMed Abstract </a> | <a target=xrefwindow id=d52561e1939 href="http://dx.doi.org/10.1097/00007890-199003000-00006">Publisher Full Text </a></span></li><li><a name=ref-48 class=n-a></a><span class=label>48. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/727219497"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d52561e1949 class=n-a></a>Garrett GL, Blanc PD, Boscardin J, <i> et al.</i>: Incidence of and Risk Factors for Skin Cancer in Organ Transplant Recipients in the United States. <i>JAMA Dermatol.</i> 2017; <b>153</b>(3): 296–303. <a target=xrefwindow id=d52561e1960 href="http://www.ncbi.nlm.nih.gov/pubmed/28097368">PubMed Abstract </a> | <a target=xrefwindow id=d52561e1963 href="http://dx.doi.org/10.1001/jamadermatol.2016.4920">Publisher Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/727219497">F1000 Recommendation</a></span></li><li><a name=ref-49 class=n-a></a><span class=label>49. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/718557489"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d52561e1976 class=n-a></a>Alexandrov LB, Nik-Zainal S, Wedge DC, <i> et al.</i>: Signatures of mutational processes in human cancer. <i>Nature.</i> 2013; <b>500</b>(7463): 415–21. <a target=xrefwindow id=d52561e1987 href="http://www.ncbi.nlm.nih.gov/pubmed/23945592">PubMed Abstract </a> | <a target=xrefwindow id=d52561e1990 href="http://dx.doi.org/10.1038/nature12477">Publisher Full Text </a> | <a target=xrefwindow id=d52561e1994 href="http://www.ncbi.nlm.nih.gov/pmc/articles/3776390">Free Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/718557489">F1000 Recommendation</a></span></li><li><a name=ref-50 class=n-a></a><span class=label>50. </span>&nbsp;<span class=citation><a name=d52561e2007 class=n-a></a>Jayaraman SS, Rayhan DJ, Hazany S, <i> et al.</i>: Mutational landscape of basal cell carcinomas by whole-exome sequencing. <i>J Invest Dermatol.</i> 2014; <b>134</b>(1): 213–20. <a target=xrefwindow id=d52561e2018 href="http://www.ncbi.nlm.nih.gov/pubmed/23774526">PubMed Abstract </a> | <a target=xrefwindow id=d52561e2021 href="http://dx.doi.org/10.1038/jid.2013.276">Publisher Full Text </a></span></li><li><a name=ref-51 class=n-a></a><span class=label>51. </span>&nbsp;<span class=citation><a name=d52561e2030 class=n-a></a>Gailani MR, Bale AE: Developmental genes and cancer: role of patched in basal cell carcinoma of the skin. <i>J Natl Cancer Inst.</i> 1997; <b>89</b>(15): 1103–9. <a target=xrefwindow id=d52561e2038 href="http://www.ncbi.nlm.nih.gov/pubmed/9262247">PubMed Abstract </a> | <a target=xrefwindow id=d52561e2041 href="http://dx.doi.org/10.1093/jnci/89.15.1103">Publisher Full Text </a></span></li><li><a name=ref-52 class=n-a></a><span class=label>52. </span>&nbsp;<span class=citation><a name=d52561e2050 class=n-a></a>Gailani MR, Bale SJ, Leffell DJ, <i> et al.</i>: Developmental defects in Gorlin syndrome related to a putative tumor suppressor gene on chromosome 9. <i>Cell.</i> 1992; <b>69</b>(1): 111–7. <a target=xrefwindow id=d52561e2061 href="http://www.ncbi.nlm.nih.gov/pubmed/1348213">PubMed Abstract </a> | <a target=xrefwindow id=d52561e2064 href="http://dx.doi.org/10.1016/0092-8674(92)90122-S">Publisher Full Text </a></span></li><li><a name=ref-53 class=n-a></a><span class=label>53. </span>&nbsp;<span class=citation><a name=d52561e2073 class=n-a></a>Quinn AG, Campbell C, Healy E, <i> et al.</i>: Chromosome 9 allele loss occurs in both basal and squamous cell carcinomas of the skin. <i>J Invest Dermatol.</i> 1994; <b>102</b>(3): 300–3. <a target=xrefwindow id=d52561e2084 href="http://www.ncbi.nlm.nih.gov/pubmed/8120412">PubMed Abstract </a></span></li><li><a name=ref-54 class=n-a></a><span class=label>54. </span>&nbsp;<span class=citation><a name=d52561e2094 class=n-a></a>van der Riet P, Karp D, Farmer E, <i> et al.</i>: Progression of basal cell carcinoma through loss of chromosome 9q and inactivation of a single p53 allele. <i>Cancer Res.</i> 1994; <b>54</b>(1): 25–7. <a target=xrefwindow id=d52561e2105 href="http://www.ncbi.nlm.nih.gov/pubmed/8261448">PubMed Abstract </a></span></li><li><a name=ref-55 class=n-a></a><span class=label>55. </span>&nbsp;<span class=citation><a name=d52561e2114 class=n-a></a>Reifenberger J, Wolter M, Knobbe CB, <i> et al.</i>: Somatic mutations in the <i>PTCH</i>, <i>SMOH</i>, <i>SUFUH</i> and <i>TP53</i> genes in sporadic basal cell carcinomas. <i>Br J Dermatol.</i> 2005; <b>152</b>(1): 43–51. <a target=xrefwindow id=d52561e2138 href="http://www.ncbi.nlm.nih.gov/pubmed/15656799">PubMed Abstract </a> | <a target=xrefwindow id=d52561e2141 href="http://dx.doi.org/10.1111/j.1365-2133.2005.06353.x">Publisher Full Text </a></span></li><li><a name=ref-56 class=n-a></a><span class=label>56. </span>&nbsp;<span class=citation><a name=d52561e2150 class=n-a></a>Kim MY, Park HJ, Baek SC, <i> et al.</i>: Mutations of the <i>p53</i> and <i>PTCH</i> gene in basal cell carcinomas: UV mutation signature and strand bias. <i>J Dermatol Sci.</i> 2002; <b>29</b>(1): 1–9. <a target=xrefwindow id=d52561e2168 href="http://www.ncbi.nlm.nih.gov/pubmed/12007715">PubMed Abstract </a> | <a target=xrefwindow id=d52561e2171 href="http://dx.doi.org/10.1016/S0923-1811(01)00170-0">Publisher Full Text </a></span></li><li><a name=ref-57 class=n-a></a><span class=label>57. </span>&nbsp;<span class=citation><a name=d52561e2180 class=n-a></a>Ling G, Ahmadian A, Persson A, <i> et al.</i>: <i>PATCHED</i> and <i>p53</i> gene alterations in sporadic and hereditary basal cell cancer. <i>Oncogene.</i> 2001; <b>20</b>(53): 7770–8. <a target=xrefwindow id=d52561e2198 href="http://www.ncbi.nlm.nih.gov/pubmed/11753655">PubMed Abstract </a> | <a target=xrefwindow id=d52561e2201 href="http://dx.doi.org/10.1038/sj.onc.1204946">Publisher Full Text </a></span></li><li><a name=ref-58 class=n-a></a><span class=label>58. </span>&nbsp;<span class=citation><a name=d52561e2210 class=n-a></a>Gorlin RJ: Nevoid basal cell carcinoma syndrome. <i>Dermatol Clin.</i> 1995; <b>13</b>(1): 113–25. <a target=xrefwindow id=d52561e2218 href="http://www.ncbi.nlm.nih.gov/pubmed/7712637">PubMed Abstract </a></span></li><li><a name=ref-59 class=n-a></a><span class=label>59. </span>&nbsp;<span class=citation><a name=d52561e2227 class=n-a></a>Epstein EH: Basal cell carcinomas: attack of the hedgehog. <i>Nat Rev Cancer.</i> 2008; <b>8</b>(10): 743–54. <a target=xrefwindow id=d52561e2235 href="http://www.ncbi.nlm.nih.gov/pubmed/18813320">PubMed Abstract </a> | <a target=xrefwindow id=d52561e2238 href="http://dx.doi.org/10.1038/nrc2503">Publisher Full Text </a> | <a target=xrefwindow id=d52561e2241 href="http://www.ncbi.nlm.nih.gov/pmc/articles/4457317">Free Full Text </a></span></li><li><a name=ref-60 class=n-a></a><span class=label>60. </span>&nbsp;<span class=citation><a name=d52561e2251 class=n-a></a>Johnson RL, Rothman AL, Xie J, <i> et al.</i>: Human homolog of <i>patched</i>, a candidate gene for the basal cell nevus syndrome. <i>Science.</i> 1996; <b>272</b>(5268): 1668–71. <a target=xrefwindow id=d52561e2265 href="http://www.ncbi.nlm.nih.gov/pubmed/8658145">PubMed Abstract </a> | <a target=xrefwindow id=d52561e2269 href="http://dx.doi.org/10.1126/science.272.5268.1668">Publisher Full Text </a></span></li><li><a name=ref-61 class=n-a></a><span class=label>61. </span>&nbsp;<span class=citation><a name=d52561e2278 class=n-a></a>Aszterbaum M, Rothman A, Johnson RL, <i> et al.</i>: Identification of mutations in the human <i>PATCHED</i> gene in sporadic basal cell carcinomas and in patients with the basal cell nevus syndrome. <i>J Invest Dermatol.</i> 1998; <b>110</b>(6): 885–8. <a target=xrefwindow id=d52561e2292 href="http://www.ncbi.nlm.nih.gov/pubmed/9620294">PubMed Abstract </a> | <a target=xrefwindow id=d52561e2296 href="http://dx.doi.org/10.1046/j.1523-1747.1998.00222.x">Publisher Full Text </a></span></li><li><a name=ref-62 class=n-a></a><span class=label>62. </span>&nbsp;<span class=citation><a name=d52561e2305 class=n-a></a>Gailani MR, Ståhle-Bäckdahl M, Leffell DJ, <i> et al.</i>: The role of the human homologue of <i>Drosophila patched</i> in sporadic basal cell carcinomas. <i>Nat Genet.</i> 1996; <b>14</b>(1): 78–81. <a target=xrefwindow id=d52561e2319 href="http://www.ncbi.nlm.nih.gov/pubmed/8782823">PubMed Abstract </a> | <a target=xrefwindow id=d52561e2323 href="http://dx.doi.org/10.1038/ng0996-78">Publisher Full Text </a></span></li><li><a name=ref-63 class=n-a></a><span class=label>63. </span>&nbsp;<span class=citation><a name=d52561e2332 class=n-a></a>Bieging KT, Mello SS, Attardi LD: Unravelling mechanisms of p53-mediated tumour suppression. <i>Nat Rev Cancer.</i> 2014; <b>14</b>(5): 359–70. <a target=xrefwindow id=d52561e2340 href="http://www.ncbi.nlm.nih.gov/pubmed/24739573">PubMed Abstract </a> | <a target=xrefwindow id=d52561e2343 href="http://dx.doi.org/10.1038/nrc3711">Publisher Full Text </a> | <a target=xrefwindow id=d52561e2346 href="http://www.ncbi.nlm.nih.gov/pmc/articles/4049238">Free Full Text </a></span></li><li><a name=ref-64 class=n-a></a><span class=label>64. </span>&nbsp;<span class=citation><a name=d52561e2355 class=n-a></a>Rady P, Scinicariello F, Wagner RF Jr, <i> et al.</i>: p53 mutations in basal cell carcinomas. <i>Cancer Res.</i> 1992; <b>52</b>(13): 3804–6. <a target=xrefwindow id=d52561e2366 href="http://www.ncbi.nlm.nih.gov/pubmed/1617650">PubMed Abstract </a></span></li><li><a name=ref-65 class=n-a></a><span class=label>65. </span>&nbsp;<span class=citation><a name=d52561e2375 class=n-a></a>Ziegler A, Leffell DJ, Kunala S, <i> et al.</i>: Mutation hotspots due to sunlight in the p53 gene of nonmelanoma skin cancers. <i>Proc Natl Acad Sci U S A.</i> 1993; <b>90</b>(9): 4216–20. <a target=xrefwindow id=d52561e2386 href="http://www.ncbi.nlm.nih.gov/pubmed/8483937">PubMed Abstract </a> | <a target=xrefwindow id=d52561e2389 href="http://dx.doi.org/ 10.1073/pnas.90.9.4216">Publisher Full Text </a> | <a target=xrefwindow id=d52561e2393 href="http://www.ncbi.nlm.nih.gov/pmc/articles/46477">Free Full Text </a></span></li><li><a name=ref-66 class=n-a></a><span class=label>66. </span>&nbsp;<span class=citation><a name=d52561e2403 class=n-a></a>Kudchadkar R, Lewis K, Gonzalez R: Advances in the treatment of Basal cell carcinoma: Hedgehog inhibitors. <i>Semin Oncol.</i> 2012; <b>39</b>(2): 139–44. <a target=xrefwindow id=d52561e2411 href="http://www.ncbi.nlm.nih.gov/pubmed/22484185">PubMed Abstract </a> | <a target=xrefwindow id=d52561e2414 href="http://dx.doi.org/10.1053/j.seminoncol.2012.01.011">Publisher Full Text </a></span></li><li><a name=ref-67 class=n-a></a><span class=label>67. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/1164783"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d52561e2423 class=n-a></a>Von Hoff DD, LoRusso PM, Rudin CM, <i> et al.</i>: Inhibition of the hedgehog pathway in advanced basal-cell carcinoma. <i>N Engl J Med.</i> 2009; <b>361</b>(12): 1164–72. <a target=xrefwindow id=d52561e2434 href="http://www.ncbi.nlm.nih.gov/pubmed/19726763">PubMed Abstract </a> | <a target=xrefwindow id=d52561e2437 href="http://dx.doi.org/10.1056/NEJMoa0905360">Publisher Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/1164783">F1000 Recommendation</a></span></li><li><a name=ref-68 class=n-a></a><span class=label>68. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/717950275"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d52561e2450 class=n-a></a>Sekulic A, Migden MR, Oro AE, <i> et al.</i>: Efficacy and safety of vismodegib in advanced basal-cell carcinoma. <i>N Engl J Med.</i> 2012; <b>366</b>(23): 2171–9. <a target=xrefwindow id=d52561e2461 href="http://www.ncbi.nlm.nih.gov/pubmed/22670903">PubMed Abstract </a> | <a target=xrefwindow id=d52561e2464 href="http://dx.doi.org/10.1056/NEJMoa1113713">Publisher Full Text </a> | <a target=xrefwindow id=d52561e2468 href="http://www.ncbi.nlm.nih.gov/pmc/articles/5278761">Free Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/717950275">F1000 Recommendation</a></span></li><li><a name=ref-69 class=n-a></a><span class=label>69. </span>&nbsp;<span class=citation><a name=d52561e2481 class=n-a></a>Rudnick EW, Thareja S, Cherpelis B: Oral therapy for nonmelanoma skin cancer in patients with advanced disease and large tumor burden: a review of the literature with focus on a new generation of targeted therapies. <i>Int J Dermatol.</i> 2016; <b>55</b>(3): 249–58; quiz 256, 258. <a target=xrefwindow id=d52561e2489 href="http://www.ncbi.nlm.nih.gov/pubmed/26566923">PubMed Abstract </a> | <a target=xrefwindow id=d52561e2492 href="http://dx.doi.org/10.1111/ijd.12961">Publisher Full Text </a></span></li><li><a name=ref-70 class=n-a></a><span class=label>70. </span>&nbsp;<span class=citation><a name=d52561e2501 class=n-a></a>Chang AL, Solomon JA, Hainsworth JD, <i> et al.</i>: Expanded access study of patients with advanced basal cell carcinoma treated with the Hedgehog pathway inhibitor, vismodegib. <i>J Am Acad Dermatol.</i> 2014; <b>70</b>(1): 60–9. <a target=xrefwindow id=d52561e2512 href="http://www.ncbi.nlm.nih.gov/pubmed/24189279">PubMed Abstract </a> | <a target=xrefwindow id=d52561e2515 href="http://dx.doi.org/10.1016/j.jaad.2013.09.012">Publisher Full Text </a></span></li><li><a name=ref-71 class=n-a></a><span class=label>71. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/725503662"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d52561e2524 class=n-a></a>Basset-Seguin N, Hauschild A, Grob JJ, <i> et al.</i>: Vismodegib in patients with advanced basal cell carcinoma (STEVIE): a pre-planned interim analysis of an international, open-label trial. <i>Lancet Oncol.</i> 2015; <b>16</b>(6): 729–36. <a target=xrefwindow id=d52561e2535 href="http://www.ncbi.nlm.nih.gov/pubmed/25981813">PubMed Abstract </a> | <a target=xrefwindow id=d52561e2538 href="http://dx.doi.org/10.1016/S1470-2045(15)70198-1">Publisher Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/725503662">F1000 Recommendation</a></span></li><li><a name=ref-72 class=n-a></a><span class=label>72. </span>&nbsp;<span class=citation><a name=d52561e2552 class=n-a></a>Ally MS, Aasi S, Wysong A, <i> et al.</i>: An investigator-initiated open-label clinical trial of vismodegib as a neoadjuvant to surgery for high-risk basal cell carcinoma. <i>J Am Acad Dermatol.</i> 2014; <b>71</b>(5): 904–911.e1. <a target=xrefwindow id=d52561e2563 href="http://www.ncbi.nlm.nih.gov/pubmed/24929884">PubMed Abstract </a> | <a target=xrefwindow id=d52561e2566 href="http://dx.doi.org/10.1016/j.jaad.2014.05.020">Publisher Full Text </a></span></li><li><a name=ref-73 class=n-a></a><span class=label>73. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/717950272"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d52561e2575 class=n-a></a>Tang JY, Mackay-Wiggan JM, Aszterbaum M, <i> et al.</i>: Inhibiting the hedgehog pathway in patients with the basal-cell nevus syndrome. <i>N Engl J Med.</i> 2012; <b>366</b>(23): 2180–8. <a target=xrefwindow id=d52561e2586 href="http://www.ncbi.nlm.nih.gov/pubmed/22670904">PubMed Abstract </a> | <a target=xrefwindow id=d52561e2589 href="http://dx.doi.org/10.1056/NEJMoa1113538">Publisher Full Text </a> | <a target=xrefwindow id=d52561e2593 href="http://www.ncbi.nlm.nih.gov/pmc/articles/4362529">Free Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/717950272">F1000 Recommendation</a></span></li><li><a name=ref-74 class=n-a></a><span class=label>74. </span>&nbsp;<span class=citation><a name=d52561e2606 class=n-a></a>Casey D, Demko S, Shord S, <i> et al.</i>: FDA Approval Summary: Sonidegib for Locally Advanced Basal Cell Carcinoma. <i>Clin Cancer Res.</i> 2017; <b>23</b>(10): 2377–81. <a target=xrefwindow id=d52561e2617 href="http://www.ncbi.nlm.nih.gov/pubmed/28073840">PubMed Abstract </a> | <a target=xrefwindow id=d52561e2620 href="http://dx.doi.org/10.1158/1078-0432.CCR-16-2051">Publisher Full Text </a></span></li><li><a name=ref-75 class=n-a></a><span class=label>75. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/725503664"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d52561e2629 class=n-a></a>Migden MR, Guminski A, Gutzmer R, <i> et al.</i>: Treatment with two different doses of sonidegib in patients with locally advanced or metastatic basal cell carcinoma (BOLT): a multicentre, randomised, double-blind phase 2 trial. <i>Lancet Oncol.</i> 2015; <b>16</b>(6): 716–28. <a target=xrefwindow id=d52561e2640 href="http://www.ncbi.nlm.nih.gov/pubmed/25981810">PubMed Abstract </a> | <a target=xrefwindow id=d52561e2643 href="http://dx.doi.org/10.1016/S1470-2045(15)70100-2">Publisher Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/725503664">F1000 Recommendation</a></span></li><li><a name=ref-76 class=n-a></a><span class=label>76. </span>&nbsp;<span class=citation><a name=d52561e2656 class=n-a></a>Chen L, Silapunt S, Migden MR: Sonidegib for the treatment of advanced basal cell carcinoma: a comprehensive review of sonidegib and the BOLT trial with 12-month update. <i>Future Oncol.</i> 2016; <b>12</b>(18): 2095–105. <a target=xrefwindow id=d52561e2664 href="http://www.ncbi.nlm.nih.gov/pubmed/27189494">PubMed Abstract </a> | <a target=xrefwindow id=d52561e2667 href="http://dx.doi.org/10.2217/fon-2016-0118">Publisher Full Text </a></span></li><li><a name=ref-77 class=n-a></a><span class=label>77. </span>&nbsp;<span class=citation><a name=d52561e2676 class=n-a></a>Dummer R, Guminski A, Gutzmer R, <i> et al.</i>: The 12-month analysis from Basal Cell Carcinoma Outcomes with LDE225 Treatment (BOLT): A phase II, randomized, double-blind study of sonidegib in patients with advanced basal cell carcinoma. <i>J Am Acad Dermatol.</i> 2016; <b>75</b>(1): 113–125.e5. <a target=xrefwindow id=d52561e2687 href="http://www.ncbi.nlm.nih.gov/pubmed/27067394">PubMed Abstract </a> | <a target=xrefwindow id=d52561e2690 href="http://dx.doi.org/10.1016/j.jaad.2016.02.1226">Publisher Full Text </a></span></li><li><a name=ref-78 class=n-a></a><span class=label>78. </span>&nbsp;<span class=citation><a name=d52561e2700 class=n-a></a>Lear J, GA, Gutzmer R: A phase 2, randomized, double-blind study of sonidegib (LDE225) in patients with advanced basalcell carcinoma: the BOLT 18-month analysis [abstract]. In: <i>24th EADV Congress</i>. 2015. </span></li><li><a name=ref-79 class=n-a></a><span class=label>79. </span>&nbsp;<span class=citation><a name=d52561e2712 class=n-a></a>Brinkhuizen T, Reinders MG, van Geel M, <i> et al.</i>: Acquired resistance to the Hedgehog pathway inhibitor vismodegib due to smoothened mutations in treatment of locally advanced basal cell carcinoma. <i>J Am Acad Dermatol.</i> 2014; <b>71</b>(5): 1005–8. <a target=xrefwindow id=d52561e2723 href="http://www.ncbi.nlm.nih.gov/pubmed/25199678">PubMed Abstract </a> | <a target=xrefwindow id=d52561e2726 href="http://dx.doi.org/10.1016/j.jaad.2014.08.001">Publisher Full Text </a></span></li><li><a name=ref-80 class=n-a></a><span class=label>80. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/723347807"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d52561e2735 class=n-a></a>Pricl S, Cortelazzi B, Dal Col V, <i> et al.</i>: Smoothened (SMO) receptor mutations dictate resistance to vismodegib in basal cell carcinoma. <i>Mol Oncol.</i> 2015; <b>9</b>(2): 389–97. <a target=xrefwindow id=d52561e2746 href="http://www.ncbi.nlm.nih.gov/pubmed/25306392">PubMed Abstract </a> | <a target=xrefwindow id=d52561e2749 href="http://dx.doi.org/10.1016/j.molonc.2014.09.003">Publisher Full Text </a> | <a target=xrefwindow id=d52561e2753 href="http://www.ncbi.nlm.nih.gov/pmc/articles/5528667">Free Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/723347807">F1000 Recommendation</a></span></li><li><a name=ref-81 class=n-a></a><span class=label>81. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/725919181"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d52561e2766 class=n-a></a>Danial C, Sarin KY, Oro AE, <i> et al.</i>: An Investigator-Initiated Open-Label Trial of Sonidegib in Advanced Basal Cell Carcinoma Patients Resistant to Vismodegib. <i>Clin Cancer Res.</i> 2016; <b>22</b>(6): 1325–9. <a target=xrefwindow id=d52561e2777 href="http://www.ncbi.nlm.nih.gov/pubmed/26546616">PubMed Abstract </a> | <a target=xrefwindow id=d52561e2780 href="http://dx.doi.org/10.1158/1078-0432.CCR-15-1588">Publisher Full Text </a> | <a target=xrefwindow id=d52561e2784 href="http://www.ncbi.nlm.nih.gov/pmc/articles/4794361">Free Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/725919181">F1000 Recommendation</a></span></li><li><a name=ref-82 class=n-a></a><span class=label>82. </span>&nbsp;<span class=citation><a name=d52561e2797 class=n-a></a>Chen JG, Fleischer AB Jr, Smith ED, <i> et al.</i>: Cost of nonmelanoma skin cancer treatment in the United States. <i>Dermatol Surg.</i> 2001; <b>27</b>(12): 1035–8. <a target=xrefwindow id=d52561e2808 href="http://www.ncbi.nlm.nih.gov/pubmed/11849266">PubMed Abstract </a> | <a target=xrefwindow id=d52561e2811 href="http://dx.doi.org/10.1046/j.1524-4725.2001.01004.x">Publisher Full Text </a></span></li><li><a name=ref-83 class=n-a></a><span class=label>83. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/727493898"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d52561e2820 class=n-a></a>Migden M, Xie J, Wei J, <i> et al.</i>: Burden and treatment patterns of advanced basal cell carcinoma among commercially insured patients in a United States database from 2010 to 2014. <i>J Am Acad Dermatol.</i> 2017; <b>77</b>(1): 55–62.e3. <a target=xrefwindow id=d52561e2831 href="http://www.ncbi.nlm.nih.gov/pubmed/28392293">PubMed Abstract </a> | <a target=xrefwindow id=d52561e2834 href="http://dx.doi.org/10.1016/j.jaad.2017.02.050">Publisher Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/727493898">F1000 Recommendation</a></span></li><li><a name=ref-84 class=n-a></a><span class=label>84. </span>&nbsp;<span class=citation><a name=d52561e2848 class=n-a></a>Haves AW, Schaffer PR, Carucci JA: The impact of inoperable advanced basal cell carcinoma: the economic, physical, and psychological burden of the disease. <i>J Drugs Dermatol.</i> 2013; <b>12</b>(10 Suppl): s151–3. <a target=xrefwindow id=d52561e2856 href="http://www.ncbi.nlm.nih.gov/pubmed/24085061">PubMed Abstract </a></span></li><li><a name=ref-85 class=n-a></a><span class=label>85. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/717973051"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d52561e2865 class=n-a></a>American Academy of Dermatology, American College of Mohs Surgery, American Society for Dermatologic Surgery Association, <i>et al.</i>: AAD/ACMS/ASDSA/ASMS 2012 appropriate use criteria for Mohs micrographic surgery: a report of the American Academy of Dermatology, American College of Mohs Surgery, American Society for Dermatologic Surgery Association, and the American Society for Mohs Surgery. <i>Dermatol Surg.</i> 2012; <b>38</b>(10): 1582–603. <a target=xrefwindow id=d52561e2876 href="http://www.ncbi.nlm.nih.gov/pubmed/22958088">PubMed Abstract </a> | <a target=xrefwindow id=d52561e2879 href="http://dx.doi.org/10.1111/j.1524-4725.2012.02574.x">Publisher Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/717973051">F1000 Recommendation</a></span></li><li><a name=ref-86 class=n-a></a><span class=label>86. </span>&nbsp;<span class=citation><a name=d52561e2892 class=n-a></a>Wolf DJ, Zitelli JA: Surgical margins for basal cell carcinoma. <i>Arch Dermatol.</i> 1987; <b>123</b>(3): 340–4. <a target=xrefwindow id=d52561e2900 href="http://www.ncbi.nlm.nih.gov/pubmed/3813602">PubMed Abstract </a> | <a target=xrefwindow id=d52561e2903 href="http://dx.doi.org/10.1001/archderm.1987.01660270078019">Publisher Full Text </a></span></li><li><a name=ref-87 class=n-a></a><span class=label>87. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/721062539"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d52561e2912 class=n-a></a>Kimyai-Asadi A, Alam M, Goldberg LH, <i> et al.</i>: Efficacy of narrow-margin excision of well-demarcated primary facial basal cell carcinomas. <i>J Am Acad Dermatol.</i> 2005; <b>53</b>(3): 464–8. <a target=xrefwindow id=d52561e2923 href="http://www.ncbi.nlm.nih.gov/pubmed/16112354">PubMed Abstract </a> | <a target=xrefwindow id=d52561e2926 href="http://dx.doi.org/10.1016/j.jaad.2005.03.038">Publisher Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/721062539">F1000 Recommendation</a></span></li><li><a name=ref-88 class=n-a></a><span class=label>88. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/722500621"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d52561e2939 class=n-a></a>Farhi D, Dupin N, Palangié A, <i> et al.</i>: Incomplete excision of basal cell carcinoma: rate and associated factors among 362 consecutive cases. <i>Dermatol Surg.</i> 2007; <b>33</b>(10): 1207–14. <a target=xrefwindow id=d52561e2950 href="http://www.ncbi.nlm.nih.gov/pubmed/17903153">PubMed Abstract </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/722500621">F1000 Recommendation</a></span></li><li><a name=ref-89 class=n-a></a><span class=label>89. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/721062541"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d52561e2963 class=n-a></a>Leibovitch I, Huilgol SC, Selva D, <i> et al.</i>: Basal cell carcinoma treated with Mohs surgery in Australia II. Outcome at 5-year follow-up. <i>J Am Acad Dermatol.</i> 2005; <b>53</b>(3): 452–7. <a target=xrefwindow id=d52561e2974 href="http://www.ncbi.nlm.nih.gov/pubmed/16112352">PubMed Abstract </a> | <a target=xrefwindow id=d52561e2977 href="http://dx.doi.org/10.1016/j.jaad.2005.04.087">Publisher Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/721062541">F1000 Recommendation</a></span></li><li><a name=ref-90 class=n-a></a><span class=label>90. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/720489290"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d52561e2991 class=n-a></a>Mosterd K, Krekels GA, Nieman FH, <i> et al.</i>: Surgical excision versus Mohs' micrographic surgery for primary and recurrent basal-cell carcinoma of the face: a prospective randomised controlled trial with 5-years' follow-up. <i>Lancet Oncol.</i> 2008; <b>9</b>(12): 1149–56. <a target=xrefwindow id=d52561e3002 href="http://www.ncbi.nlm.nih.gov/pubmed/19010733">PubMed Abstract </a> | <a target=xrefwindow id=d52561e3005 href="http://dx.doi.org/10.1016/S1470-2045(08)70260-2">Publisher Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/720489290">F1000 Recommendation</a></span></li><li><a name=ref-91 class=n-a></a><span class=label>91. </span>&nbsp;<span class=citation><a name=d52561e3018 class=n-a></a>Smeets NW, Kuijpers DI, Nelemans P, <i> et al.</i>: Mohs' micrographic surgery for treatment of basal cell carcinoma of the face--results of a retrospective study and review of the literature. <i>Br J Dermatol.</i> 2004; <b>151</b>(1): 141–7. <a target=xrefwindow id=d52561e3029 href="http://www.ncbi.nlm.nih.gov/pubmed/15270883">PubMed Abstract </a> | <a target=xrefwindow id=d52561e3032 href="http://dx.doi.org/10.1111/j.1365-2133.2004.06047.x">Publisher Full Text </a></span></li><li><a name=ref-92 class=n-a></a><span class=label>92. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/725539222"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d52561e3041 class=n-a></a>Bozan A, Gode S, Kaya I, <i> et al.</i>: Long-term Follow-up of Positive Surgical Margins in Basal Cell Carcinoma of the Face. <i>Dermatol Surg.</i> 2015; <b>41</b>(7): 761–7. <a target=xrefwindow id=d52561e3052 href="http://www.ncbi.nlm.nih.gov/pubmed/26050215">PubMed Abstract </a> | <a target=xrefwindow id=d52561e3055 href="http://dx.doi.org/10.1097/DSS.0000000000000394">Publisher Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/725539222">F1000 Recommendation</a></span></li><li><a name=ref-93 class=n-a></a><span class=label>93. </span>&nbsp;<span class=citation><a name=d52561e3068 class=n-a></a>Kopf AW, Bart RS, Schrager D, <i> et al.</i>: Curettage-electrodesiccation treatment of basal cell carcinomas. <i>Arch Dermatol.</i> 1977; <b>113</b>(4): 439–43. <a target=xrefwindow id=d52561e3079 href="http://www.ncbi.nlm.nih.gov/pubmed/848972">PubMed Abstract </a> | <a target=xrefwindow id=d52561e3082 href="http://dx.doi.org/10.1001/archderm.1977.01640040047006">Publisher Full Text </a></span></li><li><a name=ref-94 class=n-a></a><span class=label>94. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/727089005"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d52561e3091 class=n-a></a>Williams HC, Bath-Hextall F, Ozolins M, <i> et al.</i>: Surgery Versus 5% Imiquimod for Nodular and Superficial Basal Cell Carcinoma: 5-Year Results of the SINS Randomized Controlled Trial. <i>J Invest Dermatol.</i> 2017; <b>137</b>(3): 614–9. <a target=xrefwindow id=d52561e3102 href="http://www.ncbi.nlm.nih.gov/pubmed/27932240">PubMed Abstract </a> | <a target=xrefwindow id=d52561e3105 href="http://dx.doi.org/10.1016/j.jid.2016.10.019">Publisher Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/727089005">F1000 Recommendation</a></span></li><li><a name=ref-95 class=n-a></a><span class=label>95. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/721063077"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d52561e3118 class=n-a></a>Geisse J, Caro I, Lindholm J, <i> et al.</i>: Imiquimod 5% cream for the treatment of superficial basal cell carcinoma: results from two phase III, randomized, vehicle-controlled studies. <i>J Am Acad Dermatol.</i> 2004; <b>50</b>(5): 722–33. <a target=xrefwindow id=d52561e3129 href="http://www.ncbi.nlm.nih.gov/pubmed/15097956">PubMed Abstract </a> | <a target=xrefwindow id=d52561e3132 href="http://dx.doi.org/10.1016/j.jaad.2003.11.066">Publisher Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/721063077">F1000 Recommendation</a></span></li><li><a name=ref-96 class=n-a></a><span class=label>96. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/721063805"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d52561e3146 class=n-a></a>Geisse JK, Rich P, Pandya A, <i> et al.</i>: Imiquimod 5% cream for the treatment of superficial basal cell carcinoma: a double-blind, randomized, vehicle-controlled study. <i>J Am Acad Dermatol.</i> 2002; <b>47</b>(3): 390–8. <a target=xrefwindow id=d52561e3157 href="http://www.ncbi.nlm.nih.gov/pubmed/12196749">PubMed Abstract </a> | <a target=xrefwindow id=d52561e3160 href="http://dx.doi.org/10.1067/mjd.2002.126215">Publisher Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/721063805">F1000 Recommendation</a></span></li><li><a name=ref-97 class=n-a></a><span class=label>97. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/718016210"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d52561e3173 class=n-a></a>Arits H, Mosterd K, Essers BA, <i> et al.</i>: Photodynamic therapy versus topical imiquimod versus topical fluorouracil for treatment of superficial basal-cell carcinoma: a single blind, non-inferiority, randomised controlled trial. <i>Lancet Oncol.</i> 2013; <b>14</b>(7): 647–54. <a target=xrefwindow id=d52561e3184 href="http://www.ncbi.nlm.nih.gov/pubmed/23683751">PubMed Abstract </a> | <a target=xrefwindow id=d52561e3187 href="http://dx.doi.org/10.1016/S1470-2045(13)70143-8">Publisher Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/718016210">F1000 Recommendation</a></span></li><li><a name=ref-98 class=n-a></a><span class=label>98. </span>&nbsp;<span class=citation><a name=d52561e3200 class=n-a></a>Romagosa R, Saap L, Givens M, <i> et al.</i>: A pilot study to evaluate the treatment of basal cell carcinoma with 5-fluorouracil using phosphatidyl choline as a transepidermal carrier. <i>Dermatol Surg.</i> 2000; <b>26</b>(4): 338–40. <a target=xrefwindow id=d52561e3211 href="http://www.ncbi.nlm.nih.gov/pubmed/10759821">PubMed Abstract </a> | <a target=xrefwindow id=d52561e3214 href="http://dx.doi.org/10.1046/j.1524-4725.2000.99227.x">Publisher Full Text </a></span></li><li><a name=ref-99 class=n-a></a><span class=label>99. </span>&nbsp;<span class=citation><a name=d52561e3223 class=n-a></a>Zeitouni NC, Oseroff AR, Shieh S: Photodynamic therapy for nonmelanoma skin cancers. Current review and update. <i>Mol Immunol.</i> 2003; <b>39</b>(17–18): 1133–6. <a target=xrefwindow id=d52561e3231 href="http://www.ncbi.nlm.nih.gov/pubmed/12835091">PubMed Abstract </a> | <a target=xrefwindow id=d52561e3234 href="http://dx.doi.org/10.1016/S0161-5890(03)00083-X">Publisher Full Text </a></span></li><li><a name=ref-100 class=n-a></a><span class=label>100. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/1092295"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d52561e3243 class=n-a></a>Rhodes LE, de Rie MA, Leifsdottir R, <i> et al.</i>: Five-year follow-up of a randomized, prospective trial of topical methyl aminolevulinate photodynamic therapy vs surgery for nodular basal cell carcinoma. <i>Arch Dermatol.</i> 2007; <b>143</b>(9): 1131–6. <a target=xrefwindow id=d52561e3254 href="http://www.ncbi.nlm.nih.gov/pubmed/17875873">PubMed Abstract </a> | <a target=xrefwindow id=d52561e3257 href="http://dx.doi.org/10.1001/archderm.143.9.1131">Publisher Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/1092295">F1000 Recommendation</a></span></li><li><a name=ref-101 class=n-a></a><span class=label>101. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/718006556"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d52561e3270 class=n-a></a>Roozeboom MH, Aardoom MA, Nelemans PJ, <i> et al.</i>: Fractionated 5-aminolevulinic acid photodynamic therapy after partial debulking versus surgical excision for nodular basal cell carcinoma: a randomized controlled trial with at least 5-year follow-up. <i>J Am Acad Dermatol.</i> 2013; <b>69</b>(2): 280–7. <a target=xrefwindow id=d52561e3281 href="http://www.ncbi.nlm.nih.gov/pubmed/23566914">PubMed Abstract </a> | <a target=xrefwindow id=d52561e3284 href="http://dx.doi.org/10.1016/j.jaad.2013.02.014">Publisher Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/718006556">F1000 Recommendation</a></span></li><li><a name=ref-102 class=n-a></a><span class=label>102. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/721157664"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d52561e3298 class=n-a></a>Bath-Hextall FJ, Perkins W, Bong J, <i> et al.</i>: Interventions for basal cell carcinoma of the skin. <i>Cochrane Database Syst Rev.</i> 2007; (1): CD003412. <a target=xrefwindow id=d52561e3306 href="http://www.ncbi.nlm.nih.gov/pubmed/17253489">PubMed Abstract </a> | <a target=xrefwindow id=d52561e3309 href="http://dx.doi.org/10.1002/14651858.CD003412.pub2">Publisher Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/721157664">F1000 Recommendation</a></span></li><li><a name=ref-103 class=n-a></a><span class=label>103. </span>&nbsp;<span class=citation><a name=d52561e3322 class=n-a></a>Basset-Seguin N, Ibbotson SH, Emtestam L, <i> et al.</i>: Topical methyl aminolaevulinate photodynamic therapy versus cryotherapy for superficial basal cell carcinoma: a 5 year randomized trial. <i>Eur J Dermatol.</i> 2008; <b>18</b>(5): 547–53. <a target=xrefwindow id=d52561e3333 href="http://www.ncbi.nlm.nih.gov/pubmed/18693158">PubMed Abstract </a></span></li><li><a name=ref-104 class=n-a></a><span class=label>104. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/717847803"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d52561e3342 class=n-a></a>Roozeboom MH, Arits AH, Nelemans PJ, <i> et al.</i>: Overall treatment success after treatment of primary superficial basal cell carcinoma: a systematic review and meta-analysis of randomized and nonrandomized trials. <i>Br J Dermatol.</i> 2012; <b>167</b>(4): 733–56. <a target=xrefwindow id=d52561e3353 href="http://www.ncbi.nlm.nih.gov/pubmed/22612571">PubMed Abstract </a> | <a target=xrefwindow id=d52561e3356 href="http://dx.doi.org/10.1111/j.1365-2133.2012.11061.x">Publisher Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/717847803">F1000 Recommendation</a></span></li><li><a name=ref-105 class=n-a></a><span class=label>105. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/718844198"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d52561e3369 class=n-a></a>Szeimies RM, Ibbotson S, Murrell DF, <i> et al.</i>: A clinical study comparing methyl aminolevulinate photodynamic therapy and surgery in small superficial basal cell carcinoma (8-20 mm), with a 12-month follow-up. <i>J Eur Acad Dermatol Venereol.</i> 2008; <b>22</b>(11): 1302–11. <a target=xrefwindow id=d52561e3380 href="http://www.ncbi.nlm.nih.gov/pubmed/18624836">PubMed Abstract </a> | <a target=xrefwindow id=d52561e3383 href="http://dx.doi.org/10.1111/j.1468-3083.2008.02803.x">Publisher Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/718844198">F1000 Recommendation</a></span></li><li><a name=ref-106 class=n-a></a><span class=label>106. </span>&nbsp;<span class=citation><a name=d52561e3396 class=n-a></a>Wollina U, Schreiber A, Merla K, <i> et al.</i>: Combined cetuximab and volumetric modulated arc-radiotherapy in advanced recurrent squamous cell carcinoma of the scalp. <i>Dermatol Reports.</i> 2011; <b>3</b>(3): e57. <a target=xrefwindow id=d52561e3407 href="http://www.ncbi.nlm.nih.gov/pubmed/25386308">PubMed Abstract </a> | <a target=xrefwindow id=d52561e3410 href="http://dx.doi.org/10.4081/dr.2011.e57">Publisher Full Text </a> | <a target=xrefwindow id=d52561e3414 href="http://www.ncbi.nlm.nih.gov/pmc/articles/4211506">Free Full Text </a></span></li><li><a name=ref-107 class=n-a></a><span class=label>107. </span>&nbsp;<span class=citation><a name=d52561e3423 class=n-a></a>Smith V, Walton S: Treatment of facial Basal cell carcinoma: a review. <i>J Skin Cancer.</i> 2011; <b>2011</b>: 380371. <a target=xrefwindow id=d52561e3431 href="http://www.ncbi.nlm.nih.gov/pubmed/21773034">PubMed Abstract </a> | <a target=xrefwindow id=d52561e3434 href="http://dx.doi.org/10.1155/2011/380371">Publisher Full Text </a> | <a target=xrefwindow id=d52561e3437 href="http://www.ncbi.nlm.nih.gov/pmc/articles/3135095">Free Full Text </a></span></li><li><a name=ref-108 class=n-a></a><span class=label>108. </span>&nbsp;<span class=citation><a name=d52561e3447 class=n-a></a>Avril MF, Auperin A, Margulis A, <i> et al.</i>: Basal cell carcinoma of the face: surgery or radiotherapy? Results of a randomized study. <i>Br J Cancer.</i> 1997; <b>76</b>(1): 100–6. <a target=xrefwindow id=d52561e3458 href="http://www.ncbi.nlm.nih.gov/pubmed/9218740">PubMed Abstract </a> | <a target=xrefwindow id=d52561e3461 href="http://dx.doi.org/10.1038/bjc.1997.343">Publisher Full Text </a> | <a target=xrefwindow id=d52561e3465 href="http://www.ncbi.nlm.nih.gov/pmc/articles/2223779">Free Full Text </a></span></li><li><a name=ref-109 class=n-a></a><span class=label>109. </span>&nbsp;<span class=citation><a name=d52561e3474 class=n-a></a>Cognetta AB, Howard BM, Heaton HP, <i> et al.</i>: Superficial x-ray in the treatment of basal and squamous cell carcinomas: a viable option in select patients. <i>J Am Acad Dermatol.</i> 2012; <b>67</b>(6): 1235–41. <a target=xrefwindow id=d52561e3485 href="http://www.ncbi.nlm.nih.gov/pubmed/22818756">PubMed Abstract </a> | <a target=xrefwindow id=d52561e3488 href="http://dx.doi.org/10.1016/j.jaad.2012.06.001">Publisher Full Text </a></span></li><li><a name=ref-110 class=n-a></a><span class=label>110. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/728696117"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d52561e3497 class=n-a></a>Paravati AJ, Hawkins PG, Martin AN, <i> et al.</i>: Clinical and cosmetic outcomes in patients treated with high-dose-rate electronic brachytherapy for nonmelanoma skin cancer. <i>Pract Radiat Oncol.</i> 2015; <b>5</b>(6): e659–64. <a target=xrefwindow id=d52561e3508 href="http://www.ncbi.nlm.nih.gov/pubmed/26432680">PubMed Abstract </a> | <a target=xrefwindow id=d52561e3511 href="http://dx.doi.org/10.1016/j.prro.2015.07.002">Publisher Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/728696117">F1000 Recommendation</a></span></li><li><a name=ref-111 class=n-a></a><span class=label>111. </span>&nbsp;<span class=citation><a name=d52561e3524 class=n-a></a>Locke J, Karimpour S, Young G, <i> et al.</i>: Radiotherapy for epithelial skin cancer. <i>Int J Radiat Oncol Biol Phys.</i> 2001; <b>51</b>(3): 748–55. <a target=xrefwindow id=d52561e3535 href="http://www.ncbi.nlm.nih.gov/pubmed/11697321">PubMed Abstract </a> | <a target=xrefwindow id=d52561e3538 href="http://dx.doi.org/10.1016/S0360-3016(01)01656-X">Publisher Full Text </a></span></li><li><a name=ref-112 class=n-a></a><span class=label>112. </span>&nbsp;<span class=citation><a name=d52561e3547 class=n-a></a>Yiasemides E, Sivapirabu G, Halliday GM, <i> et al.</i>: Oral nicotinamide protects against ultraviolet radiation-induced immunosuppression in humans. <i>Carcinogenesis.</i> 2009; <b>30</b>(1): 101–5. <a target=xrefwindow id=d52561e3558 href="http://www.ncbi.nlm.nih.gov/pubmed/19028705">PubMed Abstract </a> | <a target=xrefwindow id=d52561e3561 href="http://dx.doi.org/10.1093/carcin/bgn248">Publisher Full Text </a></span></li><li><a name=ref-113 class=n-a></a><span class=label>113. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/725865915"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d52561e3570 class=n-a></a>Chen AC, Martin AJ, Choy B, <i> et al.</i>: A Phase 3 Randomized Trial of Nicotinamide for Skin-Cancer Chemoprevention. <i>N Engl J Med.</i> 2015; <b>373</b>(17): 1618–26. <a target=xrefwindow id=d52561e3581 href="http://www.ncbi.nlm.nih.gov/pubmed/26488693">PubMed Abstract </a> | <a target=xrefwindow id=d52561e3584 href="http://dx.doi.org/10.1056/NEJMoa1506197">Publisher Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/725865915">F1000 Recommendation</a></span></li><li><a name=ref-114 class=n-a></a><span class=label>114. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/727262093"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d52561e3598 class=n-a></a>Park SM, Li T, Wu S, <i> et al.</i>: Niacin intake and risk of skin cancer in US women and men. <i>Int J Cancer.</i> 2017; <b>140</b>(9): 2023–31. <a target=xrefwindow id=d52561e3609 href="http://www.ncbi.nlm.nih.gov/pubmed/28152570">PubMed Abstract </a> | <a target=xrefwindow id=d52561e3612 href="http://dx.doi.org/10.1002/ijc.30630">Publisher Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/727262093">F1000 Recommendation</a></span></li><li><a name=ref-115 class=n-a></a><span class=label>115. </span>&nbsp;<span class=citation><a name=d52561e3625 class=n-a></a>Kalapurakal SJ, Malone J, Robbins KT, <i> et al.</i>: Cetuximab in refractory skin cancer treatment. <i>J Cancer.</i> 2012; <b>3</b>: 257–61. <a target=xrefwindow id=d52561e3636 href="http://www.ncbi.nlm.nih.gov/pubmed/22712026">PubMed Abstract </a> | <a target=xrefwindow id=d52561e3639 href="http://dx.doi.org/10.7150/jca.3491">Publisher Full Text </a> | <a target=xrefwindow id=d52561e3643 href="http://www.ncbi.nlm.nih.gov/pmc/articles/3376776">Free Full Text </a></span></li><li><a name=ref-116 class=n-a></a><span class=label>116. </span>&nbsp;<span class=citation><a name=d52561e3652 class=n-a></a>Wollina U: Update of cetuximab for non-melanoma skin cancer. <i>Expert Opin Biol Ther.</i> 2014; <b>14</b>(2): 271–6. <a target=xrefwindow id=d52561e3660 href="http://www.ncbi.nlm.nih.gov/pubmed/24387664">PubMed Abstract </a> | <a target=xrefwindow id=d52561e3663 href="http://dx.doi.org/10.1517/14712598.2013.876406">Publisher Full Text </a></span></li><li><a name=ref-117 class=n-a></a><span class=label>117. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/727013416"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d52561e3672 class=n-a></a>Falchook GS, Leidner R, Stankevich E, <i> et al.</i>: Responses of metastatic basal cell and cutaneous squamous cell carcinomas to anti-PD1 monoclonal antibody REGN2810. <i>J Immunother Cancer.</i> 2016; <b>4</b>: 70. <a target=xrefwindow id=d52561e3683 href="http://www.ncbi.nlm.nih.gov/pubmed/27879972">PubMed Abstract </a> | <a target=xrefwindow id=d52561e3686 href="http://dx.doi.org/10.1186/s40425-016-0176-3">Publisher Full Text </a> | <a target=xrefwindow id=d52561e3690 href="http://www.ncbi.nlm.nih.gov/pmc/articles/5109769">Free Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/727013416">F1000 Recommendation</a></span></li><li><a name=ref-118 class=n-a></a><span class=label>118. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/727099507"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d52561e3703 class=n-a></a>Ikeda S, Goodman AM, Cohen PR, <i> et al.</i>: Metastatic basal cell carcinoma with amplification of PD-L1: exceptional response to anti-PD1 therapy. <i>NPJ Genom Med.</i> 2016; <b>1</b>: pii: 16037. <a target=xrefwindow id=d52561e3714 href="http://www.ncbi.nlm.nih.gov/pubmed/27942391">PubMed Abstract </a> | <a target=xrefwindow id=d52561e3717 href="http://dx.doi.org/10.1038/npjgenmed.2016.37">Publisher Full Text </a> | <a target=xrefwindow id=d52561e3721 href="http://www.ncbi.nlm.nih.gov/pmc/articles/5142752">Free Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/727099507">F1000 Recommendation</a></span></li></ul></div></div></div> </div> <div id=article-comments class="article-comments padding-bottom-20"> <div class=current-article-comment-section> <h2 class=main-title name=add-new-comment id=add-new-comment> <span class="research-layout f1r-article-mobile-inline valign-middle"> <span class="f1r-icon icon-104_comments size30"></span> </span> <span class=f1r-article-desk-inline>Comments on this article</span> <span class=f1r-article-mobile-inline>Comments (0)</span> <span class="f1r-article-mobile-inline float-right"> <span class="f1r-icon icon-14_more_small"></span> <span class="f1r-icon icon-10_less_small"></span> </span> </h2> </div> <div class="f1r-article-desk-inline referee-report-info-box referee-report-version-box"> Version 1 </div> <div class="f1r-article-mobile research-layout mobile-version-info padding-top-30"> <span class=mversion>VERSION 1</span> <span class=details>PUBLISHED 04 Dec 2017</span> <span class="article-pubinfo-mobile versions-section"> </span> </div> <div class="f1r-article-mobile research-layout margin-top-20 is-centered"> <a href="/login?originalPath=/articles/6-2085.html&scrollTo=add-new-comment" class=register-report-comment-button data-test-id=add-comment_mob> <button class="primary orange extra-padding comment-on-this-report">ADD YOUR COMMENT</button> </a> </div> <a href="/login?originalPath=/articles/6-2085.html&scrollTo=add-new-comment" class="f1r-article-desk register-report-comment-button" data-test-id=add-comment> <span class=contracted></span>Comment </a> </div> <div class="f1r-article-mobile margin-bottom-30"> <div class=contracted-details> <a href="#" class="contracted-details-label author-affiliations"><span class=contracted></span>Author details</a> <a href="#" class=section-title>Author details</a> <span class="f1r-icon icon-14_more_small section-control"></span> <span class="f1r-icon icon-10_less_small section-control"></span> <div class="expanded-details affiliations is-hidden"> <sup>1</sup> Department of Dermatology, Yale University School of Medicine, 333 Cedar Street, P.O. Box 208059, New Haven, CT 06520-8059, Connecticut, USA<br/> <sup>2</sup> Department of Dermatology, Section of Cutaneous Oncology and Dermatologic Surgery , Yale University School of Medicine, 40 Temple Street 5A, New Haven, Connecticut, USA<br/> <p> </p> </div> </div> <div class=contracted-details> <a href="#" class=section-title>Article Versions (1)</a> <span class="f1r-icon icon-14_more_small section-control"></span> <span class="f1r-icon icon-10_less_small section-control"></span> <div class="expanded-details grant-information article-page is-hidden"> <div> <a href="https://f1000research.com/articles/6-2085/v1" title="Open version 1 of this article." class="" gahelper=1>version 1</a> <span class="article-pubinfo-mobile versions-section"> </span> </div> <div> Published: 04 Dec 2017, 6:2085 </div> <div class=""><a href="https://doi.org/10.12688/f1000research.11314.1">https://doi.org/10.12688/f1000research.11314.1</a></div> </div> </div> <div class=contracted-details> <a href="#" class=section-title> <span class="f1r-icon icon-100_open_access"></span> Copyright </a> <span class="f1r-icon icon-14_more_small section-control"></span> <span class="f1r-icon icon-10_less_small section-control"></span> <div class="expanded-details grant-information article-page is-hidden"> © 2017 Totonchy M and Leffell D. This is an open access article distributed under the terms of the <a href="http://creativecommons.org/licenses/by/4.0/" target=_blank data-test-id=box-licence-link>Creative Commons Attribution License</a>, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. </div> </div> <div class="padding-top-30 research-layout"> <div class=article-toolbox-wrapper-mobile> <div class=article-tools-icon-mobile data-section=download> <span class="f1r-icon icon-76_download_file white"></span> </div> <div class="article-tools-icon-mobile mobile-metrics article-metrics-wrapper metrics-icon-wrapper" data-section=metrics data-version-id=12209 data-id=11314 data-downloads="" data-views="" data-scholar="10.12688/f1000research.11314.1" data-recommended="" data-f1r-ga-helper="Article Page Metrics (Mobile)"> <span class="f1r-icon icon-89_metrics white"></span> </div> <div class=article-tools-divider-mobile></div> <div class=article-tools-icon-mobile data-section=cite> <span class="f1r-icon icon-82_quote white"></span> </div> <div class="article-tools-icon-mobile " data-section=track> <span class="f1r-icon icon-90_track white"></span> </div> <div class=article-tools-divider-mobile></div> <div class=article-tools-icon-mobile data-section=share> <span class="f1r-icon icon-34_share white"></span> </div> <span class=article-toolbox-stretch></span> </div> <div class=article-toolbox-content-mobile> <div class="toolbox-section download"> <div class=toolbox-section-heading>Download</div> <div class=toolbox-section-content> <a href="https://f1000research.com/articles/6-2085/v1/pdf?article_uuid=074aeb04-cfd6-4281-b35d-42794bfeaa8b" title="Download PDF" class="no-decoration pdf-download-helper"> <span class="f1r-icon icon-102_download_pdf toolbox-section-icon"></span> </a> <div class=toolbox-section-option-divider>&nbsp;</div> <a id=mobile-download-xml class=no-decoration href="#" title="Download XML"> <span class="f1r-icon icon-103_download_xml toolbox-section-icon"></span> </a> </div> <div class=toolbox-section-divider></div> <div class=toolbox-section-heading>Export To</div> <div class=toolbox-section-content> <button class="primary no-fill orange-text-and-border mobile-export" data-etype=WORKSPACE>Sciwheel</button> <button class="primary no-fill orange-text-and-border mobile-export" data-etype=BIBTEX>Bibtex</button> <button class="primary no-fill orange-text-and-border mobile-export" data-etype=ENDNOTE>EndNote</button> <button class="primary no-fill orange-text-and-border mobile-export" data-etype=PROCITE>ProCite</button> <button class="primary no-fill orange-text-and-border mobile-export" data-etype=REF_MANAGER>Ref. Manager (RIS)</button> <button class="primary no-fill orange-text-and-border mobile-export" data-etype=SENTE>Sente</button> </div> </div> <div class="toolbox-section metrics"> <div class="toolbox-section-heading no-top-border">metrics</div> <div class="toolbox-section-divider toolbox-section-divider--no-height"></div> <div class=article-metrics-pageinfo> <div class=c-article-metrics-table> <table class=c-article-metrics-table__table> <thead> <tr> <th></th> <th><span class=c-article-metrics-table__heading>Views</span></th> <th><span class=c-article-metrics-table__heading>Downloads</span></th> </tr> </thead> <tbody> <tr> <th class=c-article-metrics-table__row-heading><span class="c-article-metrics-table__platform u-platform--" data-test-id=metrics_platform_name_mob>F1000Research</span></th> <td class="c-article-metrics-table__value js-article-views-count" data-test-id=metrics_platform_views_mob>-</td> <td class="c-article-metrics-table__value js-article-downloads-count" data-test-id=metrics_platform_downloads_mob>-</td> </tr> <tr> <th class=c-article-metrics-table__row-heading> <span class="u-ib u-middle c-article-metrics-table__pmc" data-test-id=metrics_pmc_name_mob>PubMed Central</span> <div class="c-block-tip c-block-tip--centered c-article-metrics-table__tooltip c-block-tip--md-padding c-block-tip--small-arrow u-ib u-middle"> <button type=button class="u-black--medium u-black--high@hover u-ib u-middle c-button--icon c-button--text c-block-tip__toggle"><i class="material-icons c-button--icon__icon">info_outline</i></button> <div class=c-block-tip__content>Data from PMC are received and updated monthly.</div> </div> </th> <td class="c-article-metrics-table__value js-pmc-views-count" data-test-id=metrics_pmc_views_mob>-</td> <td class="c-article-metrics-table__value js-pmc-downloads-count" data-test-id=metrics_pmc_downloads_mob>-</td> </tr> </tbody> </table> </div> </div> <span class=metrics-citations-container> <div class=toolbox-section-divider></div> <div class="toolbox-section-heading u-mb--1">Citations</div> <div> <div class=toolbox-section-colsplit> <div class=citations-scopus-logo> <a href="" target=_blank class="is-hidden metrics-citation-icon" title="View full citation details at www.scopus.com"><i class="material-icons scopus-icon">open_in_new</i></a> </div> <div class="toolbox-section-count scopus"> <a href='' class='scopus-citation-link is-hidden' target=_blank title='View full citation details at www.scopus.com'>0</a> </div> </div> <div class=toolbox-section-colsplit> <div class="citations-pubmed-logo f1000research"> <a href="" target=_blank class="is-hidden metrics-citation-icon f1000research" title="View full citation details"><i class="material-icons scopus-icon">open_in_new</i></a> </div> <div class="toolbox-section-count pubmed"> <a href='' class='pubmed-citation-link is-hidden' target=_blank title='View full citation details'>0</a> </div> </div> <div class=toolbox-section-divider></div> <div class=toolbox-section-content> <div class="citations-scholar-logo f1000research"> <a href="" target=_blank class="is-hidden metrics-citation-icon google-scholar f1000research" title="View full citation details" data-scholar="10.12688/f1000research.11314.1"><i class="material-icons scopus-icon">open_in_new</i></a> </div> </div> </div> </span> <span class=metrics-details-container> <div class=toolbox-section-divider></div> <div class="toolbox-section-content altmetric-section"> <div class=altmetrics-image></div> <div class=altmetrics-more-link> <a href="" target=_blank class=f1r-standard-link>SEE MORE DETAILS</a> </div> <div class=altmetric-mobile-column-counts></div> <div class=altmetric-mobile-column-readers></div> <div class=toolbox-section-divider></div> </div> </span> </div> <div class="toolbox-section cite"> <div class="toolbox-section-heading no-top-border">CITE</div> <div class=toolbox-section-divider></div> <div class=toolbox-section-heading>how to cite this article</div> <div id=citation-copy-mobile class="toolbox-section-content text-content heading9 small" data-test-id=mob_copy-citation_text> Totonchy M and Leffell D. Emerging concepts and recent advances in basal cell carcinoma [version 1; peer review: 2 approved] <i>F1000Research</i> 2017, <b>6</b>(F1000 Faculty Rev):2085 (<a href="https://doi.org/10.12688/f1000research.11314.1" target=_blank>https://doi.org/10.12688/f1000research.11314.1</a>) </div> <div class=toolbox-section-divider></div> <div class="toolbox-section-content text-content heading9 small"> NOTE: <em>it is important to ensure the information in <b>square brackets after the title</b> is included in all citations of this article.</em> </div> <div class=toolbox-section-content> <button class="primary orange extra-padding copy-cite-article-mobile js-clipboard" data-clipboard-target="#citation-copy-mobile" title="Copy the current citation details." data-test-id=mob_copy-citation_button-mob>COPY CITATION DETAILS</button> </div> </div> <div class="toolbox-section track"> <div class="toolbox-section-heading no-top-border">track</div> <div class=toolbox-section-divider></div> <div class=toolbox-section-heading>receive updates on this article</div> <div class="toolbox-section-content padding-left-20 padding-right-20 heading9 small"> Track an article to receive email alerts on any updates to this article. </div> <div class=toolbox-section-content> <a data-article-id=11314 id=mobile-track-article-signin-11314 title="Receive updates on new activity such as publication of new versions, peer reviews or author responses." href="/login?originalPath=/trackArticle/11314?target=/articles/6-2085.html"> <button class="primary orange extra-padding"> TRACK THIS ARTICLE </button> </a> </div> </div> <div class="toolbox-section share"> <div class="toolbox-section-heading no-top-border">Share</div> <div class=toolbox-section-divider></div> <div class=toolbox-section-content> <a target=_blank class="f1r-shares-icon-square f1r-shares-email" title="Email this article"></a> <a target=_blank class="f1r-shares-icon-square f1r-shares-twitter" title="Share on Twitter"></a> <a target=_blank class="f1r-shares-icon-square f1r-shares-facebook" title="Share on Facebook"></a> <a target=_blank class="f1r-shares-icon-square f1r-shares-linkedin" title="Share on LinkedIn"></a> <a target=_blank class="f1r-shares-icon-square f1r-shares-reddit" title="Share on Reddit"></a> <a target=_blank class="f1r-shares-icon-square f1r-shares-mendelay" title="Share on Mendeley"></a> <div class="email-article-wrapper email-article-version-container"> <div class=toolbox-section-divider></div> <script src='https://www.recaptcha.net/recaptcha/api.js'></script> <form class="recommend-version-form-mobile research-layout"> <p>All fields are required.</p> <input name=versionId type=hidden value=12209 /> <input name=articleId type=hidden value=11314 /> <input name=senderName class="form-input-field reg-form" value="" type=text placeholder="Your name"/> <input name=senderEmail class="form-input-field reg-form margin-top" value="" type=text placeholder="Your email address"/> <textarea name=recipientEmails class="form-textarea-field ninetynine-percent-wide margin-top no-resize" placeholder="Recipient email address(es) (comma delimited)"></textarea> <input class="form-input-field reg-form margin-top" name=subject type=text value="Interesting article on F1000Research" placeholder=Subject /> <textarea name=message class="form-textarea-field reg-form margin-top no-resize">I thought this article from F1000Research (https://f1000research.com) would be of interest to you.</textarea> <div class="g-recaptcha margin-top" data-sitekey=6LcHqxoUAAAAANP3_0TzpGG6qFvl4DhbUcuRzw7W></div> <input value="" name=captcha type=hidden /> <p>A full article citation will be automatically included.</p> <p><img class="ticker-email-article-details hidden" src="/img/ticker.gif" alt=loading /></p> <button class="secondary orange margin-bottom" data-test-id=version_share_email_send>SEND EMAIL</button> <div class="orange-message margin-bottom is-hidden" data-test-id=version_share_email_message></div> </form> </div> </div> </div> </div> </div> <a name=article-reports></a> <div id=article-reports class="u-mt--3 reports-comments no-divider"> <div class="current-referee-status current-referee-status--faculty "> <h2 class=main-title id=current-referee-status> <span class="research-layout f1r-article-mobile-inline valign-middle"> <span class="f1r-icon icon-85_peer_review size30"></span> </span> Open Peer Review <span class="f1r-article-mobile-inline float-right"> <span class="f1r-icon icon-14_more_small"></span> <span class="f1r-icon icon-10_less_small"></span> </span> </h2> <a name=current-referee-status></a> <div class=current-referee-status__content name=add-new-report-comment id=add-new-report-comment> Current Reviewer Status: <span class="research-layout f1r-article-desk-inline"> <span class="f1r-icon icon-86_approved status-green smaller" title=Approved></span> </span> <span class="research-layout f1r-article-mobile float-right"> <span class="f1r-icon icon-86_approved status-green smaller" title=Approved></span> </span> <span class="research-layout f1r-article-desk-inline"> <span class="f1r-icon icon-86_approved status-green smaller" title=Approved></span> </span> <span class="research-layout f1r-article-mobile float-right"> <span class="f1r-icon icon-86_approved status-green smaller" title=Approved></span> </span> <span class="research-layout f1r-article-mobile"> <div class=mobile-ref-status-help> Key to Reviewer Statuses <span class=referee-status-pointer></span> <span class="view-control float-right">VIEW</span> <span class="view-control float-right is-hidden">HIDE</span> <div class=mobile-ref-status-help-content> <div class="cf margin-top"> <span class="f1r-icon icon-86_approved status-green smaller float-left margin-bottom-40 margin-right" title=Approved></span> <span class=title>Approved</span>The paper is scientifically sound in its current form and only minor, if any, improvements are suggested </div> <div class="cf margin-top"> <span class="f1r-icon icon-87_approved_reservations status-green smaller float-left margin-bottom-40 margin-right" title="Approved with Reservations"></span> <span class=title>Approved with reservations</span> A number of small changes, sometimes more significant revisions are required to address specific details and improve the papers academic merit. </div> <div class="cf margin-top"> <span class="f1r-icon icon-88_not_approved status-red small float-left margin-bottom-30 margin-right" title="Not Approved"></span> <span class=title>Not approved</span>Fundamental flaws in the paper seriously undermine the findings and conclusions </div> </div> </div> </span> <div class=editorial-note> <h5 class=editorial-note__title>Editorial Note on the Review Process</h5> <p class=editorial-note__text><a href="/browse/faculty-reviews">Faculty Reviews</a> are review articles written by the prestigious Members of <a href="https://facultyopinions.com/prime/home">Faculty Opinions</a>. The articles are commissioned and peer reviewed before publication to ensure that the final, published version is comprehensive and accessible. The reviewers who approved the final version are listed with their names and affiliations.</p> </div> <div class=approved-referee> <h4 class=approved-referee__title>Reviewers who approved this article</h4> <ol class=approved-referee__list> <li class="approved-referee__list-item "> <span class=approved-referee__co-referee> <strong>Desiree Ratner</strong>, Department of Dermatology, Mount Sinai Beth Israel Cancer Center West, USA </span> <span class=approved-referee__competing-list> <strong>Competing interests:</strong> No competing interests were declared. (for version 1) <br> </span> </li> <li class="approved-referee__list-item margin-top-20"> <span class=approved-referee__co-referee> <strong>Uwe Wollina</strong>, Department of Dermatology & Allergology, Academic Teaching Hospital of the Technical University of Dresden, Germany </span> <span class=approved-referee__competing-list> <strong>Competing interests:</strong> No competing interests were declared. (for version 1) <br> </span> </li> </ol> </div> </div> </div> </div> <div class="f1r-article-mobile research-layout"> <div class="mobile-sections-divider before-comments"></div> </div> <div id=article-comments class="article-comments padding-bottom-20"> <div class=current-article-comment-section> <h2 class=main-title name=add-new-comment id=add-new-comment> <span class="research-layout f1r-article-mobile-inline valign-middle"> <span class="f1r-icon icon-104_comments size30"></span> </span> <span class=f1r-article-desk-inline>Comments on this article</span> <span class=f1r-article-mobile-inline>Comments (0)</span> <span class="f1r-article-mobile-inline float-right"> <span class="f1r-icon icon-14_more_small"></span> <span class="f1r-icon icon-10_less_small"></span> </span> </h2> </div> <div class="f1r-article-desk-inline referee-report-info-box referee-report-version-box"> Version 1 </div> <div class="f1r-article-mobile research-layout mobile-version-info padding-top-30"> <span class=mversion>VERSION 1</span> <span class=details>PUBLISHED 04 Dec 2017</span> <span class="article-pubinfo-mobile versions-section"> </span> </div> <div class="f1r-article-mobile research-layout margin-top-20 is-centered"> <a href="/login?originalPath=/articles/6-2085.html&scrollTo=add-new-comment" class=register-report-comment-button data-test-id=add-comment_mob> <button class="primary orange extra-padding comment-on-this-report">ADD YOUR COMMENT</button> </a> </div> <a href="/login?originalPath=/articles/6-2085.html&scrollTo=add-new-comment" class="f1r-article-desk register-report-comment-button" data-test-id=add-comment> <span class=contracted></span>Comment </a> </div> </div> </div> <div id=article_main-column class="p-article__sidebar o-layout__item u-1/3 not-expanded js-article-sidebar"> <div class="o-tab p-article__column-toggle-container"> <button class="c-tab c-tab--left js-column-toggle p-article__column-toggle not-expanded " type=button data-target-main=article_main-column data-target-secondary=article_secondary-column><i class="c-tab__icon material-icons u-hide@expanded">keyboard_arrow_left</i><i class="c-tab__icon material-icons u-show@expanded">keyboard_arrow_right</i></button> </div> <div class=p-article__sidebar-content> <div class="p-article__sidebar-scroller js-article-sidebar-scroller"> <section class="p-article__sidebar-view js-article-sidebar-view js-article-sidebar-main u-pt u-pb--8" data-view=peer-review> <div class="o-layout o-layout--flush"> <div class="o-layout__item u-pl"> <h3 class="u-mt--0 u-mb--2 t-h3 u-weight--md u-pl" data-test-id=article_sidebar_heading>Open Peer Review</h3> </div> <div class=o-layout__item> <section class=""> <div class="p-article__sidebar-highlight u-mb--2 u-pr--1"> <div class="o-actions o-actions--middle"> <div class=o-actions__primary> <h4 class="u-mt--0 u-mb--0 u-ib u-middle t-h4 u-weight--md u-mr--1/2">Reviewer Status</h4> <div class="c-referee-status__icons u-ib u-middle"> <i class="c-icn--f1r-icon c-icn--approved " title=Approved #data-refInfo=11837-28458></i> <i class="c-icn--f1r-icon c-icn--approved " title=Approved #data-refInfo=28478-28457></i> </div> </div> <div class="o-actions__secondary _mdl-layout"> <div class="c-block-tip p-article__sidebar-tooltip c-block-tip--below c-block-tip--small-arrow c-block-tip--sm-padding"> <button type=button class="c-button c-button--icon c-button--text c-block-tip__toggle"><i class="material-icons c-button--icon__icon">info_outline</i></button> <div class=c-block-tip__content> <p class="t-body u-mt--0 u-mb--0"><em class=u-weight--md>Alongside their report, reviewers assign a status to the article:</em></p> <dl class=c-definitions> <dt class="c-definitions__term u-upper t-control u-weight--md u-black--high"><span class="u-ib u-middle"> <i class="c-icn--f1r-icon c-icn--approved " title=Approved #data-refInfo=""></i> </span> <span class="u-middle u-ib u-ml--1/2">Approved</span></dt> <dd class="c-definitions__description t-caption">The paper is scientifically sound in its current form and only minor, if any, improvements are suggested</dd> <dt class="c-definitions__term u-upper t-control u-weight--md u-black--high"><span class="u-ib u-middle"> <i class="c-icn--f1r-icon c-icn--reservations" title="Approved with Reservations" #data-refInfo=""></i> </span> <span class="u-middle u-ib u-ml--1/2">Approved with reservations</span></dt> <dd class="c-definitions__description t-caption"> A number of small changes, sometimes more significant revisions are required to address specific details and improve the papers academic merit. </dd> <dt class="c-definitions__term u-upper t-control u-weight--md u-black--high"><span class="u-ib u-middle"> <i class="c-icn--f1r-icon c-icn--not-approved " title="Not Approved" #data-refInfo=""></i> </span> <span class="u-middle u-ib u-ml--1/2">Not approved</span></dt> <dd class="c-definitions__description t-caption">Fundamental flaws in the paper seriously undermine the findings and conclusions</dd> </dl> </div> </div> </div> </div> </div> <div class="o-layout__item u-mb--1"><h4 class="u-mt--0 u-mb--0 u-ib u-middle t-h4 u-weight--md">Reviewer Reports</h4></div> <table class="c-report-timeline u-mb--2"> <thead class=c-report-timeline__headings> <tr> <th></th> <th class="u-pb--1/2" colspan=2><em class="t-body u-weight--rg">Invited Reviewers</em></th> </tr> <tr class=c-report-timeline__headings-row> <th></th> <th class="c-report-timeline__headings-version p-article__color--dark">1</th> <th class="c-report-timeline__headings-version p-article__color--dark">2</th> </tr> </thead> <tbody> <tr class="c-report-timeline__row c-report-timeline__row--selected "> <th class=c-report-timeline__version> <a data-test-id=sidebar_timeline_v1_version href="https://f1000research.com/articles/6-2085/v1">Version 1</a><br/> <span class=p-article__color--dark> <span data-test-id=sidebar_timeline_v1_date class=c-report-timeline__date>04 Dec 17</span> </span> </th> <td class="c-report-timeline__report c-report-timeline__cell "> <i class="c-icn--f1r-icon c-icn--approved small" title=Approved #data-refInfo=""></i> </td> <td class="c-report-timeline__report c-report-timeline__cell "> <i class="c-icn--f1r-icon c-icn--approved small" title=Approved #data-refInfo=""></i> </td> </tr> </tbody> </table> <div class=o-layout__item> <hr class="c-hr c-hr--low u-mb--2"> </div> </section> </div> <div class=o-layout__item> <div class="u-pl u-pr"> <p class="t-body u-mt--0 u-mb--2"><a href="/browse/faculty-reviews">Faculty Reviews</a> are review articles written by the prestigious Members of <a href="https://facultyopinions.com/prime/home" target=_blank class=in-text-link>Faculty Opinions</a>. The articles are commissioned and peer reviewed before publication to ensure that the final, published version is comprehensive and accessible. The reviewers who approved the final version are listed with their names and affiliations.</p> <ol class="p-article__faculty-referee-list t-caption"> <li> <p class=" u-mt--0 u-mb--1/2"><strong>Desiree Ratner</strong>, Department of Dermatology, Mount Sinai Beth Israel Cancer Center West, USA </p> <div class="c-read-more js-read-more " data-lines=3> <div class="c-read-more__content js-read-more-content "> <p class="u-mt--0 u-mb--0 p-article__color--light"> <strong class=u-weight--md>Competing interests:</strong> No competing interests were declared. </p> </div> <a href="#" class="c-read-more__toggle js-read-more-toggle t-caption"> <span class=c-read-more__expand>View more</span> <span class=c-read-more__contract>View less</span> </a> </div> </li> <li> <p class=" u-mt--0 u-mb--1/2"><strong>Uwe Wollina</strong>, Department of Dermatology & Allergology, Academic Teaching Hospital of the Technical University of Dresden, Germany </p> <div class="c-read-more js-read-more " data-lines=3> <div class="c-read-more__content js-read-more-content "> <p class="u-mt--0 u-mb--0 p-article__color--light"> <strong class=u-weight--md>Competing interests:</strong> No competing interests were declared. </p> </div> <a href="#" class="c-read-more__toggle js-read-more-toggle t-caption"> <span class=c-read-more__expand>View more</span> <span class=c-read-more__contract>View less</span> </a> </div> </li> </ol> </div> </div> <section class="o-layout__item u-pl"> <div class=u-pl> <hr class="c-hr c-hr--low c-hr--md u-mb--3"> <h4 class="t-h3 u-weight--md u-mt--0 u-mb--2">Comments on this article</h4> <div class=u-mb--4> <p class="u-mt--0 u-mb--1 t-h4"><a class=p-article__color--light href="#article-comments">All Comments</a><span class=" u-ib u-ml--1/2 p-article__color--light">(0)</span></p> <a class=t-h4 href="/login?originalPath=/articles/6-2085.html&scrollTo=add-new-comment" data-test-id=add-comment>Add a comment</a> </div> <hr class="c-hr c-hr--low c-hr--md u-mb--4"> <div class="research-layout f1r-article-desk"> <div class="heading6 c-ribbon-wrapper c-ribbon-wrapper--etoc f1000research "> <div class=c-ribbon-wrapper__body>Sign up for content alerts</div> </div> </div> <div class="research-layout sidebar-sign-up-form f1r-article-desk u-mb--4 "> <form class=js-email-alert-signup action="#" method=POST data-email=tocAlertWeekly> <input type=hidden name=isUserLoggedIn class=js-email-alert-signup-logged-in value=N /> <input type=hidden name=userId class=js-email-alert-signup-user-id value=""/> <input type=hidden name=frequency class=js-email-alert-signup-frequency value=WEEKLY /> <div class="o-actions o-actions--middle"> <div class=o-actions__primary> <input type=email name=emailAddress class="form-input-field js-email-alert-signup-address u-1/1 u-bb" required=required placeholder=Email /> </div> <div class=o-actions__secondary> <div class="_mdl-layout u-ml--1/2"> <button class="mdl-button mdl-js-button mdl-button--colored mdl-button--small mdl-button--filled js-email-alert-signup-submit">Sign Up</button> </div> </div> </div> </form> <div id=sidebar-sign-up-message class="section-text js-email-alert-signup-msg is-hidden">You are now signed up to receive this alert</div> </div> <section class=js-terms-container> <hr class="c-hr c-hr--low c-hr--md u-mb--3"> <h4 class="t-h3 u-weight--md u-mt--0 u-mb--1">Browse by related subjects</h4> <div class="article-subcontainer article-subcontainer--sidebar"> <ul class=js-terms-list></ul> </div> </section> </div> </section> </div> </section> </div> <script src="/js/shared_scripts/modal-dialogue.js"></script> <script src="/js/shared_scripts/read-more.js"></script> <script src="/js/article/article-router.js"></script> <script src="/js/article/article-sidebar.js"></script> <script src="/js/referee/new/referee_helpers.js"></script> <script src="/js/article/article-column-toggle.js"></script> </div> </div> </div> </main> <input type=hidden id=_articleVersionUrl value="https://f1000research.com/articles/6-2085/v1/"> <div class=research-help id=about-referee-status> <div class="research-layout research-help-content about-referee-status"> <span class="close-research-help dark-cross" title=Close></span> Alongside their report, reviewers assign a status to the article: <div class="cf research-help-row"> <span class="f1r-icon icon-86_approved status-green smaller" title=Approved></span> <span class=research-help-text>Approved - the paper is scientifically sound in its current form and only minor, if any, improvements are suggested</span> </div> <div class="cf research-help-row"> <span class="f1r-icon icon-87_approved_reservations status-green smaller" title="Approved with Reservations"></span> <span class=research-help-text>Approved with reservations - A number of small changes, sometimes more significant revisions are required to address specific details and improve the papers academic merit. </span> </div> <div class="cf research-help-row"> <span class="f1r-icon icon-88_not_approved status-red small" title="Not Approved"></span> <span class=research-help-text>Not approved - fundamental flaws in the paper seriously undermine the findings and conclusions</span> </div> </div> </div> <div id=datasets-info class=is-hidden> </div> <div class=article-interactive-content-container style="display: none;"> <a name=f-template class=n-a></a> <div class="interactive-content-wrapper padding-20"> <img src="" class=interactive-content-image title="Open the interactive image display"> <div class=interactive-content-title></div> <div class=interactive-content-text></div> <div class="f1r-article-desk interactive-content-ribbon" data-interactive-content-type=R-Script> <div class=interactive-content-label>Adjust parameters to alter display</div> <div class=interactive-content-button></div> </div> <div class="f1r-article-mobile mobile-interactive-note"> View on desktop for interactive features <img src="/img/icon/interactive_content.png" class="float-right margin-right-40"/> </div> <div class=clearfix></div> </div> </div> <div id=article-interactive-omero-container class=article-interactive-omero-container style="display: none;"> <div class=interactive-content-wrapper> <div class="interactive-omero-button omero-content" title="Open the interactive content window." data-interactive-content-type=Omero></div> <div class=has-interactive-content-image> <span class=box-arrow></span> <span class=box-middle>Includes Interactive Elements</span> <span class=box-end></span> </div> <div class="fig panel clearfix" style="margin: 0; padding-bottom: 20px;"> <a name=templatelink class=n-a></a> <a target=_blank href="" class=link-for-omero-image> <img src="" class=interactive-omero-image title="Open the image display window."> </a> <div class=caption> <div class=interactive-content-title></div> <div class=interactive-content-text></div> </div> <div class="is-hidden omero-image-list"></div> </div> <div class="f1r-article-mobile mobile-interactive-note omero"> View on desktop for interactive features <img src="/img/icon/interactive_content.png" class="float-right margin-right-40"/> </div> <div class=clearfix></div> </div> </div> <div class="add-comment-container shadow-box is-hidden" id=save-comment-container> <span id=save-comment-text class=intro-text>Edit comment</span> <textarea id=new-comment name=new-comment class="global-textarea comment margin-bottom margin-top"></textarea> <p><strong>Competing Interests</strong></p> <textarea id=new-competing-interests name=competing-interests class="global-textarea competing-interests margin-bottom check-xss"></textarea> <div class=clearfix></div> <button id=cancelComment type=button class="general-white-orange-button float-right no-background-button margin-left"> Cancel </button> <button id=save-comment-button commentId="" type=button class="general-white-orange-button float-right"> Save </button> <div class=clearfix></div> <div class="green-message margin-top is-hidden comment-is-saved">The comment has been saved.</div> <div class="red-message margin-top is-hidden comment-not-added">An error has occurred. Please try again.</div> <div class="red-message margin-top is-hidden comment-enter-text ucf">Your must enter a comment.</div> <div class="red-message margin-top is-hidden comment-references-error references">References error.</div> </div> <div class="modal-window-wrapper is-hidden"> <div id=conflicts-interests class="modal-window padding-20"> <div class=modal-window__content> <h2 class=h2-title>Competing Interests Policy</h2> <p> Provide sufficient details of any financial or non-financial competing interests to enable users to assess whether your comments might lead a reasonable person to question your impartiality. Consider the following examples, but note that this is not an exhaustive list: </p> <div class=heading5>Examples of 'Non-Financial Competing Interests'</div> <ol class="numbered-list no-padding"> <li class=standard-padding>Within the past 4 years, you have held joint grants, published or collaborated with any of the authors of the selected paper.</li> <li class=standard-padding>You have a close personal relationship (e.g. parent, spouse, sibling, or domestic partner) with any of the authors.</li> <li class=standard-padding>You are a close professional associate of any of the authors (e.g. scientific mentor, recent student).</li> <li class=standard-padding>You work at the same institute as any of the authors.</li> <li class=standard-padding>You hope/expect to benefit (e.g. favour or employment) as a result of your submission.</li> <li class=standard-padding>You are an Editor for the journal in which the article is published.</li> </ol> <div class="heading5 padding-top">Examples of 'Financial Competing Interests'</div> <ol class="numbered-list no-padding"> <li class=standard-padding>You expect to receive, or in the past 4 years have received, any of the following from any commercial organisation that may gain financially from your submission: a salary, fees, funding, reimbursements.</li> <li class=standard-padding>You expect to receive, or in the past 4 years have received, shared grant support or other funding with any of the authors.</li> <li class=standard-padding>You hold, or are currently applying for, any patents or significant stocks/shares relating to the subject matter of the paper you are commenting on.</li> </ol> </div> <div class="f1r-article-mobile research-layout"> <span class=modal-window-close-button></span> </div> </div> </div> <div class="o-modal c-email-alert-popup js-email-alert-popup is-hidden"> <div class="o-modal__body js-modal-body c-email-alert-popup__inner"> <h3 class=c-email-alert-popup__title>Stay Updated</h3> <p class=c-email-alert-popup__sub>Sign up for content alerts and receive a weekly or monthly email with all newly published articles</p> <p><a href="/register?originalPath=" class="c-email-alert-popup__lnk c-email-alert-popup__button js-email-alert-popup-action">Register with F1000Research</a></p> <p>Already registered? <a href="/login?originalPath=" class="c-email-alert-popup__lnk js-email-alert-popup-action">Sign in</a></p> <p class=c-email-alert-popup__footer><a class="c-email-alert-popup__lnk js-email-alert-popup-cancel" href="#">Not now, thanks</a></p> </div> </div> <div id=addCommentModal role=dialog aria-labelledby=addCommentModal_title aria-describedby=addCommentModal_description> <div class="c-modal js-modal is-closed p-article__add-comment-modal c-modal--xlarge js-article-comment-modal c-modal--scroll "> <aside class="c-modal__content u-black--high o-box u-pb--0 u-bg--2 c-modal--scroll-always "> <div class=c-modal__close> <button type=button class="c-button c-button--icon c-button--medium c-button--full@hover js-modal__close"><i class="c-button--icon__icon material-icons">close</i></button> </div> <div id=addCommentModal_description class="c-modal__description js-modal__content t-h4 u-mt--0 u-mb--2 u-black--medium"> <div class="js-add-comment-container t-caption u-black--high"> <div class=u-weight--bd>PLEASE NOTE</div> <div class=u-mt--1> <span class="red u-weight--bd">If you are an AUTHOR of this article,</span> please check that you signed in with the account associated with this article otherwise we cannot automatically identify your role as an author and your comment will be labelled as a &ldquo;User Comment&rdquo;. </div> <div class=u-mt--1> <span class="red u-weight--bd">If you are a REVIEWER of this article,</span> please check that you have signed in with the account associated with this article and then go to your <a href="/my/referee">account</a> to submit your report, please do not post your review here. </div> <div class="u-mt--1 u-mb--1"> If you do not have access to your original account, please <a href="mailto:research@f1000.com">contact us</a>. </div> <p class=no-top-margin>All commenters must hold a formal affiliation as per our <a href="/about/policies#commentspolicy" target=_blank>Policies</a>. The information that you give us will be displayed next to your comment.</p> <p>User comments must be in English, comprehensible and relevant to the article under discussion. We reserve the right to remove any comments that we consider to be inappropriate, offensive or otherwise in breach of the <a href="/about/legal/usercommenttermsandconditions" target=_blank>User Comment Terms and Conditions</a>. Commenters must not use a comment for personal attacks. When criticisms of the article are based on unpublished data, the data should be made available.</p> <div class="comments-note margin-bottom" id=accept-user-comments> <input class=js-add-comment-accept-terms type=checkbox id=acceptedTermsAndConditions name=acceptedTermsAndConditions> I accept the <a href="/about/legal/usercommenttermsandconditions" target=_blank> User Comment Terms and Conditions</a> <span class=required>&nbsp;</span> </div> <div class="default-error margin-top is-hidden comment-accept-conditions utac">Please confirm that you accept the User Comment Terms and Conditions.</div> <div class="research-layout registration-form u-mb--2"> <div class="u-mb--1 u-mt--2"> <strong>Affiliation</strong> </div> <div class=form-field> <input type=text name=institution class="form-input-field check-xss js-add-comment-institution" placeholder="Organization *" autocomplete=off /> <div class="default-error margin-top is-hidden comment-enter-institution institution">Please enter your organisation.</div> </div> <div class=form-field> <input type=text name=place class="form-input-field check-xss js-add-comment-place" placeholder=Place> </div> <div class=form-field> <div class="form-input-wrapper hundred-percent-wide"> <div class="new-select-standard-wrapper half-width inline-display heading10"> <select name=countryId id=country class="form-select-menu smaller js-add-comment-country"> <option value=-1>Country*</option> <option value=840>USA</option> <option value=826>UK</option> <option value=124>Canada</option> <option value=156>China</option> <option value=250>France</option> <option value=276>Germany</option> <optgroup label=-----------------------------------------------></optgroup> <option value=4>Afghanistan</option> <option value=248>Aland Islands</option> <option value=8>Albania</option> <option value=12>Algeria</option> <option value=16>American Samoa</option> <option value=20>Andorra</option> <option value=24>Angola</option> <option value=660>Anguilla</option> <option value=10>Antarctica</option> <option value=28>Antigua and Barbuda</option> <option value=32>Argentina</option> <option value=51>Armenia</option> <option value=533>Aruba</option> <option value=36>Australia</option> <option value=40>Austria</option> <option value=31>Azerbaijan</option> <option value=44>Bahamas</option> <option value=48>Bahrain</option> <option value=50>Bangladesh</option> <option value=52>Barbados</option> <option value=112>Belarus</option> <option value=56>Belgium</option> <option value=84>Belize</option> <option value=204>Benin</option> <option value=60>Bermuda</option> <option value=64>Bhutan</option> <option value=68>Bolivia</option> <option value=70>Bosnia and Herzegovina</option> <option value=72>Botswana</option> <option value=74>Bouvet Island</option> <option value=76>Brazil</option> <option value=86>British Indian Ocean Territory</option> <option value=92>British Virgin Islands</option> <option value=96>Brunei</option> <option value=100>Bulgaria</option> <option value=854>Burkina Faso</option> <option value=108>Burundi</option> <option value=116>Cambodia</option> <option value=120>Cameroon</option> <option value=124>Canada</option> <option value=132>Cape Verde</option> <option value=136>Cayman Islands</option> <option value=140>Central African Republic</option> <option value=148>Chad</option> <option value=152>Chile</option> <option value=156>China</option> <option value=162>Christmas Island</option> <option value=166>Cocos (Keeling) Islands</option> <option value=170>Colombia</option> <option value=174>Comoros</option> <option value=178>Congo</option> <option value=184>Cook Islands</option> <option value=188>Costa Rica</option> <option value=384>Cote d'Ivoire</option> <option value=191>Croatia</option> <option value=192>Cuba</option> <option value=196>Cyprus</option> <option value=203>Czech Republic</option> <option value=180>Democratic Republic of the Congo</option> <option value=208>Denmark</option> <option value=262>Djibouti</option> <option value=212>Dominica</option> <option value=214>Dominican Republic</option> <option value=218>Ecuador</option> <option value=818>Egypt</option> <option value=222>El Salvador</option> <option value=226>Equatorial Guinea</option> <option value=232>Eritrea</option> <option value=233>Estonia</option> <option value=231>Ethiopia</option> <option value=238>Falkland Islands</option> <option value=234>Faroe Islands</option> <option value=583>Federated States of Micronesia</option> <option value=242>Fiji</option> <option value=246>Finland</option> <option value=250>France</option> <option value=254>French Guiana</option> <option value=258>French Polynesia</option> <option value=260>French Southern Territories</option> <option value=266>Gabon</option> <option value=268>Georgia</option> <option value=276>Germany</option> <option value=288>Ghana</option> <option value=292>Gibraltar</option> <option value=300>Greece</option> <option value=304>Greenland</option> <option value=308>Grenada</option> <option value=312>Guadeloupe</option> <option value=316>Guam</option> <option value=320>Guatemala</option> <option value=831>Guernsey</option> <option value=324>Guinea</option> <option value=624>Guinea-Bissau</option> <option value=328>Guyana</option> <option value=332>Haiti</option> <option value=334>Heard Island and Mcdonald Islands</option> <option value=336>Holy See (Vatican City State)</option> <option value=340>Honduras</option> <option value=344>Hong Kong</option> <option value=348>Hungary</option> <option value=352>Iceland</option> <option value=356>India</option> <option value=360>Indonesia</option> <option value=364>Iran</option> <option value=368>Iraq</option> <option value=372>Ireland</option> <option value=376>Israel</option> <option value=380>Italy</option> <option value=388>Jamaica</option> <option value=392>Japan</option> <option value=832>Jersey</option> <option value=400>Jordan</option> <option value=398>Kazakhstan</option> <option value=404>Kenya</option> <option value=296>Kiribati</option> <option value=901>Kosovo (Serbia and Montenegro)</option> <option value=414>Kuwait</option> <option value=417>Kyrgyzstan</option> <option value=418>Lao People's Democratic Republic</option> <option value=428>Latvia</option> <option value=422>Lebanon</option> <option value=426>Lesotho</option> <option value=430>Liberia</option> <option value=434>Libya</option> <option value=438>Liechtenstein</option> <option value=440>Lithuania</option> <option value=442>Luxembourg</option> <option value=446>Macao</option> <option value=807>Macedonia</option> <option value=450>Madagascar</option> <option value=454>Malawi</option> <option value=458>Malaysia</option> <option value=462>Maldives</option> <option value=466>Mali</option> <option value=470>Malta</option> <option value=584>Marshall Islands</option> <option value=474>Martinique</option> <option value=478>Mauritania</option> <option value=480>Mauritius</option> <option value=175>Mayotte</option> <option value=484>Mexico</option> <option value=581>Minor Outlying Islands of the United States</option> <option value=498>Moldova</option> <option value=492>Monaco</option> <option value=496>Mongolia</option> <option value=499>Montenegro</option> <option value=500>Montserrat</option> <option value=504>Morocco</option> <option value=508>Mozambique</option> <option value=104>Myanmar</option> <option value=516>Namibia</option> <option value=520>Nauru</option> <option value=524>Nepal</option> <option value=530>Netherlands Antilles</option> <option value=540>New Caledonia</option> <option value=554>New Zealand</option> <option value=558>Nicaragua</option> <option value=562>Niger</option> <option value=566>Nigeria</option> <option value=570>Niue</option> <option value=574>Norfolk Island</option> <option value=580>Northern Mariana Islands</option> <option value=408>North Korea</option> <option value=578>Norway</option> <option value=512>Oman</option> <option value=586>Pakistan</option> <option value=585>Palau</option> <option value=275>Palestinian Territory</option> <option value=591>Panama</option> <option value=598>Papua New Guinea</option> <option value=600>Paraguay</option> <option value=604>Peru</option> <option value=608>Philippines</option> <option value=612>Pitcairn</option> <option value=616>Poland</option> <option value=620>Portugal</option> <option value=630>Puerto Rico</option> <option value=634>Qatar</option> <option value=638>Reunion</option> <option value=642>Romania</option> <option value=643>Russian Federation</option> <option value=646>Rwanda</option> <option value=654>Saint Helena</option> <option value=659>Saint Kitts and Nevis</option> <option value=662>Saint Lucia</option> <option value=666>Saint Pierre and Miquelon</option> <option value=670>Saint Vincent and the Grenadines</option> <option value=882>Samoa</option> <option value=674>San Marino</option> <option value=678>Sao Tome and Principe</option> <option value=682>Saudi Arabia</option> <option value=686>Senegal</option> <option value=688>Serbia</option> <option value=690>Seychelles</option> <option value=694>Sierra Leone</option> <option value=702>Singapore</option> <option value=703>Slovakia</option> <option value=705>Slovenia</option> <option value=90>Solomon Islands</option> <option value=706>Somalia</option> <option value=710>South Africa</option> <option value=239>South Georgia and the South Sandwich Is</option> <option value=410>South Korea</option> <option value=724>Spain</option> <option value=144>Sri Lanka</option> <option value=736>Sudan</option> <option value=740>Suriname</option> <option value=744>Svalbard and Jan Mayen</option> <option value=748>Swaziland</option> <option value=752>Sweden</option> <option value=756>Switzerland</option> <option value=760>Syria</option> <option value=158>Taiwan</option> <option value=762>Tajikistan</option> <option value=834>Tanzania</option> <option value=764>Thailand</option> <option value=270>The Gambia</option> <option value=528>The Netherlands</option> <option value=626>Timor-Leste</option> <option value=768>Togo</option> <option value=772>Tokelau</option> <option value=776>Tonga</option> <option value=780>Trinidad and Tobago</option> <option value=788>Tunisia</option> <option value=792>Turkey</option> <option value=795>Turkmenistan</option> <option value=796>Turks and Caicos Islands</option> <option value=798>Tuvalu</option> <option value=800>Uganda</option> <option value=826>UK</option> <option value=804>Ukraine</option> <option value=784>United Arab Emirates</option> <option value=850>United States Virgin Islands</option> <option value=858>Uruguay</option> <option value=840>USA</option> <option value=860>Uzbekistan</option> <option value=548>Vanuatu</option> <option value=862>Venezuela</option> <option value=704>Vietnam</option> <option value=876>Wallis and Futuna</option> <option value=905>West Bank and Gaza Strip</option> <option value=732>Western Sahara</option> <option value=887>Yemen</option> <option value=894>Zambia</option> <option value=716>Zimbabwe</option> </select> </div> </div> <div class="default-error margin-top is-hidden comment-enter-country country">Please select your country.</div> </div> </div> <textarea data-test-id=article_add-comment_comment name=new-comment class="js-add-comment-comment comment margin-bottom margin-top"></textarea> <div class="default-error margin-top comment-enter-text comment-error is-hidden ">You must enter a comment.</div> <label class="comments-note u-mt--2 u-mb--2" for=competingInterests_1> <div class="u-mb--1 u-mt--2"><strong data-test-id=article_report-add-comment_competing-interests-title>Competing Interests</strong></div> <p class="u-mb--2 u-mt--0" data-test-id=article_report-add-comment_competing-interests-description>Please disclose any <a href="#article-competing-intersts-policy" class=js-modal-competing-intersts-toggle>competing interests</a> that might be construed to influence your judgment of the article's or peer review report's validity or importance.</p> </label> <div id=article-competing-intersts-policy class=js-article-competing-interests-policy style="display: none;"> <h2 class="h2-title u-mt--0 u-pt--0">Competing Interests Policy</h2> <p> Provide sufficient details of any financial or non-financial competing interests to enable users to assess whether your comments might lead a reasonable person to question your impartiality. Consider the following examples, but note that this is not an exhaustive list: </p> <div class=heading5>Examples of 'Non-Financial Competing Interests'</div> <ol class="numbered-list no-padding"> <li class=standard-padding>Within the past 4 years, you have held joint grants, published or collaborated with any of the authors of the selected paper.</li> <li class=standard-padding>You have a close personal relationship (e.g. parent, spouse, sibling, or domestic partner) with any of the authors.</li> <li class=standard-padding>You are a close professional associate of any of the authors (e.g. scientific mentor, recent student).</li> <li class=standard-padding>You work at the same institute as any of the authors.</li> <li class=standard-padding>You hope/expect to benefit (e.g. favour or employment) as a result of your submission.</li> <li class=standard-padding>You are an Editor for the journal in which the article is published.</li> </ol> <div class="heading5 padding-top">Examples of 'Financial Competing Interests'</div> <ol class="numbered-list no-padding"> <li class=standard-padding>You expect to receive, or in the past 4 years have received, any of the following from any commercial organisation that may gain financially from your submission: a salary, fees, funding, reimbursements.</li> <li class=standard-padding>You expect to receive, or in the past 4 years have received, shared grant support or other funding with any of the authors.</li> <li class=standard-padding>You hold, or are currently applying for, any patents or significant stocks/shares relating to the subject matter of the paper you are commenting on.</li> </ol> </div> <div id=competingInterests_1 class="c-inline-editor js-inline-editor js-form_input u-bb--all u-mb--2 js-comment-competing-interests" data-name=competing-interests data-rows=3> <textarea id=competingInterests_1_input name=competing-interests placeholder="&nbsp;" required=false class="u-hide-visually js-inline-editor_input" tabindex=-1></textarea> <div class="c-inline-editor__editor js-inline-editor_editor o-box c-box o-box--tiny u-bg--11" data-target=competingInterests_1_input role=textbox required=false data-placeholder="&nbsp;" contenteditable=true></div> <span class="c-inline-editor__error js-inline-editor-message">Please state your competing interests</span> </div> <div data-test-id=article_add-comment_saved class="green-message comments is-hidden comment-is-saved">The comment has been saved.</div> <div data-test-id=article_add-comment_error class="default-error comments is-hidden comment-not-added">An error has occurred. Please try again.</div> <div class=clearfix></div> <div class=js-hook></div> </div> <div class="c-modal__extra-message js-modal__extra-message t-h4 u-black--medium"></div></div> <div class="c-modal__actions o-box__actions"> <a href="#" data-test-id=article_add-comment_cancel class="c-button c-button--full js-modal__close c-button--secondary">Cancel</a> <a href="#" data-test-id=article_add-comment_post class="c-button c-button--full js-modal__confirm c-button--primary">Post</a> </div> </aside> </div> </div> <style>
                .at-icon-wrapper {
        background-size: 100% !important;
    }
</style> <script src="/js/namespace.js"></script> <script src="/js/constants.js"></script> <script src="/js/utilities.js"></script> <script src="/js/article/alert-signup.js"></script> <script type='text/javascript'>
    var lTitle = "Emerging concepts and recent advances in...".replace("'", '');
    var linkedInUrl = "http://www.linkedin.com/shareArticle?url=https://f1000research.com/articles/6-2085/v1" + "&title=" + encodeURIComponent(lTitle) + "&summary=" + encodeURIComponent('Read the article by ');

    var deliciousUrl = "https://del.icio.us/post?url=https://f1000research.com/articles/6-2085/v1&title=" + encodeURIComponent(lTitle);

    var redditUrl = "http://reddit.com/submit?url=https://f1000research.com/articles/6-2085/v1" + "&title=" + encodeURIComponent(lTitle);

            linkedInUrl += encodeURIComponent('Totonchy M and Leffell D');
    
    var offsetTop = /chrome/i.test( navigator.userAgent ) ? 4 : -10; 
    var addthis_config = {
            ui_offset_top: offsetTop,
                                    services_compact : "facebook,twitter,www.linkedin.com,www.mendeley.com,reddit.com",
            services_expanded : "facebook,twitter,www.linkedin.com,www.mendeley.com,reddit.com",
            services_custom : [
                {
                    name: "LinkedIn",
                    url:  linkedInUrl,
                    icon:"/img/icon/at_linkedin.svg"
                },
                {
                    name: "Mendeley",
                    url:  "http://www.mendeley.com/import/?url=https://f1000research.com/articles/6-2085/v1/mendeley",
                    icon:"/img/icon/at_mendeley.svg"
                },
                {
                    name: "Reddit",
                    url:  redditUrl,
                    icon:"/img/icon/at_reddit.svg"
                },
            ]
        };


    var addthis_share = {
            url: "https://f1000research.com/articles/6-2085",
            templates : {
                twitter : "Emerging concepts and recent advances in basal cell carcinoma. Totonchy M and Leffell D, published by " + 
               "@F1000Research"
       + ", https://f1000research.com/articles/6-2085/v1"
            }
        };

    if (typeof(addthis) != "undefined"){
        addthis.addEventListener('addthis.ready', checkCount);
        addthis.addEventListener('addthis.menu.share', checkCount);
    }

        $(".f1r-shares-twitter").attr("href", "https://twitter.com/intent/tweet?text=" + addthis_share.templates.twitter);
    $(".f1r-shares-facebook").attr("href", "https://www.facebook.com/sharer/sharer.php?u=" + addthis_share.url);
    $(".f1r-shares-linkedin").attr("href", addthis_config.services_custom[0].url);
    $(".f1r-shares-reddit").attr("href", addthis_config.services_custom[2].url);
    $(".f1r-shares-mendelay").attr("href", addthis_config.services_custom[1].url);

    function checkCount(){
        setTimeout(function(){
            $(".addthis_button_expanded").each(function(){
                var count = $(this).text();
                if (count !== "" && count != "0")
                    $(this).removeClass("is-hidden");
                else
                    $(this).addClass("is-hidden");
            });
        }, 1000);
    }
</script> <div id=citeReportModal role=dialog aria-labelledby=citeReportModal_title aria-describedby=citeReportModal_description> <div class="c-modal js-modal is-closed c-modal--large js-cite-report-modal "> <aside class="c-modal__content u-black--high o-box u-pb--0 u-black--high "> <div class=c-modal__close> <button type=button class="c-button c-button--icon c-button--medium c-button--full@hover js-modal__close"><i class="c-button--icon__icon material-icons">close</i></button> </div> <h1 id=citeReportModal_title class="c-modal__title t-h3 u-mt--0 u-mb--2 u-weight--md">How to cite this report</h1> <div id=citeReportModal_description class="c-modal__description js-modal__content t-h4 u-mt--0 u-mb--2 u-black--medium"> <div id="" class=js-report-citation-container>{{reportCitation}}</div> <div class="c-modal__extra-message js-modal__extra-message t-h4 u-black--medium"></div></div> <div class="c-modal__actions o-box__actions"> <a href="#" class="c-button c-button--full js-modal__close c-button--secondary">Cancel</a> <a href="#" title="Copy the current citation details to the clipboard." data-clipboard-target="#referee-report-citation" data-test-id=report_copy-citation_button class="c-button c-button--full js-modal__confirm c-button--primary js-clipboard c-mini-tooltip--above">Copy Citation Details</a> </div> </aside> </div> </div> <script src="/js/referee/new/referee_validators.js"></script> <script src="/js/referee/new/referee_helpers.js"></script> <script src="/js/referee/new/referee_checkbox-input.js"></script> <script src="/js/referee/new/referee_inline-editor.js"></script> <script type="text/javascript">
    $(function(){
        var gaCat = "F1000Research";
        if (gaCat === "") {
            gaCat = $("body").hasClass("wellcome-brand") ? "Wellcome Open Research" : "F1000Research";
        }
        GAHelper.track({category: gaCat, action: "Article Page: Emerging concepts and recent advances in basal cell carcinoma", label: "pageviews"});
        GAHelper.track({category: gaCat, action: "Article Type: Review", label: "Article Page"});
        $(".f1r-article-desk .collection-image").each(function (idx, el) {
            var whatChannel = $(el).find("a").attr("href"),
                channelName = $.trim($(el).parent().find(".collection-detail a").text()),
                gaRef = "(ID: " + whatChannel.replace("/collections/", "") + ") " + channelName;
            GAHelper.track({category: 'ChannelStats', action: "Article Page: Emerging concepts and recent advances in basal cell carcinoma", label: gaRef});
        });
    });
</script> <script>
    $(function(){R.ui.buttonDropdowns('.dropdown-for-downloads');});
    $(function(){R.ui.toolbarDropdowns('.toolbar-dropdown-for-downloads');});
</script> <script src="/js/article/track_article.js" type="text/javascript"></script> <script type="text/javascript">
    $.get("/articles/acj/11314/12209")
</script> <script type="text/javascript" src="https://d1bxh8uas1mnw7.cloudfront.net/assets/embed.js"></script> <script type="text/javascript" src="/js/app/messenger.js"></script> <script type="text/javascript" src="/js/article/article_mobiles.js"></script> <script src="/js/vendor/clipboard.min.js"></script> <script src="/js/shared_scripts/modal-dialogue.js"></script> <script src="/js/shared_scripts/clipboard.js"></script> <script src="/js/article/thesaurus-terms-display.js"></script> <script>
    new F1000.Clipboard();
    new F1000.ThesaurusTermsDisplay("faculty-reviews", "article", "12209");
</script> <script>
    $(document).ready(function() {
        $( "#frame1" ).on('load', function() {
            var mydiv = $(this).contents().find("div");
            var h     = mydiv.height();
            console.log(h)
        });

        
        var tooltipLivingFigure = jQuery(".interactive-living-figure-label .icon-more-info"),
            titleLivingFigure = tooltipLivingFigure.attr("title");
        tooltipLivingFigure.simpletip({
            fixed: true,
            position: ["-115", "30"],
            baseClass: 'small-tooltip',
            content:titleLivingFigure + "<div class='tooltip-arrow'></div>"
        });
        tooltipLivingFigure.removeAttr("title");

        $("body").on("click", ".cite-living-figure", function(e) {
            e.preventDefault();
            var ref = $(this).attr("data-ref");
            $(this).closest(".living-figure-list-container").find("#" + ref).fadeIn(200);
        });
        $("body").on("click", ".close-cite-living-figure", function(e) {
            e.preventDefault();
            $(this).closest(".popup-window-wrapper").fadeOut(200);
        });

                $(document).on("mouseup", function(e) {
            var metricsContainer = $(".article-metrics-popover-wrapper");
            if (!metricsContainer.is(e.target) && metricsContainer.has(e.target).length === 0) {
                $(".article-metrics-close-button").click();
            }
        });

        var articleId = $('#articleId').val();

        if($("#main-article-count-box").attachArticleMetrics) {
            $("#main-article-count-box").attachArticleMetrics(articleId, {
                articleMetricsView: true
            });
        }
    });

    var figshareWidget = $(".new_figshare_widget");
    if (figshareWidget.length > 0) {
        window.figshare.load("f1000", function(Widget) {
            // Select a tag/tags defined in your page. In this tag we will place the widget.
            _.map(figshareWidget, function(el){
                var widget = new Widget({
                    articleId: $(el).attr("figshare_articleId")
                    //height:300 // this is the height of the viewer part. [Default: 550]
                });
                widget.initialize(); // initialize the widget
                widget.mount(el); // mount it in a tag that's on your page
                // this will save the widget on the global scope for later use from
                // your JS scripts. This line is optional.
                //window.widget = widget;
            });
        });
    }
</script>

<script>
    $(document).ready(function () {

        
        var reportIds = {
                           "28457": 0,
                           "28458": 0,
                    };

        $(".referee-response-container,.js-referee-report").each(function(index, el) {
            var reportId = $(el).attr("data-reportid"),
                reportCount = reportIds[reportId] || 0;
            $(el).find(".comments-count-container,.js-referee-report-views").html(reportCount);
        });

        var uuidInput = $("#article_uuid"),
            oldUUId = uuidInput.val(),
            newUUId = "d8adf500-2c76-4c7e-b7b3-deb608b5a338";
        uuidInput.val(newUUId);

        $("a[href*='article_uuid=']").each(function(index, el) {
            var newHref = $(el).attr("href").replace(oldUUId, newUUId);
            $(el).attr("href", newHref);
        });

    });
</script>              </div>
        </div>

        
            
            <div class="o-page__footer sticky-email-wrapper">
                
                

                


<footer class="c-footer t-inverted">

    <div class="o-wrapper">
        <div class="o-layout">


                        
            <div class="o-layout__item u-mb--3">
                <div class="c-branding c-branding--research">
                    <img src="/img/research/F1000Research_white.svg" alt="F1000Research">
                </div>
            </div>


                        
            <div class="o-layout__item u-1/3@md u-mb--3">

                <span class="c-hr c-hr--thick c-hr--low u-mb--2"></span>

                <p class="t-h3 u-mt--0 u-mb--0">An innovative open access publishing platform offering rapid publication and open peer review, whilst supporting data deposition and sharing.</p>

            </div>


                        
            <div class="o-layout__item u-2/3@md">

                <span class="c-hr c-hr--thick c-hr--low u-mb--2"></span>

                <div class="o-layout">
                    <nav class="c-footer__nav">

                            <div class="o-layout__item u-3/5@sm u-mb--3">


                                <div class="o-columns o-columns--2">

                                                                            <a href="/browse/articles" class="t-body c-footer__nav-item "      >Browse</a>
                                                                            <a href="/gateways" class="t-body c-footer__nav-item "      >Gateways</a>
                                                                            <a href="/collections" class="t-body c-footer__nav-item "      >Collections</a>
                                                                            <a href="/about" class="t-body c-footer__nav-item "      >How it Works</a>
                                                                            <a href="https://blog.f1000.com/blogs/f1000research/" class="t-body c-footer__nav-item "      >Blog</a>
                                                                            <a href="/contact" class="t-body c-footer__nav-item "      >Contact</a>
                                                                            <a href="/developers" class="t-body c-footer__nav-item u-hide u-show@navbar"      >For Developers</a>
                                                                            <a href="/published/rss" class="t-body c-footer__nav-item "   title="RSS feed of published articles"     >RSS</a>
                                    
                                </div>

                            </div>

                            <div class="o-layout__item u-2/5@sm u-center u-right@sm u-mb--3">

                                <div class="u-hide u-show@lg">
                                    <div class="_mdl-layout">
                                        <a class="mdl-button mdl-js-button mdl-button--inverted mdl-button--no-shadow mdl-js-ripple-effect mdl-button--outline" href="/for-authors/publish-your-research"   data-test-id="footer_submit_research"  >Submit Your Research</a>
                                    </div>
                                </div>

                            </div>

                    </nav>
                </div>

            </div>

            <div class="o-layout__item u-mb--2">
                <div class="c-footer__share">
                        <div class="c-footer__share">
        <span class="c-footer__share-icon" title="Open Access">
            <span class="f1r-icon icon-100_open_access license-icon"></span>
        </span>

        <a class="c-footer__share-icon" href="//creativecommons.org/licenses" target="_blank" title="Creative Commons License CC-BY">
            <span class="f1r-icon icon-116_cc license-icon license-icon-cc"></span>
            <span class="f1r-icon icon-117_ccby license-icon license-icon-cc"></span>
        </a>

        <a class="c-footer__share-icon" href="//creativecommons.org/about/cc0" target="_blank" title="Creative Commons License CC0">
            <span class="f1r-icon icon-118_cco license-icon"></span>
        </a>

    </div>
                </div>
            </div>


                        
            <div class="o-layout__item u-1/3@md u-mb--3">

                <span class="c-hr c-hr--low u-mb--3"></span>

                <p class="c-footer__social u-mt--0 u-mb--0 u-white--low-med">Follow us
                    <a href="https://www.facebook.com/F1000" target="_blank" class="c-footer__social-icon f1r-icon icon-55_footer_facebook"></a>
                    <a href="https://twitter.com/#!/F1000Research" target="_blank" class="c-footer__social-icon f1r-icon icon-56_footer_twitter"></a>
                    <a href="http://www.youtube.com/user/F1000research" target="_blank" class="c-footer__social-icon f1r-icon icon-57_footer_youtube"></a></p>

            </div>


                        
            <div class="o-layout__item u-2/3@md u-right@md">

                <span class="c-hr c-hr--low u-mb--3"></span>

                <p class="t-caption u-white--low-med">&copy; 2012-2020 F1000 Research Ltd. ISSN 2046-1402 | <a href="/about/legal" class="copyrightLegal">Legal</a> | Partner of <a target="_blank" href="http://www.who.int/hinari/en/">HINARI</a>  &bull; <a target="_blank" href="http://crossref.org/">CrossRef</a> &bull; <a target="_blank" href="http://about.orcid.org/">ORCID</a> &bull; <a target="_blank" href="http://www.fairsharing.org">FAIRSharing</a></p>

            </div>
        </div>
    </div>

</footer>            </div>
        
    </div>

            <div class="js-cookie-spacer"></div>
        <div class="cookie-warning">
            <div class="instruction">The F1000Research website uses cookies. By continuing to browse the site, you are agreeing to our use of cookies. <a class="js-scroll-to" href="/about/legal/privacypolicy#use-of-cookies" data-scroll-target="#use-of-cookies">Find out more &raquo;</a></div>
            <div class="close-button"></div>
        </div>
    
    <script>
                    R.templateTests.simpleTemplate = R.template('<p class="$variable.one">$text</p><p class="${variable.two}">$text</p><p class="$!variable.three">$text</p><p class="$!{variable.four}">$text</p><p class="${selector}.five">$text</p>');
            R.templateTests.runTests();
        
        var F1000platform = new F1000.Platform({
            name: "f1000research",
            displayName: "F1000Research",
            hostName: "f1000research.com",
            id: "1",
            editorialEmail: "research@f1000.com",
            infoEmail: "info@f1000.com",
            usePmcStats: true
        });

                    $(function(){R.ui.dropdowns('.dropdown-for-authors, .dropdown-for-about, .dropdown-for-myresearch');});
            // $(function(){R.ui.dropdowns('.dropdown-for-referees');});

            $(document).ready(function () {
                if ($(".cookie-warning").is(":visible")) {
                    $(".sticky").css("margin-bottom", "35px");
                    $(".devices").addClass("devices-and-cookie-warning");
                }
                $(".cookie-warning .close-button").click(function (e) {
                    $(".devices").removeClass("devices-and-cookie-warning");
                    $(".sticky").css("margin-bottom", "0");
                });

                $("#tweeter-feed .tweet-message").each(function (i, message) {
                    var self = $(message);
                    self.html(linkify(self.html()));
                });

                $(".partner").on("mouseenter mouseleave", function() {
                    $(this).find(".gray-scale, .colour").toggleClass("is-hidden");
                });
            });
        
    </script>

            
<div class="sign-in-popup">
	<!-- <a href="#" class="sign-in shadow">Sign in <span class="sign-in-image-active"></span></a> -->
	<a href="#" class="sign-in ${locale}">Sign In <span class="arrow-closed sign-in-arrow-padding arrow-opened"></span></a>
	<div class="sign-in-form">

            <form action="https://f1000research.com/j_spring_oauth_security_check" id="googleOAuth" method="post"  target="_top" >
                                    <input class="target-field" type="hidden" name="target" value="/articles/6-2085.html"/>
                            <input id="google-remember-me" name="_spring_security_oauth_remember_me" type="hidden" value="true"/>
        <input id="system-google" name="system" type="hidden" value="GOOGLE"/>
    </form>
            <form action="https://f1000research.com/j_spring_oauth_security_check" id="facebookOAuth" method="post"  target="_top" >
                                    <input class="target-field" type="hidden" name="target" value="/articles/6-2085.html"/>
                            <input id="facebook-remember-me" name="_spring_security_oauth_remember_me" type="hidden" value="true"/>
        <input id="system-fb" name="system" type="hidden" value="FACEBOOK"/>
    </form>
            <form action="https://f1000research.com/j_spring_oauth_security_check" id="orcidOAuth" method="post"  target="_top" >
                                    <input class="target-field" type="hidden" name="target" value="/articles/6-2085.html"/>
                            <input id="orcid-remember-me" name="_spring_security_oauth_remember_me" type="hidden" value="true"/>
        <input id="system-orcid" name="system" type="hidden" value="ORCID"/>
    </form>
		<form id="sign-in-form" class="login-container" action="https://f1000research.com/login" method="post" name="f">
           <div id="sign-in-form-gfb-popup"></div>

                                                            <input class="target-field" type="hidden" name="target" value="/articles/6-2085.html"/>
                            			<input type="text" name="username" id="signin-email-box" class="sign-in-input" placeholder="Email address" autocomplete="email">
			<input type="password" name="password" id="signin-password-box" class="sign-in-input" placeholder="Password" autocomplete="current-password">
			<div class="sign-in-remember">
                <div class="checkbox-wrapper">
    				<input type="checkbox" id="remember-me" name="remember_me" class="checkbox is-hidden">
                </div>
                <span class="checkbox-label">Remember me</span>
			</div>
			<a href="#" class="sign-in-link" id="forgot-password-link">Forgotten your password?</a>
			<div class="sign-in-button-container margin-top margin-left-20 margin-bottom">
				<button type="submit" id="sign-in-button" class="sign-in-buttons general-white-orange-button">Sign In</button>
				<button type="button" id="sign-in-cancel" class="sign-in-buttons sign-in-cancel-button margin-left">Cancel</button>
				<div class="clearfix"></div>
			</div>
			<div class="sign-in-error">Email or password not correct. Please try again</div>
			<div class="sign-in-loading">Please wait...</div>
		</form>
		<div class="forgot-password-container">
			
<script type="text/javascript">
	$(function(){
		// Note: All the setup needs to run against a name attribute and *not* the id due the clonish
		// nature of facebox...
		$("a[id=googleSignInButton]").click(function(event){
            event.preventDefault();
            $("input[id=oAuthSystem]").val("GOOGLE");
            $("form[id=oAuthForm]").submit();
        });
        $("a[id=facebookSignInButton]").click(function(event){
            event.preventDefault();
            $("input[id=oAuthSystem]").val("FACEBOOK");
            $("form[id=oAuthForm]").submit();
        });
        $("a[id=orcidSignInButton]").click(function(event){
            event.preventDefault();
            $("input[id=oAuthSystem]").val("ORCID");
            $("form[id=oAuthForm]").submit();
        });
	});
</script>

<span class="text first">
	If you've forgotten your password, please enter your email address below and we'll send you instructions on how to reset your password.
    <p>The email address should be the one you originally registered with F1000.</p>
</span>
<input name="email" class="sign-in-input" id="email-forgot-password" type="text" placeholder="Email address">
<div class="forgot-password-email-error">
	Email address not valid, please try again
</div>
<div class="forgot-password-google-email-error">
    <p>You registered with F1000 via Google, so we cannot reset your password.</p>
	<p>To sign in, please click <a href="#" id="googleSignInButton">here</a>.</p>
    <p>If you still need help with your Google account password, please click <a href="https://www.google.com/accounts/recovery">here</a>.</p>
</div>
<div class="forgot-password-facebook-email-error">
    <p>You registered with F1000 via Facebook, so we cannot reset your password.</p>
    <p>To sign in, please click <a href="#" id="facebookSignInButton">here</a>.</p>
	<p>If you still need help with your Facebook account password, please click <a href="https://www.facebook.com/recover/initiate">here</a>.</p>
</div>
<div class="clearfix"></div>
<div class="forgot-password-captcha-error">
	Code not correct, please try again
</div>
<div class="clearfix"></div>
<div class="sign-in-button-container margin-left-20 margin-bottom">
	<button type="button" id="sign-in-reset-password" class="sign-in-buttons general-white-orange-button">Reset password</button>
	<button type="button" id="forgot-password-cancel" class="sign-in-buttons sign-in-cancel-button margin-left">Cancel</button>
	<div class="clearfix"></div>
</div>
<span class="text last">
	<a href="mailto:">Email us</a> for further assistance.
</span>
<form action="https://f1000research.com/j_spring_oauth_security_check" id="oAuthForm" method="post" target="_top">
                        <input class="target-field" type="hidden" name="target" value="/articles/6-2085.html"/>
                <input id="oAuthSystem" name="system" type="hidden"/>
</form>
			<div class="forgot-password-server-error">Server error, please try again.</div>
			<div class="sign-in-success">
                <p>We have sent an email to <span id="email-value"></span>, please follow the instructions to reset your password.</p>
                <p>If you don't receive this email, please check your spam filters and/or contact .</p>
            </div>
			<div class="sign-in-loading">Please wait...</div>
		</div>

		<div class="sign-in-form-register-section">
			<div class="sign-in-button-container margin-left-20 margin-bottom">
				<a href="/register" title="Register"><button type="button" id="sign-in-register-button" class="sign-in-buttons general-white-orange-button">Register</button></a>
				<div class="clearfix"></div>
			</div>
		</div>

	</div>
</div>

<script type="text/javascript">
$(document).ready(function () {

    signIn.createSignInAsRow($("#sign-in-form-gfb-popup"));

    $(".target-field").each(function () {
        var uris = $(this).val().split("/");
        if (uris.pop() === "login") {
        	$(this).val(uris.toString().replace(",","/"));
        }
    });
});
</script>
        <div id="templateOverlay" class="is-hidden" hidden="hidden">
  <div class="o-overlay js-overlay is-hidden" hidden="hidden"></div>
</div>

<div id="templateExternalMessages" class="is-hidden" hidden="hidden">
  <div class="o-modal o-modal--auto@md js-external-messages is-hidden" hidden="hidden">
    <div class="o-modal__body">
      <section class="c-console">
        <div class="_mdl-layout c-console__bdy js-external-messages-body"></div>
        <footer class="_mdl-layout c-console__ftr o-flex o-flex--reverse js-external-messages-footer">
          <button type="button" class="mdl-button mdl-js-button mdl-button--raised mdl-button--colored c-console__btn js-external-messages-close" data-action="maintenance-close">I Understand</button>
        </footer>
      </section>
    </div>
  </div>
</div>

<script src="https://cdnjs.cloudflare.com/ajax/libs/moment.js/2.22.1/moment.min.js"></script>

<script src="/js/namespace.js"></script>
<script src="/js/constants.js"></script>
<script src="/js/utilities.js"></script>

<script>
                  F1000.ExtenalMaintenanceItems = [
    {
      start: '2018-12-10T14:21:00Z',
      end: '2018-12-13T16:00:00Z',
      msg: 'This site will be down for a short time on XX December. It is advisable not to start any submissions on that day or you may lose your work unless you save regularly.',
      cookieName: 'outage23122018',
      editor: false,
    }
  ];
</script>

<script src="/js/shared_scripts/cookie-helper.js"></script>
<script src="/js/shared_scripts/mdl-helper.js"></script>

<script src="/js/app/external-maintenance.js"></script>

                <script type="text/javascript">
            (function(i,s,o,g,r,a,m){i['GoogleAnalyticsObject']=r;i[r]=i[r]||function(){
            (i[r].q=i[r].q||[]).push(arguments)},i[r].l=1*new Date();a=s.createElement(o),
            m=s.getElementsByTagName(o)[0];a.async=1;a.src=g;m.parentNode.insertBefore(a,m)
            })(window,document,'script','//www.google-analytics.com/analytics.js','ga');

            ga('create', 'UA-5646075-11', 'auto');
            ga('require', 'displayfeatures');
            ga('send', 'pageview');
        </script>
        
                <script type="text/javascript" src="/js/app/research.analytics.js"></script>

        <!-- Start of HubSpot Embed Code -->
        <script type="text/javascript" id="hs-script-loader" async defer src="//js.hs-scripts.com/4475190.js"></script>
        <!-- End of HubSpot Embed Code -->
    
            <script src="https://my.hellobar.com/4e0495c6f18cbd68731a1dc1978195a144e767ba.js" type="text/javascript" charset="utf-8" async="async"></script>
    </body>

</html>